id	sid	tid	token	lemma	pos
cuesj-1224	1	1	tx_1	tx_1	PROPN
cuesj-1224	1	2	~	~	X
cuesj-1224	1	3	abs	ab	NOUN
cuesj-1224	1	4	:	:	PUNCT
cuesj-1224	1	5	at	at	ADP
cuesj-1224	1	6	/	/	SYM
cuesj-1224	1	7	add	add	VERB
cuesj-1224	1	8	:	:	PUNCT
cuesj-1224	1	9	tx_2	tx_2	PROPN
cuesj-1224	1	10	~	~	NOUN
cuesj-1224	1	11	abs	ab	NOUN
cuesj-1224	1	12	:	:	PUNCT
cuesj-1224	1	13	at	at	ADP
cuesj-1224	1	14	104	104	NUM
cuesj-1224	1	15	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	1	16	cuesj	cuesj	ADJ
cuesj-1224	1	17	2024	2024	NUM
cuesj-1224	1	18	,	,	PUNCT
cuesj-1224	1	19	8	8	NUM
cuesj-1224	1	20	(	(	PUNCT
cuesj-1224	1	21	2	2	NUM
cuesj-1224	1	22	):	):	PUNCT
cuesj-1224	1	23	104	104	NUM
cuesj-1224	1	24	-	-	SYM
cuesj-1224	1	25	109	109	NUM
cuesj-1224	1	26	research	research	NOUN
cuesj-1224	1	27	article	article	NOUN
cuesj-1224	1	28	a	a	DET
cuesj-1224	1	29	comparative	comparative	ADJ
cuesj-1224	1	30	study	study	NOUN
cuesj-1224	1	31	of	of	ADP
cuesj-1224	1	32	efficacy	efficacy	NOUN
cuesj-1224	1	33	and	and	CCONJ
cuesj-1224	1	34	safety	safety	NOUN
cuesj-1224	1	35	among	among	ADP
cuesj-1224	1	36	metformin	metformin	NOUN
cuesj-1224	1	37	,	,	PUNCT
cuesj-1224	1	38	sitagliptin	sitagliptin	NOUN
cuesj-1224	1	39	,	,	PUNCT
cuesj-1224	1	40	and	and	CCONJ
cuesj-1224	1	41	glimepiride	glimepiride	NOUN
cuesj-1224	1	42	monotherapies	monotherapie	NOUN
cuesj-1224	1	43	in	in	ADP
cuesj-1224	1	44	patients	patient	NOUN
cuesj-1224	1	45	with	with	ADP
cuesj-1224	1	46	type	type	NOUN
cuesj-1224	1	47	2	2	NUM
cuesj-1224	1	48	diabetes	diabetes	NOUN
cuesj-1224	1	49	mellitus	mellitus	NOUN
cuesj-1224	1	50	ali	ali	PROPN
cuesj-1224	1	51	o.	o.	PROPN
cuesj-1224	1	52	yassen1	yassen1	PROPN
cuesj-1224	1	53	,	,	PUNCT
cuesj-1224	1	54	asmaa	asmaa	PROPN
cuesj-1224	1	55	a.	a.	PROPN
cuesj-1224	1	56	haydar2	haydar2	PROPN
cuesj-1224	1	57	,	,	PUNCT
cuesj-1224	1	58	mohammed	mohammed	PROPN
cuesj-1224	1	59	r.	r.	PROPN
cuesj-1224	1	60	yaseen3	yaseen3	PROPN
cuesj-1224	1	61	,	,	PUNCT
cuesj-1224	1	62	suzan	suzan	PROPN
cuesj-1224	1	63	n.	n.	PROPN
cuesj-1224	1	64	a.	a.	PROPN
cuesj-1224	1	65	alamdar4	alamdar4	PROPN
cuesj-1224	1	66	,	,	PUNCT
cuesj-1224	1	67	muhamed	muhamed	PROPN
cuesj-1224	1	68	a.	a.	PROPN
cuesj-1224	1	69	abbas3	abbas3	PROPN
cuesj-1224	2	1	1pharmacy	1pharmacy	NUM
cuesj-1224	2	2	department	department	NOUN
cuesj-1224	2	3	,	,	PUNCT
cuesj-1224	2	4	tishk	tishk	PROPN
cuesj-1224	2	5	international	international	ADJ
cuesj-1224	2	6	university	university	PROPN
cuesj-1224	2	7	,	,	PUNCT
cuesj-1224	2	8	kurdistan	kurdistan	PROPN
cuesj-1224	2	9	region	region	NOUN
cuesj-1224	2	10	,	,	PUNCT
cuesj-1224	2	11	iraq	iraq	PROPN
cuesj-1224	2	12	,	,	PUNCT
cuesj-1224	2	13	2department	2department	NUM
cuesj-1224	2	14	of	of	ADP
cuesj-1224	2	15	pharmacology	pharmacology	NOUN
cuesj-1224	2	16	and	and	CCONJ
cuesj-1224	2	17	toxicology	toxicology	NOUN
cuesj-1224	2	18	,	,	PUNCT
cuesj-1224	2	19	college	college	NOUN
cuesj-1224	2	20	of	of	ADP
cuesj-1224	2	21	pharmacy	pharmacy	NOUN
cuesj-1224	2	22	,	,	PUNCT
cuesj-1224	2	23	hmu	hmu	PROPN
cuesj-1224	2	24	,	,	PUNCT
cuesj-1224	2	25	erbil	erbil	PROPN
cuesj-1224	2	26	,	,	PUNCT
cuesj-1224	2	27	iraq	iraq	PROPN
cuesj-1224	2	28	,	,	PUNCT
cuesj-1224	2	29	3department	3department	NUM
cuesj-1224	2	30	of	of	ADP
cuesj-1224	2	31	pharmacy	pharmacy	NOUN
cuesj-1224	2	32	,	,	PUNCT
cuesj-1224	2	33	college	college	NOUN
cuesj-1224	2	34	of	of	ADP
cuesj-1224	2	35	pharmacy	pharmacy	NOUN
cuesj-1224	2	36	,	,	PUNCT
cuesj-1224	2	37	cihan	cihan	VERB
cuesj-1224	2	38	university	university	NOUN
cuesj-1224	2	39	-	-	PUNCT
cuesj-1224	2	40	erbil	erbil	PROPN
cuesj-1224	2	41	,	,	PUNCT
cuesj-1224	2	42	kurdistan	kurdistan	PROPN
cuesj-1224	2	43	region	region	NOUN
cuesj-1224	2	44	,	,	PUNCT
cuesj-1224	2	45	iraq	iraq	PROPN
cuesj-1224	2	46	,	,	PUNCT
cuesj-1224	2	47	4department	4department	NUM
cuesj-1224	2	48	of	of	ADP
cuesj-1224	2	49	pharmacy	pharmacy	NOUN
cuesj-1224	2	50	,	,	PUNCT
cuesj-1224	2	51	raparin	raparin	NOUN
cuesj-1224	2	52	teaching	teaching	NOUN
cuesj-1224	2	53	hospital	hospital	NOUN
cuesj-1224	2	54	,	,	PUNCT
cuesj-1224	2	55	erbil	erbil	PROPN
cuesj-1224	2	56	,	,	PUNCT
cuesj-1224	2	57	iraq	iraq	PROPN
cuesj-1224	2	58	.	.	PUNCT
cuesj-1224	3	1	abstract	abstract	ADJ
cuesj-1224	3	2	effective	effective	ADJ
cuesj-1224	3	3	management	management	NOUN
cuesj-1224	3	4	of	of	ADP
cuesj-1224	3	5	type	type	NOUN
cuesj-1224	3	6	 	 	SPACE
cuesj-1224	3	7	2	2	NUM
cuesj-1224	3	8	diabetes	diabetes	NOUN
cuesj-1224	3	9	mellitus	mellitus	NOUN
cuesj-1224	3	10	(	(	PUNCT
cuesj-1224	3	11	t2	t2	NOUN
cuesj-1224	3	12	dm	dm	NOUN
cuesj-1224	3	13	)	)	PUNCT
cuesj-1224	3	14	requires	require	VERB
cuesj-1224	3	15	lifestyle	lifestyle	NOUN
cuesj-1224	3	16	changes	change	NOUN
cuesj-1224	3	17	and	and	CCONJ
cuesj-1224	3	18	suitable	suitable	ADJ
cuesj-1224	3	19	medications	medication	NOUN
cuesj-1224	3	20	to	to	PART
cuesj-1224	3	21	enhance	enhance	VERB
cuesj-1224	3	22	quality	quality	NOUN
cuesj-1224	3	23	of	of	ADP
cuesj-1224	3	24	life	life	NOUN
cuesj-1224	3	25	and	and	CCONJ
cuesj-1224	3	26	prevent	prevent	VERB
cuesj-1224	3	27	complications	complication	NOUN
cuesj-1224	3	28	.	.	PUNCT
cuesj-1224	4	1	choosing	choose	VERB
cuesj-1224	4	2	the	the	DET
cuesj-1224	4	3	right	right	ADJ
cuesj-1224	4	4	treatment	treatment	NOUN
cuesj-1224	4	5	involves	involve	VERB
cuesj-1224	4	6	considering	consider	VERB
cuesj-1224	4	7	the	the	DET
cuesj-1224	4	8	patient	patient	NOUN
cuesj-1224	4	9	’s	’s	PART
cuesj-1224	4	10	clinical	clinical	ADJ
cuesj-1224	4	11	profile	profile	NOUN
cuesj-1224	4	12	,	,	PUNCT
cuesj-1224	4	13	drug	drug	NOUN
cuesj-1224	4	14	efficacy	efficacy	NOUN
cuesj-1224	4	15	,	,	PUNCT
cuesj-1224	4	16	side	side	NOUN
cuesj-1224	4	17	effects	effect	NOUN
cuesj-1224	4	18	,	,	PUNCT
cuesj-1224	4	19	and	and	CCONJ
cuesj-1224	4	20	cost	cost	NOUN
cuesj-1224	4	21	.	.	PUNCT
cuesj-1224	5	1	this	this	DET
cuesj-1224	5	2	study	study	NOUN
cuesj-1224	5	3	compares	compare	VERB
cuesj-1224	5	4	the	the	DET
cuesj-1224	5	5	safety	safety	NOUN
cuesj-1224	5	6	and	and	CCONJ
cuesj-1224	5	7	efficacy	efficacy	NOUN
cuesj-1224	5	8	of	of	ADP
cuesj-1224	5	9	sitagliptin	sitagliptin	NOUN
cuesj-1224	5	10	,	,	PUNCT
cuesj-1224	5	11	glimepiride	glimepiride	NOUN
cuesj-1224	5	12	,	,	PUNCT
cuesj-1224	5	13	and	and	CCONJ
cuesj-1224	5	14	metformin	metformin	NOUN
cuesj-1224	5	15	in	in	ADP
cuesj-1224	5	16	t2	t2	NOUN
cuesj-1224	5	17	dm	dm	PROPN
cuesj-1224	5	18	patients	patient	NOUN
cuesj-1224	5	19	.	.	PUNCT
cuesj-1224	6	1	a	a	DET
cuesj-1224	6	2	 	 	SPACE
cuesj-1224	6	3	prospective	prospective	ADJ
cuesj-1224	6	4	crosssectional	crosssectional	ADJ
cuesj-1224	6	5	study	study	NOUN
cuesj-1224	6	6	was	be	AUX
cuesj-1224	6	7	conducted	conduct	VERB
cuesj-1224	6	8	at	at	ADP
cuesj-1224	6	9	the	the	DET
cuesj-1224	6	10	diabetes	diabetes	NOUN
cuesj-1224	6	11	center	center	NOUN
cuesj-1224	6	12	of	of	ADP
cuesj-1224	6	13	layla	layla	PROPN
cuesj-1224	6	14	qasim	qasim	PROPN
cuesj-1224	6	15	,	,	PUNCT
cuesj-1224	6	16	erbil	erbil	PROPN
cuesj-1224	6	17	,	,	PUNCT
cuesj-1224	6	18	iraq	iraq	PROPN
cuesj-1224	6	19	,	,	PUNCT
cuesj-1224	6	20	that	that	PRON
cuesj-1224	6	21	included	include	VERB
cuesj-1224	6	22	143	143	NUM
cuesj-1224	6	23	diabetic	diabetic	ADJ
cuesj-1224	6	24	patients	patient	NOUN
cuesj-1224	6	25	.	.	PUNCT
cuesj-1224	7	1	they	they	PRON
cuesj-1224	7	2	were	be	AUX
cuesj-1224	7	3	divided	divide	VERB
cuesj-1224	7	4	into	into	ADP
cuesj-1224	7	5	three	three	NUM
cuesj-1224	7	6	groups	group	NOUN
cuesj-1224	7	7	:	:	PUNCT
cuesj-1224	7	8	group	group	NOUN
cuesj-1224	7	9	 	 	SPACE
cuesj-1224	7	10	a	a	DET
cuesj-1224	7	11	received	receive	VERB
cuesj-1224	7	12	glimepiride	glimepiride	NOUN
cuesj-1224	7	13	(	(	PUNCT
cuesj-1224	7	14	n	n	NOUN
cuesj-1224	7	15	=	=	SYM
cuesj-1224	7	16	50	50	NUM
cuesj-1224	7	17	)	)	PUNCT
cuesj-1224	7	18	,	,	PUNCT
cuesj-1224	7	19	group	group	NOUN
cuesj-1224	7	20	 	 	SPACE
cuesj-1224	7	21	b	b	PROPN
cuesj-1224	7	22	metformin	metformin	NOUN
cuesj-1224	7	23	(	(	PUNCT
cuesj-1224	7	24	n	n	NOUN
cuesj-1224	7	25	=	=	SYM
cuesj-1224	7	26	48	48	NUM
cuesj-1224	7	27	)	)	PUNCT
cuesj-1224	7	28	,	,	PUNCT
cuesj-1224	7	29	and	and	CCONJ
cuesj-1224	7	30	group	group	NOUN
cuesj-1224	7	31	 	 	SPACE
cuesj-1224	7	32	c	c	PROPN
cuesj-1224	7	33	sitagliptin	sitagliptin	NOUN
cuesj-1224	7	34	(	(	PUNCT
cuesj-1224	7	35	n	n	NOUN
cuesj-1224	7	36	=	=	SYM
cuesj-1224	7	37	45	45	NUM
cuesj-1224	7	38	)	)	PUNCT
cuesj-1224	7	39	.	.	PUNCT
cuesj-1224	8	1	drug	drug	NOUN
cuesj-1224	8	2	costs	cost	NOUN
cuesj-1224	8	3	,	,	PUNCT
cuesj-1224	8	4	therapeutic	therapeutic	ADJ
cuesj-1224	8	5	outcomes	outcome	NOUN
cuesj-1224	8	6	,	,	PUNCT
cuesj-1224	8	7	and	and	CCONJ
cuesj-1224	8	8	side	side	NOUN
cuesj-1224	8	9	effects	effect	NOUN
cuesj-1224	8	10	were	be	AUX
cuesj-1224	8	11	analyzed	analyze	VERB
cuesj-1224	8	12	.	.	PUNCT
cuesj-1224	9	1	patients	patient	NOUN
cuesj-1224	9	2	aged	age	VERB
cuesj-1224	9	3	30–78	30–78	NUM
cuesj-1224	9	4	participated	participate	VERB
cuesj-1224	9	5	,	,	PUNCT
cuesj-1224	9	6	with	with	ADP
cuesj-1224	9	7	a	a	DET
cuesj-1224	9	8	female	female	NOUN
cuesj-1224	9	9	-	-	PUNCT
cuesj-1224	9	10	to	to	ADP
cuesj-1224	9	11	-	-	PUNCT
cuesj-1224	9	12	male	male	NOUN
cuesj-1224	9	13	ratio	ratio	NOUN
cuesj-1224	9	14	of	of	ADP
cuesj-1224	9	15	83:60	83:60	NUM
cuesj-1224	9	16	.	.	PUNCT
cuesj-1224	10	1	all	all	DET
cuesj-1224	10	2	groups	group	NOUN
cuesj-1224	10	3	showed	show	VERB
cuesj-1224	10	4	statistically	statistically	ADV
cuesj-1224	10	5	significant	significant	ADJ
cuesj-1224	10	6	differences	difference	NOUN
cuesj-1224	10	7	in	in	ADP
cuesj-1224	10	8	hemoglobin	hemoglobin	NOUN
cuesj-1224	10	9	a1c	a1c	PROPN
cuesj-1224	10	10	(	(	PUNCT
cuesj-1224	10	11	hba1c	hba1c	NOUN
cuesj-1224	10	12	)	)	PUNCT
cuesj-1224	10	13	levels	level	NOUN
cuesj-1224	10	14	(	(	PUNCT
cuesj-1224	10	15	p	p	NOUN
cuesj-1224	10	16	=	=	NOUN
cuesj-1224	10	17	0.001	0.001	NUM
cuesj-1224	10	18	)	)	PUNCT
cuesj-1224	10	19	.	.	PUNCT
cuesj-1224	11	1	total	total	ADJ
cuesj-1224	11	2	cholesterol	cholesterol	NOUN
cuesj-1224	11	3	and	and	CCONJ
cuesj-1224	11	4	low	low	ADJ
cuesj-1224	11	5	-	-	PUNCT
cuesj-1224	11	6	density	density	NOUN
cuesj-1224	11	7	lipoprotein	lipoprotein	ADJ
cuesj-1224	11	8	levels	level	NOUN
cuesj-1224	11	9	were	be	AUX
cuesj-1224	11	10	also	also	ADV
cuesj-1224	11	11	significantly	significantly	ADV
cuesj-1224	11	12	different	different	ADJ
cuesj-1224	11	13	(	(	PUNCT
cuesj-1224	11	14	p	p	X
cuesj-1224	11	15	=	=	NOUN
cuesj-1224	11	16	0.047	0.047	NUM
cuesj-1224	11	17	and	and	CCONJ
cuesj-1224	11	18	p	p	NOUN
cuesj-1224	11	19	=	=	NOUN
cuesj-1224	11	20	0.010	0.010	NUM
cuesj-1224	11	21	,	,	PUNCT
cuesj-1224	11	22	respectively	respectively	ADV
cuesj-1224	11	23	)	)	PUNCT
cuesj-1224	11	24	.	.	PUNCT
cuesj-1224	12	1	sitagliptin	sitagliptin	PROPN
cuesj-1224	12	2	group	group	PROPN
cuesj-1224	12	3	had	have	VERB
cuesj-1224	12	4	higher	high	ADJ
cuesj-1224	12	5	triglycerides	triglyceride	NOUN
cuesj-1224	12	6	and	and	CCONJ
cuesj-1224	12	7	high	high	ADJ
cuesj-1224	12	8	-	-	PUNCT
cuesj-1224	12	9	density	density	NOUN
cuesj-1224	12	10	lipoprotein	lipoprotein	ADJ
cuesj-1224	12	11	-	-	PUNCT
cuesj-1224	12	12	cholesterol	cholesterol	NOUN
cuesj-1224	12	13	.	.	PUNCT
cuesj-1224	13	1	gastrointestinal	gastrointestinal	ADJ
cuesj-1224	13	2	side	side	NOUN
cuesj-1224	13	3	effects	effect	NOUN
cuesj-1224	13	4	were	be	AUX
cuesj-1224	13	5	prominent	prominent	ADJ
cuesj-1224	13	6	in	in	ADP
cuesj-1224	13	7	the	the	DET
cuesj-1224	13	8	metformin	metformin	NOUN
cuesj-1224	13	9	group	group	NOUN
cuesj-1224	13	10	.	.	PUNCT
cuesj-1224	14	1	when	when	SCONJ
cuesj-1224	14	2	selecting	select	VERB
cuesj-1224	14	3	medication	medication	NOUN
cuesj-1224	14	4	for	for	ADP
cuesj-1224	14	5	t2	t2	NOUN
cuesj-1224	14	6	dm	dm	PROPN
cuesj-1224	14	7	,	,	PUNCT
cuesj-1224	14	8	factors	factor	NOUN
cuesj-1224	14	9	such	such	ADJ
cuesj-1224	14	10	as	as	ADP
cuesj-1224	14	11	age	age	NOUN
cuesj-1224	14	12	,	,	PUNCT
cuesj-1224	14	13	hba1c	hba1c	PROPN
cuesj-1224	14	14	,	,	PUNCT
cuesj-1224	14	15	glucose	glucose	NOUN
cuesj-1224	14	16	levels	level	NOUN
cuesj-1224	14	17	,	,	PUNCT
cuesj-1224	14	18	obesity	obesity	NOUN
cuesj-1224	14	19	,	,	PUNCT
cuesj-1224	14	20	metabolic	metabolic	NOUN
cuesj-1224	14	21	syndrome	syndrome	NOUN
cuesj-1224	14	22	,	,	PUNCT
cuesj-1224	14	23	insulin	insulin	NOUN
cuesj-1224	14	24	secretion	secretion	NOUN
cuesj-1224	14	25	,	,	PUNCT
cuesj-1224	14	26	and	and	CCONJ
cuesj-1224	14	27	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	14	28	risk	risk	NOUN
cuesj-1224	14	29	should	should	AUX
cuesj-1224	14	30	be	be	AUX
cuesj-1224	14	31	considered	consider	VERB
cuesj-1224	14	32	.	.	PUNCT
cuesj-1224	15	1	both	both	PRON
cuesj-1224	15	2	sitagliptin	sitagliptin	NOUN
cuesj-1224	15	3	and	and	CCONJ
cuesj-1224	15	4	glimepiride	glimepiride	NOUN
cuesj-1224	15	5	were	be	AUX
cuesj-1224	15	6	well	well	ADV
cuesj-1224	15	7	tolerated	tolerate	VERB
cuesj-1224	15	8	,	,	PUNCT
cuesj-1224	15	9	with	with	ADP
cuesj-1224	15	10	minimal	minimal	ADJ
cuesj-1224	15	11	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	15	12	risk	risk	NOUN
cuesj-1224	15	13	and	and	CCONJ
cuesj-1224	15	14	no	no	DET
cuesj-1224	15	15	significant	significant	ADJ
cuesj-1224	15	16	weight	weight	NOUN
cuesj-1224	15	17	differences	difference	NOUN
cuesj-1224	15	18	between	between	ADP
cuesj-1224	15	19	groups	group	NOUN
cuesj-1224	15	20	.	.	PUNCT
cuesj-1224	16	1	glimepiride	glimepiride	NOUN
cuesj-1224	16	2	is	be	AUX
cuesj-1224	16	3	an	an	DET
cuesj-1224	16	4	effective	effective	ADJ
cuesj-1224	16	5	,	,	PUNCT
cuesj-1224	16	6	safe	safe	ADJ
cuesj-1224	16	7	,	,	PUNCT
cuesj-1224	16	8	and	and	CCONJ
cuesj-1224	16	9	weightneutral	weightneutral	PROPN
cuesj-1224	16	10	adjunct	adjunct	VERB
cuesj-1224	16	11	to	to	ADP
cuesj-1224	16	12	metformin	metformin	NOUN
cuesj-1224	16	13	,	,	PUNCT
cuesj-1224	16	14	offering	offer	VERB
cuesj-1224	16	15	extrapancreatic	extrapancreatic	ADJ
cuesj-1224	16	16	benefits	benefit	NOUN
cuesj-1224	16	17	and	and	CCONJ
cuesj-1224	16	18	remains	remain	VERB
cuesj-1224	16	19	a	a	DET
cuesj-1224	16	20	viable	viable	ADJ
cuesj-1224	16	21	second	second	ADJ
cuesj-1224	16	22	-	-	PUNCT
cuesj-1224	16	23	line	line	NOUN
cuesj-1224	16	24	treatment	treatment	NOUN
cuesj-1224	16	25	option	option	NOUN
cuesj-1224	16	26	for	for	ADP
cuesj-1224	16	27	t2	t2	NOUN
cuesj-1224	16	28	dm	dm	PROPN
cuesj-1224	16	29	patients	patient	NOUN
cuesj-1224	16	30	.	.	PUNCT
cuesj-1224	17	1	keywords	keyword	NOUN
cuesj-1224	17	2	:	:	PUNCT
cuesj-1224	17	3	diabetes	diabetes	NOUN
cuesj-1224	17	4	,	,	PUNCT
cuesj-1224	17	5	hemoglobin	hemoglobin	NOUN
cuesj-1224	17	6	a1c	a1c	PROPN
cuesj-1224	17	7	,	,	PUNCT
cuesj-1224	17	8	metformin	metformin	NOUN
cuesj-1224	17	9	,	,	PUNCT
cuesj-1224	17	10	glimepiride	glimepiride	NOUN
cuesj-1224	17	11	,	,	PUNCT
cuesj-1224	17	12	sitagliptin	sitagliptin	NOUN
cuesj-1224	17	13	introduction	introduction	NOUN
cuesj-1224	17	14	type	type	NOUN
cuesj-1224	17	15	2	2	NUM
cuesj-1224	17	16	diabetes	diabetes	NOUN
cuesj-1224	17	17	mellitus	mellitus	NOUN
cuesj-1224	17	18	(	(	PUNCT
cuesj-1224	17	19	t2	t2	NOUN
cuesj-1224	17	20	dm	dm	NOUN
cuesj-1224	17	21	)	)	PUNCT
cuesj-1224	17	22	is	be	AUX
cuesj-1224	17	23	the	the	DET
cuesj-1224	17	24	most	most	ADV
cuesj-1224	17	25	prevalent	prevalent	ADJ
cuesj-1224	17	26	form	form	NOUN
cuesj-1224	17	27	of	of	ADP
cuesj-1224	17	28	the	the	DET
cuesj-1224	17	29	chronic	chronic	ADJ
cuesj-1224	17	30	metabolic	metabolic	NOUN
cuesj-1224	17	31	disease	disease	NOUN
cuesj-1224	17	32	known	know	VERB
cuesj-1224	17	33	as	as	ADP
cuesj-1224	17	34	diabetes	diabetes	NOUN
cuesj-1224	17	35	mellitus.[1	mellitus.[1	NOUN
cuesj-1224	17	36	]	]	PUNCT
cuesj-1224	17	37	diabetes	diabetes	NOUN
cuesj-1224	17	38	is	be	AUX
cuesj-1224	17	39	a	a	DET
cuesj-1224	17	40	chronic	chronic	ADJ
cuesj-1224	17	41	condition	condition	NOUN
cuesj-1224	17	42	;	;	PUNCT
cuesj-1224	17	43	thus	thus	ADV
cuesj-1224	17	44	,	,	PUNCT
cuesj-1224	17	45	patients	patient	NOUN
cuesj-1224	17	46	frequently	frequently	ADV
cuesj-1224	17	47	require	require	VERB
cuesj-1224	17	48	long	long	ADJ
cuesj-1224	17	49	-	-	PUNCT
cuesj-1224	17	50	term	term	NOUN
cuesj-1224	17	51	care	care	NOUN
cuesj-1224	17	52	.	.	PUNCT
cuesj-1224	18	1	t2	t2	NOUN
cuesj-1224	18	2	dm	dm	PROPN
cuesj-1224	18	3	is	be	AUX
cuesj-1224	18	4	a	a	DET
cuesj-1224	18	5	global	global	ADJ
cuesj-1224	18	6	epidemic	epidemic	NOUN
cuesj-1224	18	7	that	that	PRON
cuesj-1224	18	8	is	be	AUX
cuesj-1224	18	9	expected	expect	VERB
cuesj-1224	18	10	to	to	PART
cuesj-1224	18	11	impact	impact	VERB
cuesj-1224	18	12	more	more	ADJ
cuesj-1224	18	13	than	than	ADP
cuesj-1224	18	14	550	550	NUM
cuesj-1224	18	15	million	million	NUM
cuesj-1224	18	16	people	people	NOUN
cuesj-1224	18	17	by	by	ADP
cuesj-1224	18	18	2035.[2	2035.[2	NUM
cuesj-1224	18	19	]	]	PUNCT
cuesj-1224	18	20	despite	despite	SCONJ
cuesj-1224	18	21	receiving	receive	VERB
cuesj-1224	18	22	medication	medication	NOUN
cuesj-1224	18	23	and	and	CCONJ
cuesj-1224	18	24	making	make	VERB
cuesj-1224	18	25	lifestyle	lifestyle	NOUN
cuesj-1224	18	26	changes	change	NOUN
cuesj-1224	18	27	patients	patient	NOUN
cuesj-1224	18	28	with	with	ADP
cuesj-1224	18	29	t2	t2	NOUN
cuesj-1224	18	30	dm	dm	NUM
cuesj-1224	18	31	show	show	VERB
cuesj-1224	18	32	increasing	increase	VERB
cuesj-1224	18	33	glucose	glucose	NOUN
cuesj-1224	18	34	levels	level	NOUN
cuesj-1224	18	35	over	over	ADP
cuesj-1224	18	36	time	time	NOUN
cuesj-1224	18	37	,	,	PUNCT
cuesj-1224	18	38	which	which	PRON
cuesj-1224	18	39	is	be	AUX
cuesj-1224	18	40	probably	probably	ADV
cuesj-1224	18	41	due	due	ADJ
cuesj-1224	18	42	to	to	ADP
cuesj-1224	18	43	deteriorating	deteriorate	VERB
cuesj-1224	18	44	β	β	NOUN
cuesj-1224	18	45	-	-	NOUN
cuesj-1224	18	46	cell	cell	NOUN
cuesj-1224	18	47	activity	activity	NOUN
cuesj-1224	18	48	.	.	PUNCT
cuesj-1224	19	1	the	the	DET
cuesj-1224	19	2	defining	define	VERB
cuesj-1224	19	3	features	feature	NOUN
cuesj-1224	19	4	of	of	ADP
cuesj-1224	19	5	type	type	NOUN
cuesj-1224	19	6	2	2	NUM
cuesj-1224	19	7	diabetes	diabetes	NOUN
cuesj-1224	19	8	include	include	VERB
cuesj-1224	19	9	insulin	insulin	NOUN
cuesj-1224	19	10	resistance	resistance	NOUN
cuesj-1224	19	11	in	in	ADP
cuesj-1224	19	12	peripheral	peripheral	ADJ
cuesj-1224	19	13	tissues	tissue	NOUN
cuesj-1224	19	14	and	and	CCONJ
cuesj-1224	19	15	insufficient	insufficient	ADJ
cuesj-1224	19	16	insulin	insulin	NOUN
cuesj-1224	19	17	production.[3	production.[3	NOUN
cuesj-1224	19	18	]	]	PUNCT
cuesj-1224	19	19	according	accord	VERB
cuesj-1224	19	20	to	to	ADP
cuesj-1224	19	21	one	one	NUM
cuesj-1224	19	22	study	study	NOUN
cuesj-1224	19	23	,	,	PUNCT
cuesj-1224	19	24	an	an	DET
cuesj-1224	19	25	even	even	ADV
cuesj-1224	19	26	higher	high	ADJ
cuesj-1224	19	27	percentage	percentage	NOUN
cuesj-1224	19	28	of	of	ADP
cuesj-1224	19	29	people	people	NOUN
cuesj-1224	19	30	with	with	ADP
cuesj-1224	19	31	type	type	NOUN
cuesj-1224	19	32	2	2	NUM
cuesj-1224	19	33	diabetes	diabetes	NOUN
cuesj-1224	19	34	do	do	AUX
cuesj-1224	19	35	not	not	PART
cuesj-1224	19	36	adequately	adequately	ADV
cuesj-1224	19	37	regulate	regulate	VERB
cuesj-1224	19	38	their	their	PRON
cuesj-1224	19	39	blood	blood	NOUN
cuesj-1224	19	40	sugar	sugar	NOUN
cuesj-1224	19	41	levels	level	NOUN
cuesj-1224	19	42	in	in	ADP
cuesj-1224	19	43	emerging	emerge	VERB
cuesj-1224	19	44	nations	nation	NOUN
cuesj-1224	19	45	,	,	PUNCT
cuesj-1224	19	46	particularly	particularly	ADV
cuesj-1224	19	47	china	china	PROPN
cuesj-1224	19	48	,	,	PUNCT
cuesj-1224	19	49	and	and	CCONJ
cuesj-1224	19	50	about	about	ADV
cuesj-1224	19	51	two	two	NUM
cuesj-1224	19	52	-	-	PUNCT
cuesj-1224	19	53	thirds	third	NOUN
cuesj-1224	19	54	of	of	ADP
cuesj-1224	19	55	patients	patient	NOUN
cuesj-1224	19	56	in	in	ADP
cuesj-1224	19	57	wealthy	wealthy	ADJ
cuesj-1224	19	58	countries.[4	countries.[4	NOUN
cuesj-1224	19	59	]	]	PUNCT
cuesj-1224	19	60	a	a	DET
cuesj-1224	19	61	study	study	NOUN
cuesj-1224	19	62	conducted	conduct	VERB
cuesj-1224	19	63	in	in	ADP
cuesj-1224	19	64	the	the	DET
cuesj-1224	19	65	kurdistan	kurdistan	ADJ
cuesj-1224	19	66	region	region	NOUN
cuesj-1224	19	67	of	of	ADP
cuesj-1224	19	68	iraq	iraq	PROPN
cuesj-1224	19	69	,	,	PUNCT
cuesj-1224	19	70	which	which	PRON
cuesj-1224	19	71	included	include	VERB
cuesj-1224	19	72	patients	patient	NOUN
cuesj-1224	19	73	from	from	ADP
cuesj-1224	19	74	the	the	DET
cuesj-1224	19	75	diabetes	diabetes	NOUN
cuesj-1224	19	76	centers	center	NOUN
cuesj-1224	19	77	in	in	ADP
cuesj-1224	19	78	the	the	DET
cuesj-1224	19	79	provinces	province	NOUN
cuesj-1224	19	80	of	of	ADP
cuesj-1224	19	81	erbil	erbil	PROPN
cuesj-1224	19	82	,	,	PUNCT
cuesj-1224	19	83	duhok	duhok	NOUN
cuesj-1224	19	84	,	,	PUNCT
cuesj-1224	19	85	and	and	CCONJ
cuesj-1224	19	86	suleimania	suleimania	NOUN
cuesj-1224	19	87	,	,	PUNCT
cuesj-1224	19	88	showed	show	VERB
cuesj-1224	19	89	that	that	SCONJ
cuesj-1224	19	90	92	92	NUM
cuesj-1224	19	91	%	%	NOUN
cuesj-1224	19	92	of	of	ADP
cuesj-1224	19	93	patients	patient	NOUN
cuesj-1224	19	94	had	have	VERB
cuesj-1224	19	95	hemoglobin	hemoglobin	NOUN
cuesj-1224	19	96	a1c	a1c	PROPN
cuesj-1224	19	97	(	(	PUNCT
cuesj-1224	19	98	hba1c	hba1c	NOUN
cuesj-1224	19	99	)	)	PUNCT
cuesj-1224	19	100	levels	level	NOUN
cuesj-1224	19	101	at	at	ADP
cuesj-1224	19	102	and	and	CCONJ
cuesj-1224	19	103	above	above	ADP
cuesj-1224	19	104	7	7	NUM
cuesj-1224	19	105	%	%	NOUN
cuesj-1224	19	106	,	,	PUNCT
cuesj-1224	19	107	indicating	indicate	VERB
cuesj-1224	19	108	non	non	ADJ
cuesj-1224	19	109	-	-	ADJ
cuesj-1224	19	110	optimal	optimal	ADJ
cuesj-1224	19	111	glycemic	glycemic	NOUN
cuesj-1224	19	112	control.[5	control.[5	X
cuesj-1224	19	113	]	]	PUNCT
cuesj-1224	19	114	in	in	ADP
cuesj-1224	19	115	every	every	DET
cuesj-1224	19	116	country	country	NOUN
cuesj-1224	19	117	in	in	ADP
cuesj-1224	19	118	the	the	DET
cuesj-1224	19	119	globe	globe	NOUN
cuesj-1224	19	120	,	,	PUNCT
cuesj-1224	19	121	obesity	obesity	NOUN
cuesj-1224	19	122	continues	continue	VERB
cuesj-1224	19	123	to	to	PART
cuesj-1224	19	124	be	be	AUX
cuesj-1224	19	125	a	a	DET
cuesj-1224	19	126	serious	serious	ADJ
cuesj-1224	19	127	threat	threat	NOUN
cuesj-1224	19	128	to	to	ADP
cuesj-1224	19	129	public	public	ADJ
cuesj-1224	19	130	health.[6	health.[6	PUNCT
cuesj-1224	19	131	]	]	PUNCT
cuesj-1224	19	132	diabetes	diabetes	NOUN
cuesj-1224	19	133	rates	rate	NOUN
cuesj-1224	19	134	have	have	AUX
cuesj-1224	19	135	quadrupled	quadruple	VERB
cuesj-1224	19	136	globally	globally	ADV
cuesj-1224	19	137	since	since	SCONJ
cuesj-1224	19	138	1980	1980	NUM
cuesj-1224	19	139	due	due	ADP
cuesj-1224	19	140	to	to	ADP
cuesj-1224	19	141	obesity.[7	obesity.[7	NOUN
cuesj-1224	19	142	]	]	PUNCT
cuesj-1224	19	143	assessing	assess	VERB
cuesj-1224	19	144	the	the	DET
cuesj-1224	19	145	effectiveness	effectiveness	NOUN
cuesj-1224	19	146	of	of	ADP
cuesj-1224	19	147	diabetes	diabetes	NOUN
cuesj-1224	19	148	treatment	treatment	NOUN
cuesj-1224	19	149	often	often	ADV
cuesj-1224	19	150	relies	rely	VERB
cuesj-1224	19	151	on	on	ADP
cuesj-1224	19	152	hba1c	hba1c	PROPN
cuesj-1224	19	153	;	;	PUNCT
cuesj-1224	19	154	corresponding	corresponding	ADJ
cuesj-1224	19	155	author	author	NOUN
cuesj-1224	19	156	:	:	PUNCT
cuesj-1224	19	157	ali	ali	PROPN
cuesj-1224	19	158	o.	o.	PROPN
cuesj-1224	19	159	yassen	yassen	PROPN
cuesj-1224	19	160	,	,	PUNCT
cuesj-1224	19	161	pharmacy	pharmacy	NOUN
cuesj-1224	19	162	department	department	NOUN
cuesj-1224	19	163	,	,	PUNCT
cuesj-1224	19	164	tishk	tishk	PROPN
cuesj-1224	19	165	international	international	ADJ
cuesj-1224	19	166	university	university	PROPN
cuesj-1224	19	167	,	,	PUNCT
cuesj-1224	19	168	kurdistan	kurdistan	PROPN
cuesj-1224	19	169	region	region	NOUN
cuesj-1224	19	170	,	,	PUNCT
cuesj-1224	19	171	iraq	iraq	PROPN
cuesj-1224	19	172	.	.	PUNCT
cuesj-1224	20	1	e	e	X
cuesj-1224	20	2	-	-	NOUN
cuesj-1224	20	3	mail	mail	NOUN
cuesj-1224	20	4	:	:	PUNCT
cuesj-1224	20	5	ali.yassen@tiu.edu.iq	ali.yassen@tiu.edu.iq	PROPN
cuesj-1224	20	6	received	receive	VERB
cuesj-1224	20	7	:	:	PUNCT
cuesj-1224	20	8	june	june	PROPN
cuesj-1224	20	9	25	25	NUM
cuesj-1224	20	10	,	,	PUNCT
cuesj-1224	20	11	2024	2024	NUM
cuesj-1224	20	12	accepted	accept	VERB
cuesj-1224	20	13	:	:	PUNCT
cuesj-1224	20	14	september	september	PROPN
cuesj-1224	20	15	20	20	NUM
cuesj-1224	20	16	,	,	PUNCT
cuesj-1224	20	17	2024	2024	NUM
cuesj-1224	20	18	published	publish	VERB
cuesj-1224	20	19	:	:	PUNCT
cuesj-1224	20	20	october	october	PROPN
cuesj-1224	20	21	30	30	NUM
cuesj-1224	20	22	,	,	PUNCT
cuesj-1224	20	23	2024	2024	NUM
cuesj-1224	20	24	doi	doi	NOUN
cuesj-1224	20	25	:	:	PUNCT
cuesj-1224	20	26	10.24086	10.24086	NUM
cuesj-1224	20	27	/	/	SYM
cuesj-1224	20	28	cuesj.v8n2y2024.pp104	cuesj.v8n2y2024.pp104	NOUN
cuesj-1224	20	29	-	-	PUNCT
cuesj-1224	20	30	109	109	NUM
cuesj-1224	20	31	copyright	copyright	NOUN
cuesj-1224	20	32	©	©	PROPN
cuesj-1224	20	33	2024	2024	NUM
cuesj-1224	20	34	ali	ali	PROPN
cuesj-1224	20	35	o.	o.	PROPN
cuesj-1224	20	36	yassen	yassen	PROPN
cuesj-1224	20	37	,	,	PUNCT
cuesj-1224	20	38	asmaa	asmaa	PROPN
cuesj-1224	20	39	a.	a.	PROPN
cuesj-1224	20	40	haydar	haydar	PROPN
cuesj-1224	20	41	,	,	PUNCT
cuesj-1224	20	42	mohammed	mohammed	PROPN
cuesj-1224	20	43	r.	r.	PROPN
cuesj-1224	20	44	yaseen	yaseen	PROPN
cuesj-1224	20	45	,	,	PUNCT
cuesj-1224	20	46	suzan	suzan	PROPN
cuesj-1224	20	47	n.	n.	PROPN
cuesj-1224	20	48	a.	a.	PROPN
cuesj-1224	20	49	alamdar	alamdar	PROPN
cuesj-1224	20	50	,	,	PUNCT
cuesj-1224	20	51	muhamed	muhamed	PROPN
cuesj-1224	20	52	a.	a.	NOUN
cuesj-1224	20	53	abbas	abbas	PROPN
cuesj-1224	20	54	.	.	PUNCT
cuesj-1224	21	1	this	this	PRON
cuesj-1224	21	2	is	be	AUX
cuesj-1224	21	3	an	an	DET
cuesj-1224	21	4	open	open	ADJ
cuesj-1224	21	5	-	-	PUNCT
cuesj-1224	21	6	access	access	NOUN
cuesj-1224	21	7	article	article	NOUN
cuesj-1224	21	8	distributed	distribute	VERB
cuesj-1224	21	9	under	under	ADP
cuesj-1224	21	10	the	the	DET
cuesj-1224	21	11	creative	creative	ADJ
cuesj-1224	21	12	commons	common	NOUN
cuesj-1224	21	13	attribution	attribution	NOUN
cuesj-1224	21	14	license	license	NOUN
cuesj-1224	21	15	.	.	PUNCT
cuesj-1224	22	1	cihan	cihan	VERB
cuesj-1224	22	2	university	university	NOUN
cuesj-1224	22	3	-	-	PUNCT
cuesj-1224	22	4	erbil	erbil	PROPN
cuesj-1224	22	5	scientific	scientific	ADJ
cuesj-1224	22	6	journal	journal	NOUN
cuesj-1224	22	7	(	(	PUNCT
cuesj-1224	22	8	cuesj	cuesj	PROPN
cuesj-1224	22	9	)	)	PUNCT
cuesj-1224	22	10	yassen	yassen	PROPN
cuesj-1224	22	11	,	,	PUNCT
cuesj-1224	22	12	et	et	PROPN
cuesj-1224	22	13	al	al	PROPN
cuesj-1224	22	14	.	.	PUNCT
cuesj-1224	22	15	:	:	PUNCT
cuesj-1224	23	1	efficacy	efficacy	NOUN
cuesj-1224	23	2	and	and	CCONJ
cuesj-1224	23	3	safety	safety	NOUN
cuesj-1224	23	4	of	of	ADP
cuesj-1224	23	5	metformin	metformin	PROPN
cuesj-1224	23	6	,	,	PUNCT
cuesj-1224	23	7	sitagliptin	sitagliptin	NOUN
cuesj-1224	23	8	,	,	PUNCT
cuesj-1224	23	9	and	and	CCONJ
cuesj-1224	23	10	glimepiride	glimepiride	NOUN
cuesj-1224	23	11	in	in	ADP
cuesj-1224	23	12	type	type	NOUN
cuesj-1224	23	13	2	2	NUM
cuesj-1224	23	14	diabetes	diabetes	NOUN
cuesj-1224	23	15	105	105	NUM
cuesj-1224	23	16	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	23	17	cuesj	cuesj	ADJ
cuesj-1224	23	18	2024	2024	NUM
cuesj-1224	23	19	,	,	PUNCT
cuesj-1224	23	20	8	8	NUM
cuesj-1224	23	21	(	(	PUNCT
cuesj-1224	23	22	2	2	NUM
cuesj-1224	23	23	):	):	PUNCT
cuesj-1224	23	24	104	104	NUM
cuesj-1224	23	25	-	-	SYM
cuesj-1224	23	26	109	109	NUM
cuesj-1224	23	27	however	however	ADV
cuesj-1224	23	28	,	,	PUNCT
cuesj-1224	23	29	this	this	DET
cuesj-1224	23	30	measurement	measurement	NOUN
cuesj-1224	23	31	does	do	AUX
cuesj-1224	23	32	not	not	PART
cuesj-1224	23	33	provide	provide	VERB
cuesj-1224	23	34	information	information	NOUN
cuesj-1224	23	35	on	on	ADP
cuesj-1224	23	36	how	how	SCONJ
cuesj-1224	23	37	the	the	DET
cuesj-1224	23	38	treatment	treatment	NOUN
cuesj-1224	23	39	affects	affect	VERB
cuesj-1224	23	40	insulin	insulin	NOUN
cuesj-1224	23	41	secretion	secretion	NOUN
cuesj-1224	23	42	or	or	CCONJ
cuesj-1224	23	43	insulin	insulin	NOUN
cuesj-1224	23	44	resistance.[8	resistance.[8	NOUN
cuesj-1224	23	45	]	]	X
cuesj-1224	23	46	oral	oral	ADJ
cuesj-1224	23	47	hypoglycemic	hypoglycemic	ADJ
cuesj-1224	23	48	medications	medication	NOUN
cuesj-1224	23	49	come	come	VERB
cuesj-1224	23	50	in	in	ADP
cuesj-1224	23	51	a	a	DET
cuesj-1224	23	52	wide	wide	ADJ
cuesj-1224	23	53	variety	variety	NOUN
cuesj-1224	23	54	of	of	ADP
cuesj-1224	23	55	forms	form	NOUN
cuesj-1224	23	56	,	,	PUNCT
cuesj-1224	23	57	and	and	CCONJ
cuesj-1224	23	58	there	there	PRON
cuesj-1224	23	59	are	be	VERB
cuesj-1224	23	60	significant	significant	ADJ
cuesj-1224	23	61	variations	variation	NOUN
cuesj-1224	23	62	among	among	ADP
cuesj-1224	23	63	them	they	PRON
cuesj-1224	23	64	in	in	ADP
cuesj-1224	23	65	terms	term	NOUN
cuesj-1224	23	66	of	of	ADP
cuesj-1224	23	67	their	their	PRON
cuesj-1224	23	68	effects	effect	NOUN
cuesj-1224	23	69	and	and	CCONJ
cuesj-1224	23	70	price	price	NOUN
cuesj-1224	23	71	.	.	PUNCT
cuesj-1224	24	1	most	most	ADJ
cuesj-1224	24	2	patients	patient	NOUN
cuesj-1224	24	3	need	need	VERB
cuesj-1224	24	4	to	to	PART
cuesj-1224	24	5	choose	choose	VERB
cuesj-1224	24	6	medications	medication	NOUN
cuesj-1224	24	7	with	with	ADP
cuesj-1224	24	8	a	a	DET
cuesj-1224	24	9	curative	curative	ADJ
cuesj-1224	24	10	effect	effect	NOUN
cuesj-1224	24	11	and	and	CCONJ
cuesj-1224	24	12	at	at	ADP
cuesj-1224	24	13	a	a	DET
cuesj-1224	24	14	reasonable	reasonable	ADJ
cuesj-1224	24	15	cost	cost	NOUN
cuesj-1224	24	16	if	if	SCONJ
cuesj-1224	24	17	they	they	PRON
cuesj-1224	24	18	want	want	VERB
cuesj-1224	24	19	to	to	PART
cuesj-1224	24	20	take	take	VERB
cuesj-1224	24	21	them	they	PRON
cuesj-1224	24	22	for	for	ADP
cuesj-1224	24	23	a	a	DET
cuesj-1224	24	24	long	long	ADJ
cuesj-1224	24	25	time.[9	time.[9	NUM
cuesj-1224	24	26	]	]	PUNCT
cuesj-1224	24	27	metformin	metformin	NOUN
cuesj-1224	24	28	,	,	PUNCT
cuesj-1224	24	29	which	which	PRON
cuesj-1224	24	30	is	be	AUX
cuesj-1224	24	31	the	the	DET
cuesj-1224	24	32	first	first	ADJ
cuesj-1224	24	33	line	line	NOUN
cuesj-1224	24	34	and	and	CCONJ
cuesj-1224	24	35	primary	primary	ADJ
cuesj-1224	24	36	medication	medication	NOUN
cuesj-1224	24	37	used	use	VERB
cuesj-1224	24	38	in	in	ADP
cuesj-1224	24	39	the	the	DET
cuesj-1224	24	40	treatment	treatment	NOUN
cuesj-1224	24	41	of	of	ADP
cuesj-1224	24	42	type	type	NOUN
cuesj-1224	24	43	2	2	NUM
cuesj-1224	24	44	diabetes	diabetes	NOUN
cuesj-1224	24	45	,	,	PUNCT
cuesj-1224	24	46	is	be	AUX
cuesj-1224	24	47	a	a	DET
cuesj-1224	24	48	biguanide	biguanide	NOUN
cuesj-1224	24	49	insulin	insulin	NOUN
cuesj-1224	24	50	-	-	PUNCT
cuesj-1224	24	51	sensitizing	sensitize	VERB
cuesj-1224	24	52	agent	agent	NOUN
cuesj-1224	24	53	that	that	PRON
cuesj-1224	24	54	works	work	VERB
cuesj-1224	24	55	by	by	ADP
cuesj-1224	24	56	preventing	prevent	VERB
cuesj-1224	24	57	the	the	DET
cuesj-1224	24	58	production	production	NOUN
cuesj-1224	24	59	of	of	ADP
cuesj-1224	24	60	glucose	glucose	NOUN
cuesj-1224	24	61	in	in	ADP
cuesj-1224	24	62	the	the	DET
cuesj-1224	24	63	liver	liver	NOUN
cuesj-1224	24	64	,	,	PUNCT
cuesj-1224	24	65	improving	improve	VERB
cuesj-1224	24	66	insulin	insulin	NOUN
cuesj-1224	24	67	’s	’s	PART
cuesj-1224	24	68	effect	effect	NOUN
cuesj-1224	24	69	on	on	ADP
cuesj-1224	24	70	glucose	glucose	NOUN
cuesj-1224	24	71	uptake	uptake	NOUN
cuesj-1224	24	72	in	in	ADP
cuesj-1224	24	73	peripheral	peripheral	ADJ
cuesj-1224	24	74	tissues	tissue	NOUN
cuesj-1224	24	75	,	,	PUNCT
cuesj-1224	24	76	and	and	CCONJ
cuesj-1224	24	77	lowering	lower	VERB
cuesj-1224	24	78	the	the	DET
cuesj-1224	24	79	absorption	absorption	NOUN
cuesj-1224	24	80	of	of	ADP
cuesj-1224	24	81	glucose	glucose	NOUN
cuesj-1224	24	82	from	from	ADP
cuesj-1224	24	83	the	the	DET
cuesj-1224	24	84	intestine	intestine	NOUN
cuesj-1224	24	85	.	.	PUNCT
cuesj-1224	25	1	the	the	DET
cuesj-1224	25	2	decrease	decrease	NOUN
cuesj-1224	25	3	in	in	ADP
cuesj-1224	25	4	liver	liver	NOUN
cuesj-1224	25	5	energy	energy	NOUN
cuesj-1224	25	6	generation	generation	NOUN
cuesj-1224	25	7	triggers	trigger	VERB
cuesj-1224	25	8	adenosine	adenosine	NOUN
cuesj-1224	25	9	monophosphateactivated	monophosphateactivate	VERB
cuesj-1224	25	10	protein	protein	NOUN
cuesj-1224	25	11	kinase	kinase	NOUN
cuesj-1224	25	12	,	,	PUNCT
cuesj-1224	25	13	which	which	PRON
cuesj-1224	25	14	is	be	AUX
cuesj-1224	25	15	a	a	DET
cuesj-1224	25	16	cellular	cellular	ADJ
cuesj-1224	25	17	metabolic	metabolic	NOUN
cuesj-1224	25	18	sensor.[10	sensor.[10	NOUN
cuesj-1224	25	19	]	]	PUNCT
cuesj-1224	25	20	metformin	metformin	NOUN
cuesj-1224	25	21	is	be	AUX
cuesj-1224	25	22	effective	effective	ADJ
cuesj-1224	25	23	on	on	ADP
cuesj-1224	25	24	its	its	PRON
cuesj-1224	25	25	own	own	ADJ
cuesj-1224	25	26	and	and	CCONJ
cuesj-1224	25	27	also	also	ADV
cuesj-1224	25	28	when	when	SCONJ
cuesj-1224	25	29	used	use	VERB
cuesj-1224	25	30	in	in	ADP
cuesj-1224	25	31	conjunction	conjunction	NOUN
cuesj-1224	25	32	with	with	ADP
cuesj-1224	25	33	other	other	ADJ
cuesj-1224	25	34	medications	medication	NOUN
cuesj-1224	25	35	that	that	PRON
cuesj-1224	25	36	reduce	reduce	VERB
cuesj-1224	25	37	blood	blood	NOUN
cuesj-1224	25	38	glucose	glucose	NOUN
cuesj-1224	25	39	levels	level	NOUN
cuesj-1224	25	40	.	.	PUNCT
cuesj-1224	26	1	it	it	PRON
cuesj-1224	26	2	is	be	AUX
cuesj-1224	26	3	generally	generally	ADV
cuesj-1224	26	4	considered	consider	VERB
cuesj-1224	26	5	a	a	DET
cuesj-1224	26	6	first	first	ADJ
cuesj-1224	26	7	-	-	PUNCT
cuesj-1224	26	8	line	line	NOUN
cuesj-1224	26	9	treatment	treatment	NOUN
cuesj-1224	26	10	of	of	ADP
cuesj-1224	26	11	t2	t2	NOUN
cuesj-1224	26	12	dm	dm	PROPN
cuesj-1224	26	13	well	well	ADV
cuesj-1224	26	14	-	-	PUNCT
cuesj-1224	26	15	tolerated	tolerate	VERB
cuesj-1224	26	16	,	,	PUNCT
cuesj-1224	26	17	has	have	VERB
cuesj-1224	26	18	minimal	minimal	ADJ
cuesj-1224	26	19	adverse	adverse	ADJ
cuesj-1224	26	20	effects	effect	NOUN
cuesj-1224	26	21	,	,	PUNCT
cuesj-1224	26	22	and	and	CCONJ
cuesj-1224	26	23	is	be	AUX
cuesj-1224	26	24	inexpensive.[11	inexpensive.[11	PROPN
cuesj-1224	26	25	]	]	PUNCT
cuesj-1224	26	26	the	the	DET
cuesj-1224	26	27	incretin	incretin	ADJ
cuesj-1224	26	28	effect	effect	NOUN
cuesj-1224	26	29	is	be	AUX
cuesj-1224	26	30	explained	explain	VERB
cuesj-1224	26	31	by	by	ADP
cuesj-1224	26	32	hormones	hormone	NOUN
cuesj-1224	26	33	glucagonlike	glucagonlike	NOUN
cuesj-1224	26	34	peptide-1	peptide-1	PROPN
cuesj-1224	26	35	(	(	PUNCT
cuesj-1224	26	36	glp-1	glp-1	X
cuesj-1224	26	37	)	)	PUNCT
cuesj-1224	26	38	and	and	CCONJ
cuesj-1224	26	39	glucose	glucose	NOUN
cuesj-1224	26	40	-	-	PUNCT
cuesj-1224	26	41	dependent	dependent	ADJ
cuesj-1224	26	42	insulinotropic	insulinotropic	NOUN
cuesj-1224	26	43	polypeptide	polypeptide	ADJ
cuesj-1224	26	44	(	(	PUNCT
cuesj-1224	26	45	gip	gip	PROPN
cuesj-1224	26	46	)	)	PUNCT
cuesj-1224	26	47	,	,	PUNCT
cuesj-1224	26	48	both	both	PRON
cuesj-1224	26	49	of	of	ADP
cuesj-1224	26	50	which	which	PRON
cuesj-1224	26	51	are	be	AUX
cuesj-1224	26	52	produced	produce	VERB
cuesj-1224	26	53	in	in	ADP
cuesj-1224	26	54	the	the	DET
cuesj-1224	26	55	intestine	intestine	NOUN
cuesj-1224	26	56	.	.	PUNCT
cuesj-1224	27	1	this	this	DET
cuesj-1224	27	2	effect	effect	NOUN
cuesj-1224	27	3	produces	produce	VERB
cuesj-1224	27	4	a	a	DET
cuesj-1224	27	5	greater	great	ADJ
cuesj-1224	27	6	insulin	insulin	NOUN
cuesj-1224	27	7	secretory	secretory	ADJ
cuesj-1224	27	8	response	response	NOUN
cuesj-1224	27	9	when	when	SCONJ
cuesj-1224	27	10	glucose	glucose	NOUN
cuesj-1224	27	11	is	be	AUX
cuesj-1224	27	12	taken	take	VERB
cuesj-1224	27	13	orally	orally	ADV
cuesj-1224	27	14	compared	compare	VERB
cuesj-1224	27	15	to	to	ADP
cuesj-1224	27	16	when	when	SCONJ
cuesj-1224	27	17	it	it	PRON
cuesj-1224	27	18	is	be	AUX
cuesj-1224	27	19	administered	administer	VERB
cuesj-1224	27	20	intravenously	intravenously	ADV
cuesj-1224	27	21	to	to	PART
cuesj-1224	27	22	maintain	maintain	VERB
cuesj-1224	27	23	the	the	DET
cuesj-1224	27	24	same	same	ADJ
cuesj-1224	27	25	blood	blood	NOUN
cuesj-1224	27	26	sugar	sugar	NOUN
cuesj-1224	27	27	levels	level	NOUN
cuesj-1224	27	28	.	.	PUNCT
cuesj-1224	28	1	incretin	incretin	ADJ
cuesj-1224	28	2	action	action	NOUN
cuesj-1224	28	3	is	be	AUX
cuesj-1224	28	4	impaired	impair	VERB
cuesj-1224	28	5	in	in	ADP
cuesj-1224	28	6	type	type	NOUN
cuesj-1224	28	7	2	2	NUM
cuesj-1224	28	8	diabetic	diabetic	ADJ
cuesj-1224	28	9	patients	patient	NOUN
cuesj-1224	28	10	due	due	ADP
cuesj-1224	28	11	to	to	ADP
cuesj-1224	28	12	the	the	DET
cuesj-1224	28	13	lack	lack	NOUN
cuesj-1224	28	14	of	of	ADP
cuesj-1224	28	15	response	response	NOUN
cuesj-1224	28	16	of	of	ADP
cuesj-1224	28	17	diabetic	diabetic	ADJ
cuesj-1224	28	18	β	β	NOUN
cuesj-1224	28	19	-	-	NOUN
cuesj-1224	28	20	cells	cell	NOUN
cuesj-1224	28	21	to	to	ADP
cuesj-1224	28	22	gip.[12	gip.[12	NOUN
cuesj-1224	28	23	]	]	PUNCT
cuesj-1224	28	24	after	after	ADP
cuesj-1224	28	25	eating	eat	VERB
cuesj-1224	28	26	a	a	DET
cuesj-1224	28	27	meal	meal	NOUN
cuesj-1224	28	28	,	,	PUNCT
cuesj-1224	28	29	the	the	DET
cuesj-1224	28	30	incretin	incretin	ADJ
cuesj-1224	28	31	hormones	hormone	NOUN
cuesj-1224	28	32	that	that	PRON
cuesj-1224	28	33	are	be	AUX
cuesj-1224	28	34	released	release	VERB
cuesj-1224	28	35	from	from	ADP
cuesj-1224	28	36	the	the	DET
cuesj-1224	28	37	gut	gut	NOUN
cuesj-1224	28	38	encourage	encourage	VERB
cuesj-1224	28	39	the	the	DET
cuesj-1224	28	40	release	release	NOUN
cuesj-1224	28	41	of	of	ADP
cuesj-1224	28	42	insulin	insulin	NOUN
cuesj-1224	28	43	.	.	PUNCT
cuesj-1224	29	1	evidence	evidence	NOUN
cuesj-1224	29	2	shows	show	VERB
cuesj-1224	29	3	that	that	SCONJ
cuesj-1224	29	4	glp-1	glp-1	VERB
cuesj-1224	29	5	and	and	CCONJ
cuesj-1224	29	6	gip	gip	NOUN
cuesj-1224	29	7	are	be	AUX
cuesj-1224	29	8	the	the	DET
cuesj-1224	29	9	two	two	NUM
cuesj-1224	29	10	most	most	ADV
cuesj-1224	29	11	important	important	ADJ
cuesj-1224	29	12	incretins	incretin	NOUN
cuesj-1224	29	13	.	.	PUNCT
cuesj-1224	30	1	both	both	DET
cuesj-1224	30	2	hormones	hormone	NOUN
cuesj-1224	30	3	significantly	significantly	ADV
cuesj-1224	30	4	increase	increase	VERB
cuesj-1224	30	5	the	the	DET
cuesj-1224	30	6	release	release	NOUN
cuesj-1224	30	7	of	of	ADP
cuesj-1224	30	8	insulin	insulin	NOUN
cuesj-1224	30	9	.	.	PUNCT
cuesj-1224	31	1	the	the	DET
cuesj-1224	31	2	availability	availability	NOUN
cuesj-1224	31	3	of	of	ADP
cuesj-1224	31	4	endogenous	endogenous	ADJ
cuesj-1224	31	5	glp-1	glp-1	NOUN
cuesj-1224	31	6	is	be	AUX
cuesj-1224	31	7	increased	increase	VERB
cuesj-1224	31	8	by	by	ADP
cuesj-1224	31	9	oral	oral	ADJ
cuesj-1224	31	10	dipeptidyl	dipeptidyl	NOUN
cuesj-1224	31	11	peptidase-4	peptidase-4	X
cuesj-1224	31	12	(	(	PUNCT
cuesj-1224	31	13	dpp4	dpp4	PROPN
cuesj-1224	31	14	)	)	PUNCT
cuesj-1224	31	15	inhibitors	inhibitor	NOUN
cuesj-1224	31	16	,	,	PUNCT
cuesj-1224	31	17	which	which	PRON
cuesj-1224	31	18	improves	improve	VERB
cuesj-1224	31	19	glucose	glucose	NOUN
cuesj-1224	31	20	-	-	PUNCT
cuesj-1224	31	21	induced	induce	VERB
cuesj-1224	31	22	insulin	insulin	NOUN
cuesj-1224	31	23	secretion	secretion	NOUN
cuesj-1224	31	24	and	and	CCONJ
cuesj-1224	31	25	reduces	reduce	VERB
cuesj-1224	31	26	glucagon	glucagon	NOUN
cuesj-1224	31	27	release	release	NOUN
cuesj-1224	31	28	.	.	PUNCT
cuesj-1224	32	1	both	both	DET
cuesj-1224	32	2	body	body	NOUN
cuesj-1224	32	3	weight	weight	NOUN
cuesj-1224	32	4	and	and	CCONJ
cuesj-1224	32	5	stomach	stomach	NOUN
cuesj-1224	32	6	emptying	empty	VERB
cuesj-1224	32	7	are	be	AUX
cuesj-1224	32	8	unaffected	unaffected	ADJ
cuesj-1224	32	9	by	by	ADP
cuesj-1224	32	10	these	these	DET
cuesj-1224	32	11	substances.[13	substances.[13	PROPN
cuesj-1224	32	12	]	]	X
cuesj-1224	32	13	the	the	DET
cuesj-1224	32	14	first	first	ADJ
cuesj-1224	32	15	drugs	drug	NOUN
cuesj-1224	32	16	in	in	ADP
cuesj-1224	32	17	this	this	DET
cuesj-1224	32	18	class	class	NOUN
cuesj-1224	32	19	to	to	PART
cuesj-1224	32	20	get	get	VERB
cuesj-1224	32	21	food	food	NOUN
cuesj-1224	32	22	and	and	CCONJ
cuesj-1224	32	23	drug	drug	PROPN
cuesj-1224	32	24	administration	administration	PROPN
cuesj-1224	32	25	(	(	PUNCT
cuesj-1224	32	26	fda	fda	PROPN
cuesj-1224	32	27	)	)	PUNCT
cuesj-1224	32	28	approval	approval	NOUN
cuesj-1224	32	29	are	be	AUX
cuesj-1224	32	30	vildagliptin	vildagliptin	NOUN
cuesj-1224	32	31	and	and	CCONJ
cuesj-1224	32	32	sitagliptin	sitagliptin	NOUN
cuesj-1224	32	33	.	.	PUNCT
cuesj-1224	33	1	sitagliptin	sitagliptin	PROPN
cuesj-1224	33	2	achieves	achieve	VERB
cuesj-1224	33	3	its	its	PRON
cuesj-1224	33	4	antihyperglycemic	antihyperglycemic	ADJ
cuesj-1224	33	5	action	action	NOUN
cuesj-1224	33	6	by	by	ADP
cuesj-1224	33	7	reducing	reduce	VERB
cuesj-1224	33	8	the	the	DET
cuesj-1224	33	9	inactivation	inactivation	NOUN
cuesj-1224	33	10	of	of	ADP
cuesj-1224	33	11	incretin	incretin	ADJ
cuesj-1224	33	12	hormones	hormone	NOUN
cuesj-1224	33	13	.	.	PUNCT
cuesj-1224	34	1	sitagliptin	sitagliptin	NOUN
cuesj-1224	34	2	is	be	AUX
cuesj-1224	34	3	a	a	DET
cuesj-1224	34	4	potent	potent	ADJ
cuesj-1224	34	5	,	,	PUNCT
cuesj-1224	34	6	highly	highly	ADV
cuesj-1224	34	7	specific	specific	ADJ
cuesj-1224	34	8	,	,	PUNCT
cuesj-1224	34	9	reversible	reversible	ADJ
cuesj-1224	34	10	,	,	PUNCT
cuesj-1224	34	11	and	and	CCONJ
cuesj-1224	34	12	competitive	competitive	ADJ
cuesj-1224	34	13	inhibitor	inhibitor	NOUN
cuesj-1224	34	14	of	of	ADP
cuesj-1224	34	15	the	the	DET
cuesj-1224	34	16	dpp-4	dpp-4	ADJ
cuesj-1224	34	17	enzyme	enzyme	NOUN
cuesj-1224	34	18	.	.	PUNCT
cuesj-1224	35	1	sitagliptin	sitagliptin	NOUN
cuesj-1224	35	2	has	have	AUX
cuesj-1224	35	3	been	be	AUX
cuesj-1224	35	4	associated	associate	VERB
cuesj-1224	35	5	with	with	ADP
cuesj-1224	35	6	a	a	DET
cuesj-1224	35	7	twofold	twofold	NOUN
cuesj-1224	35	8	increase	increase	NOUN
cuesj-1224	35	9	in	in	ADP
cuesj-1224	35	10	postprandial	postprandial	ADJ
cuesj-1224	35	11	glp-1	glp-1	VERB
cuesj-1224	35	12	plasma	plasma	NOUN
cuesj-1224	35	13	levels	level	NOUN
cuesj-1224	35	14	in	in	ADP
cuesj-1224	35	15	both	both	CCONJ
cuesj-1224	35	16	healthy	healthy	ADJ
cuesj-1224	35	17	individuals	individual	NOUN
cuesj-1224	35	18	and	and	CCONJ
cuesj-1224	35	19	patients	patient	NOUN
cuesj-1224	35	20	with	with	ADP
cuesj-1224	35	21	t2	t2	PROPN
cuesj-1224	35	22	dm	dm	PROPN
cuesj-1224	35	23	compared	compare	VERB
cuesj-1224	35	24	to	to	ADP
cuesj-1224	35	25	a	a	DET
cuesj-1224	35	26	placebo.[14	placebo.[14	PROPN
cuesj-1224	35	27	]	]	PUNCT
cuesj-1224	35	28	sulfonylureas	sulfonylurea	NOUN
cuesj-1224	35	29	,	,	PUNCT
cuesj-1224	35	30	such	such	ADJ
cuesj-1224	35	31	as	as	ADP
cuesj-1224	35	32	glimepiride	glimepiride	NOUN
cuesj-1224	35	33	or	or	CCONJ
cuesj-1224	35	34	glipizide	glipizide	ADJ
cuesj-1224	35	35	,	,	PUNCT
cuesj-1224	35	36	either	either	CCONJ
cuesj-1224	35	37	alone	alone	ADJ
cuesj-1224	35	38	or	or	CCONJ
cuesj-1224	35	39	in	in	ADP
cuesj-1224	35	40	combination	combination	NOUN
cuesj-1224	35	41	with	with	ADP
cuesj-1224	35	42	metformin	metformin	NOUN
cuesj-1224	35	43	,	,	PUNCT
cuesj-1224	35	44	are	be	AUX
cuesj-1224	35	45	one	one	NUM
cuesj-1224	35	46	of	of	ADP
cuesj-1224	35	47	the	the	DET
cuesj-1224	35	48	oral	oral	ADJ
cuesj-1224	35	49	anti	anti	ADJ
cuesj-1224	35	50	-	-	ADJ
cuesj-1224	35	51	hyperglycemic	hyperglycemic	ADJ
cuesj-1224	35	52	agents	agent	NOUN
cuesj-1224	35	53	that	that	PRON
cuesj-1224	35	54	are	be	AUX
cuesj-1224	35	55	frequently	frequently	ADV
cuesj-1224	35	56	recommended	recommend	VERB
cuesj-1224	35	57	in	in	ADP
cuesj-1224	35	58	lowand	lowand	ADJ
cuesj-1224	35	59	middle	middle	ADJ
cuesj-1224	35	60	-	-	PUNCT
cuesj-1224	35	61	income	income	NOUN
cuesj-1224	35	62	nations	nation	NOUN
cuesj-1224	35	63	of	of	ADP
cuesj-1224	35	64	asia	asia	PROPN
cuesj-1224	35	65	and	and	CCONJ
cuesj-1224	35	66	africa	africa	PROPN
cuesj-1224	35	67	.	.	PUNCT
cuesj-1224	36	1	this	this	DET
cuesj-1224	36	2	family	family	NOUN
cuesj-1224	36	3	of	of	ADP
cuesj-1224	36	4	medications	medication	NOUN
cuesj-1224	36	5	lowers	lower	VERB
cuesj-1224	36	6	hyperglycemia	hyperglycemia	NOUN
cuesj-1224	36	7	and	and	CCONJ
cuesj-1224	36	8	glycated	glycate	VERB
cuesj-1224	36	9	hba1c	hba1c	PROPN
cuesj-1224	36	10	levels	level	NOUN
cuesj-1224	36	11	in	in	ADP
cuesj-1224	36	12	persons	person	NOUN
cuesj-1224	36	13	with	with	ADP
cuesj-1224	36	14	t2	t2	NOUN
cuesj-1224	36	15	dm	dm	NUM
cuesj-1224	36	16	by	by	ADP
cuesj-1224	36	17	increasing	increase	VERB
cuesj-1224	36	18	the	the	DET
cuesj-1224	36	19	release	release	NOUN
cuesj-1224	36	20	of	of	ADP
cuesj-1224	36	21	insulin	insulin	NOUN
cuesj-1224	36	22	from	from	ADP
cuesj-1224	36	23	beta	beta	NOUN
cuesj-1224	36	24	cells.[15	cells.[15	PROPN
cuesj-1224	36	25	]	]	PUNCT
cuesj-1224	36	26	this	this	DET
cuesj-1224	36	27	study	study	NOUN
cuesj-1224	36	28	aimed	aim	VERB
cuesj-1224	36	29	to	to	PART
cuesj-1224	36	30	examine	examine	VERB
cuesj-1224	36	31	the	the	DET
cuesj-1224	36	32	impact	impact	NOUN
cuesj-1224	36	33	of	of	ADP
cuesj-1224	36	34	a	a	DET
cuesj-1224	36	35	variety	variety	NOUN
cuesj-1224	36	36	of	of	ADP
cuesj-1224	36	37	antidiabetic	antidiabetic	ADJ
cuesj-1224	36	38	medications	medication	NOUN
cuesj-1224	36	39	(	(	PUNCT
cuesj-1224	36	40	metformin	metformin	NOUN
cuesj-1224	36	41	,	,	PUNCT
cuesj-1224	36	42	glimepiride	glimepiride	NOUN
cuesj-1224	36	43	,	,	PUNCT
cuesj-1224	36	44	and	and	CCONJ
cuesj-1224	36	45	sitagliptin	sitagliptin	NOUN
cuesj-1224	36	46	)	)	PUNCT
cuesj-1224	36	47	on	on	ADP
cuesj-1224	36	48	the	the	DET
cuesj-1224	36	49	serum	serum	NOUN
cuesj-1224	36	50	levels	level	NOUN
cuesj-1224	36	51	of	of	ADP
cuesj-1224	36	52	hba1c	hba1c	PROPN
cuesj-1224	36	53	and	and	CCONJ
cuesj-1224	36	54	other	other	ADJ
cuesj-1224	36	55	specific	specific	ADJ
cuesj-1224	36	56	analytical	analytical	ADJ
cuesj-1224	36	57	parameters	parameter	NOUN
cuesj-1224	36	58	.	.	PUNCT
cuesj-1224	37	1	methodology	methodology	NOUN
cuesj-1224	37	2	study	study	NOUN
cuesj-1224	37	3	design	design	VERB
cuesj-1224	37	4	a	a	DET
cuesj-1224	37	5	cross	cross	ADJ
cuesj-1224	37	6	-	-	ADJ
cuesj-1224	37	7	sectional	sectional	ADJ
cuesj-1224	37	8	prospective	prospective	ADJ
cuesj-1224	37	9	study	study	NOUN
cuesj-1224	37	10	was	be	AUX
cuesj-1224	37	11	performed	perform	VERB
cuesj-1224	37	12	at	at	ADP
cuesj-1224	37	13	the	the	DET
cuesj-1224	37	14	diabetes	diabetes	NOUN
cuesj-1224	37	15	center	center	NOUN
cuesj-1224	37	16	of	of	ADP
cuesj-1224	37	17	layla	layla	PROPN
cuesj-1224	37	18	qasim	qasim	PROPN
cuesj-1224	37	19	/	/	SYM
cuesj-1224	37	20	erbil	erbil	PROPN
cuesj-1224	37	21	/	/	SYM
cuesj-1224	37	22	iraq	iraq	PROPN
cuesj-1224	37	23	to	to	PART
cuesj-1224	37	24	compare	compare	VERB
cuesj-1224	37	25	the	the	DET
cuesj-1224	37	26	safety	safety	NOUN
cuesj-1224	37	27	profile	profile	NOUN
cuesj-1224	37	28	and	and	CCONJ
cuesj-1224	37	29	efficacy	efficacy	NOUN
cuesj-1224	37	30	of	of	ADP
cuesj-1224	37	31	sitagliptin	sitagliptin	NOUN
cuesj-1224	37	32	,	,	PUNCT
cuesj-1224	37	33	glimepiride	glimepiride	NOUN
cuesj-1224	37	34	,	,	PUNCT
cuesj-1224	37	35	and	and	CCONJ
cuesj-1224	37	36	metformin	metformin	NOUN
cuesj-1224	37	37	among	among	ADP
cuesj-1224	37	38	individuals	individual	NOUN
cuesj-1224	37	39	suffering	suffer	VERB
cuesj-1224	37	40	from	from	ADP
cuesj-1224	37	41	t2	t2	NOUN
cuesj-1224	37	42	dm	dm	PROPN
cuesj-1224	37	43	.	.	PUNCT
cuesj-1224	38	1	the	the	DET
cuesj-1224	38	2	study	study	NOUN
cuesj-1224	38	3	was	be	AUX
cuesj-1224	38	4	approved	approve	VERB
cuesj-1224	38	5	by	by	ADP
cuesj-1224	38	6	hawler	hawler	PROPN
cuesj-1224	38	7	medical	medical	PROPN
cuesj-1224	38	8	university	university	PROPN
cuesj-1224	38	9	,	,	PUNCT
cuesj-1224	38	10	ethics	ethic	NOUN
cuesj-1224	38	11	committee	committee	PROPN
cuesj-1224	38	12	college	college	PROPN
cuesj-1224	38	13	of	of	ADP
cuesj-1224	38	14	pharmacy	pharmacy	NOUN
cuesj-1224	38	15	.	.	PUNCT
cuesj-1224	39	1	in	in	ADP
cuesj-1224	39	2	this	this	DET
cuesj-1224	39	3	study	study	NOUN
cuesj-1224	39	4	,	,	PUNCT
cuesj-1224	39	5	patients	patient	NOUN
cuesj-1224	39	6	who	who	PRON
cuesj-1224	39	7	were	be	AUX
cuesj-1224	39	8	taking	take	VERB
cuesj-1224	39	9	metformin	metformin	NOUN
cuesj-1224	39	10	500	500	NUM
cuesj-1224	39	11	mg	mg	PROPN
cuesj-1224	39	12	,	,	PUNCT
cuesj-1224	39	13	sitagliptin	sitagliptin	VERB
cuesj-1224	39	14	100	100	NUM
cuesj-1224	39	15	mg	mg	NOUN
cuesj-1224	39	16	,	,	PUNCT
cuesj-1224	39	17	and	and	CCONJ
cuesj-1224	39	18	glimepiride	glimepiride	NOUN
cuesj-1224	39	19	2	2	NUM
cuesj-1224	39	20	mg	mg	NOUN
cuesj-1224	39	21	in	in	ADP
cuesj-1224	39	22	fixed	fix	VERB
cuesj-1224	39	23	dosage	dosage	NOUN
cuesj-1224	39	24	forms	form	NOUN
cuesj-1224	39	25	as	as	SCONJ
cuesj-1224	39	26	monotherapies	monotherapie	NOUN
cuesj-1224	39	27	were	be	AUX
cuesj-1224	39	28	recruited	recruit	VERB
cuesj-1224	39	29	and	and	CCONJ
cuesj-1224	39	30	divided	divide	VERB
cuesj-1224	39	31	into	into	ADP
cuesj-1224	39	32	three	three	NUM
cuesj-1224	39	33	treatment	treatment	NOUN
cuesj-1224	39	34	groups	group	NOUN
cuesj-1224	39	35	.	.	PUNCT
cuesj-1224	40	1	the	the	DET
cuesj-1224	40	2	duration	duration	NOUN
cuesj-1224	40	3	of	of	ADP
cuesj-1224	40	4	treatment	treatment	NOUN
cuesj-1224	40	5	varied	varied	ADJ
cuesj-1224	40	6	for	for	ADP
cuesj-1224	40	7	each	each	DET
cuesj-1224	40	8	patient	patient	NOUN
cuesj-1224	40	9	ranging	range	VERB
cuesj-1224	40	10	from	from	ADP
cuesj-1224	40	11	3	3	NUM
cuesj-1224	40	12	months	month	NOUN
cuesj-1224	40	13	to	to	ADP
cuesj-1224	40	14	1	1	NUM
cuesj-1224	40	15	year	year	NOUN
cuesj-1224	40	16	.	.	PUNCT
cuesj-1224	41	1	in	in	ADP
cuesj-1224	41	2	this	this	DET
cuesj-1224	41	3	study	study	NOUN
cuesj-1224	41	4	,	,	PUNCT
cuesj-1224	41	5	the	the	DET
cuesj-1224	41	6	medonic	medonic	ADJ
cuesj-1224	41	7	hematology	hematology	NOUN
cuesj-1224	41	8	analyzer	analyzer	NOUN
cuesj-1224	41	9	was	be	AUX
cuesj-1224	41	10	used	use	VERB
cuesj-1224	41	11	for	for	ADP
cuesj-1224	41	12	hemoglobin	hemoglobin	NOUN
cuesj-1224	41	13	measurement	measurement	NOUN
cuesj-1224	41	14	,	,	PUNCT
cuesj-1224	41	15	along	along	ADP
cuesj-1224	41	16	with	with	ADP
cuesj-1224	41	17	the	the	DET
cuesj-1224	41	18	lyse	lyse	NOUN
cuesj-1224	41	19	reagent	reagent	NOUN
cuesj-1224	41	20	.	.	PUNCT
cuesj-1224	42	1	for	for	ADP
cuesj-1224	42	2	the	the	DET
cuesj-1224	42	3	tests	test	NOUN
cuesj-1224	42	4	of	of	ADP
cuesj-1224	42	5	hba1c	hba1c	PROPN
cuesj-1224	42	6	,	,	PUNCT
cuesj-1224	42	7	fasting	fast	VERB
cuesj-1224	42	8	blood	blood	NOUN
cuesj-1224	42	9	sugar	sugar	NOUN
cuesj-1224	42	10	(	(	PUNCT
cuesj-1224	42	11	fbs	fbs	PROPN
cuesj-1224	42	12	)	)	PUNCT
cuesj-1224	42	13	,	,	PUNCT
cuesj-1224	42	14	lipid	lipid	NOUN
cuesj-1224	42	15	profile	profile	NOUN
cuesj-1224	42	16	,	,	PUNCT
cuesj-1224	42	17	kidney	kidney	NOUN
cuesj-1224	42	18	function	function	NOUN
cuesj-1224	42	19	,	,	PUNCT
cuesj-1224	42	20	and	and	CCONJ
cuesj-1224	42	21	bilirubin	bilirubin	NOUN
cuesj-1224	42	22	,	,	PUNCT
cuesj-1224	42	23	cobas	cobas	NUM
cuesj-1224	42	24	®	®	NOUN
cuesj-1224	42	25	c	c	PROPN
cuesj-1224	42	26	111	111	NUM
cuesj-1224	42	27	analyzer	analyzer	NOUN
cuesj-1224	42	28	was	be	AUX
cuesj-1224	42	29	used	use	VERB
cuesj-1224	42	30	,	,	PUNCT
cuesj-1224	42	31	conducted	conduct	VERB
cuesj-1224	42	32	using	use	VERB
cuesj-1224	42	33	the	the	DET
cuesj-1224	42	34	corresponding	correspond	VERB
cuesj-1224	42	35	test	test	NOUN
cuesj-1224	42	36	kits	kit	NOUN
cuesj-1224	42	37	designed	design	VERB
cuesj-1224	42	38	for	for	ADP
cuesj-1224	42	39	each	each	PRON
cuesj-1224	42	40	of	of	ADP
cuesj-1224	42	41	these	these	DET
cuesj-1224	42	42	tests	test	NOUN
cuesj-1224	42	43	for	for	ADP
cuesj-1224	42	44	the	the	DET
cuesj-1224	42	45	cobas	cobas	ADJ
cuesj-1224	42	46	®	®	NOUN
cuesj-1224	42	47	system	system	NOUN
cuesj-1224	42	48	.	.	PUNCT
cuesj-1224	43	1	study	study	NOUN
cuesj-1224	43	2	setting	set	VERB
cuesj-1224	43	3	the	the	DET
cuesj-1224	43	4	patients	patient	NOUN
cuesj-1224	43	5	were	be	AUX
cuesj-1224	43	6	recruited	recruit	VERB
cuesj-1224	43	7	from	from	ADP
cuesj-1224	43	8	the	the	DET
cuesj-1224	43	9	diabetic	diabetic	ADJ
cuesj-1224	43	10	center	center	NOUN
cuesj-1224	43	11	of	of	ADP
cuesj-1224	43	12	layla	layla	PROPN
cuesj-1224	43	13	qasim	qasim	PROPN
cuesj-1224	43	14	in	in	ADP
cuesj-1224	43	15	the	the	DET
cuesj-1224	43	16	city	city	NOUN
cuesj-1224	43	17	of	of	ADP
cuesj-1224	43	18	erbil	erbil	PROPN
cuesj-1224	43	19	in	in	ADP
cuesj-1224	43	20	the	the	DET
cuesj-1224	43	21	kurdistan	kurdistan	ADJ
cuesj-1224	43	22	region	region	NOUN
cuesj-1224	43	23	of	of	ADP
cuesj-1224	43	24	iraq	iraq	PROPN
cuesj-1224	43	25	from	from	ADP
cuesj-1224	43	26	november	november	PROPN
cuesj-1224	43	27	2022	2022	NUM
cuesj-1224	43	28	to	to	ADP
cuesj-1224	43	29	february	february	PROPN
cuesj-1224	43	30	2023	2023	NUM
cuesj-1224	43	31	.	.	PUNCT
cuesj-1224	44	1	study	study	NOUN
cuesj-1224	44	2	population	population	NOUN
cuesj-1224	44	3	eligible	eligible	ADJ
cuesj-1224	44	4	individuals	individual	NOUN
cuesj-1224	44	5	included	include	VERB
cuesj-1224	44	6	both	both	DET
cuesj-1224	44	7	sexes	sex	NOUN
cuesj-1224	44	8	,	,	PUNCT
cuesj-1224	44	9	regardless	regardless	ADV
cuesj-1224	44	10	of	of	ADP
cuesj-1224	44	11	age	age	NOUN
cuesj-1224	44	12	,	,	PUNCT
cuesj-1224	44	13	with	with	ADP
cuesj-1224	44	14	different	different	ADJ
cuesj-1224	44	15	anti	anti	ADJ
cuesj-1224	44	16	-	-	ADJ
cuesj-1224	44	17	diabetic	diabetic	ADJ
cuesj-1224	44	18	pharmacological	pharmacological	NOUN
cuesj-1224	44	19	modalities	modality	NOUN
cuesj-1224	44	20	taken	take	VERB
cuesj-1224	44	21	as	as	ADP
cuesj-1224	44	22	monotherapy	monotherapy	NOUN
cuesj-1224	44	23	.	.	PUNCT
cuesj-1224	45	1	patients	patient	NOUN
cuesj-1224	45	2	with	with	ADP
cuesj-1224	45	3	a	a	DET
cuesj-1224	45	4	history	history	NOUN
cuesj-1224	45	5	of	of	ADP
cuesj-1224	45	6	connective	connective	ADJ
cuesj-1224	45	7	tissue	tissue	NOUN
cuesj-1224	45	8	disease	disease	NOUN
cuesj-1224	45	9	,	,	PUNCT
cuesj-1224	45	10	terminal	terminal	ADJ
cuesj-1224	45	11	illness	illness	NOUN
cuesj-1224	45	12	,	,	PUNCT
cuesj-1224	45	13	liver	liver	NOUN
cuesj-1224	45	14	disease	disease	NOUN
cuesj-1224	45	15	,	,	PUNCT
cuesj-1224	45	16	kidney	kidney	NOUN
cuesj-1224	45	17	disease	disease	NOUN
cuesj-1224	45	18	,	,	PUNCT
cuesj-1224	45	19	or	or	CCONJ
cuesj-1224	45	20	pregnancy	pregnancy	NOUN
cuesj-1224	45	21	were	be	AUX
cuesj-1224	45	22	excluded	exclude	VERB
cuesj-1224	45	23	from	from	ADP
cuesj-1224	45	24	the	the	DET
cuesj-1224	45	25	study	study	NOUN
cuesj-1224	45	26	.	.	PUNCT
cuesj-1224	46	1	a	a	DET
cuesj-1224	46	2	total	total	ADJ
cuesj-1224	46	3	number	number	NOUN
cuesj-1224	46	4	of	of	ADP
cuesj-1224	46	5	143	143	NUM
cuesj-1224	46	6	patients	patient	NOUN
cuesj-1224	46	7	with	with	ADP
cuesj-1224	46	8	diabetes	diabetes	NOUN
cuesj-1224	46	9	were	be	AUX
cuesj-1224	46	10	included	include	VERB
cuesj-1224	46	11	in	in	ADP
cuesj-1224	46	12	this	this	DET
cuesj-1224	46	13	study	study	NOUN
cuesj-1224	46	14	.	.	PUNCT
cuesj-1224	47	1	statistical	statistical	ADJ
cuesj-1224	47	2	analysis	analysis	NOUN
cuesj-1224	47	3	statistical	statistical	ADJ
cuesj-1224	47	4	package	package	NOUN
cuesj-1224	47	5	for	for	ADP
cuesj-1224	47	6	the	the	DET
cuesj-1224	47	7	social	social	ADJ
cuesj-1224	47	8	sciences	sciences	PROPN
cuesj-1224	47	9	version	version	NOUN
cuesj-1224	47	10	23	23	NUM
cuesj-1224	47	11	was	be	AUX
cuesj-1224	47	12	used	use	VERB
cuesj-1224	47	13	in	in	ADP
cuesj-1224	47	14	conjunction	conjunction	NOUN
cuesj-1224	47	15	with	with	ADP
cuesj-1224	47	16	microsoft	microsoft	PROPN
cuesj-1224	47	17	excel	excel	VERB
cuesj-1224	47	18	2010	2010	NUM
cuesj-1224	47	19	to	to	PART
cuesj-1224	47	20	conduct	conduct	VERB
cuesj-1224	47	21	table	table	NOUN
cuesj-1224	47	22	1	1	NUM
cuesj-1224	47	23	:	:	PUNCT
cuesj-1224	47	24	baseline	baseline	NOUN
cuesj-1224	47	25	traits	trait	NOUN
cuesj-1224	47	26	of	of	ADP
cuesj-1224	47	27	study	study	NOUN
cuesj-1224	47	28	participants	participant	NOUN
cuesj-1224	47	29	variable	variable	ADJ
cuesj-1224	47	30	frequency	frequency	NOUN
cuesj-1224	47	31	percentage	percentage	NOUN
cuesj-1224	47	32	gender	gender	NOUN
cuesj-1224	47	33	female	female	NOUN
cuesj-1224	47	34	83	83	NUM
cuesj-1224	47	35	58	58	NUM
cuesj-1224	47	36	male	male	NOUN
cuesj-1224	47	37	60	60	NUM
cuesj-1224	47	38	42	42	NUM
cuesj-1224	47	39	education	education	NOUN
cuesj-1224	47	40	primary	primary	ADJ
cuesj-1224	47	41	school	school	NOUN
cuesj-1224	47	42	18	18	NUM
cuesj-1224	47	43	12.6	12.6	NUM
cuesj-1224	47	44	high	high	ADJ
cuesj-1224	47	45	school	school	NOUN
cuesj-1224	47	46	32	32	NUM
cuesj-1224	47	47	22.4	22.4	NUM
cuesj-1224	47	48	university	university	NOUN
cuesj-1224	47	49	13	13	NUM
cuesj-1224	47	50	9.1	9.1	NUM
cuesj-1224	47	51	illiterate	illiterate	ADJ
cuesj-1224	47	52	80	80	NUM
cuesj-1224	47	53	55.9	55.9	NUM
cuesj-1224	47	54	smoker	smoker	ADV
cuesj-1224	48	1	yes	yes	INTJ
cuesj-1224	48	2	66	66	NUM
cuesj-1224	48	3	46.2	46.2	NUM
cuesj-1224	49	1	no	no	DET
cuesj-1224	49	2	77	77	NUM
cuesj-1224	49	3	53.8	53.8	NUM
cuesj-1224	49	4	exercise	exercise	NOUN
cuesj-1224	49	5	yes	yes	INTJ
cuesj-1224	49	6	73	73	NUM
cuesj-1224	49	7	51	51	NUM
cuesj-1224	49	8	no	no	DET
cuesj-1224	49	9	70	70	NUM
cuesj-1224	49	10	49	49	NUM
cuesj-1224	49	11	yassen	yassen	NOUN
cuesj-1224	49	12	,	,	PUNCT
cuesj-1224	49	13	et	et	PROPN
cuesj-1224	49	14	al	al	PROPN
cuesj-1224	49	15	.	.	PUNCT
cuesj-1224	49	16	:	:	PUNCT
cuesj-1224	50	1	efficacy	efficacy	NOUN
cuesj-1224	50	2	and	and	CCONJ
cuesj-1224	50	3	safety	safety	NOUN
cuesj-1224	50	4	of	of	ADP
cuesj-1224	50	5	metformin	metformin	PROPN
cuesj-1224	50	6	,	,	PUNCT
cuesj-1224	50	7	sitagliptin	sitagliptin	NOUN
cuesj-1224	50	8	,	,	PUNCT
cuesj-1224	50	9	and	and	CCONJ
cuesj-1224	50	10	glimepiride	glimepiride	NOUN
cuesj-1224	50	11	in	in	ADP
cuesj-1224	50	12	type	type	NOUN
cuesj-1224	50	13	2	2	NUM
cuesj-1224	50	14	diabetes	diabetes	NOUN
cuesj-1224	50	15	106	106	NUM
cuesj-1224	50	16	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	50	17	cuesj	cuesj	ADJ
cuesj-1224	50	18	2024	2024	NUM
cuesj-1224	50	19	,	,	PUNCT
cuesj-1224	50	20	8	8	NUM
cuesj-1224	50	21	(	(	PUNCT
cuesj-1224	50	22	2	2	NUM
cuesj-1224	50	23	):	):	PUNCT
cuesj-1224	50	24	104	104	NUM
cuesj-1224	50	25	-	-	SYM
cuesj-1224	50	26	109	109	NUM
cuesj-1224	50	27	the	the	DET
cuesj-1224	50	28	statistical	statistical	ADJ
cuesj-1224	50	29	study	study	NOUN
cuesj-1224	50	30	.	.	PUNCT
cuesj-1224	51	1	the	the	DET
cuesj-1224	51	2	mean	mean	ADJ
cuesj-1224	51	3	and	and	CCONJ
cuesj-1224	51	4	standard	standard	ADJ
cuesj-1224	51	5	deviation	deviation	NOUN
cuesj-1224	51	6	were	be	AUX
cuesj-1224	51	7	used	use	VERB
cuesj-1224	51	8	to	to	PART
cuesj-1224	51	9	characterize	characterize	VERB
cuesj-1224	51	10	the	the	DET
cuesj-1224	51	11	quantitative	quantitative	ADJ
cuesj-1224	51	12	data	datum	NOUN
cuesj-1224	51	13	.	.	PUNCT
cuesj-1224	52	1	one	one	NUM
cuesj-1224	52	2	-	-	PUNCT
cuesj-1224	52	3	way	way	NOUN
cuesj-1224	52	4	analysis	analysis	NOUN
cuesj-1224	52	5	of	of	ADP
cuesj-1224	52	6	variance	variance	NOUN
cuesj-1224	52	7	was	be	AUX
cuesj-1224	52	8	used	use	VERB
cuesj-1224	52	9	to	to	PART
cuesj-1224	52	10	determine	determine	VERB
cuesj-1224	52	11	the	the	DET
cuesj-1224	52	12	statistical	statistical	ADJ
cuesj-1224	52	13	significance	significance	NOUN
cuesj-1224	52	14	of	of	ADP
cuesj-1224	52	15	the	the	DET
cuesj-1224	52	16	differences	difference	NOUN
cuesj-1224	52	17	between	between	ADP
cuesj-1224	52	18	the	the	DET
cuesj-1224	52	19	three	three	NUM
cuesj-1224	52	20	groups	group	NOUN
cuesj-1224	52	21	,	,	PUNCT
cuesj-1224	52	22	and	and	CCONJ
cuesj-1224	52	23	a	a	DET
cuesj-1224	52	24	descriptive	descriptive	ADJ
cuesj-1224	52	25	statistic	statistic	NOUN
cuesj-1224	52	26	was	be	AUX
cuesj-1224	52	27	deemed	deem	VERB
cuesj-1224	52	28	significant	significant	ADJ
cuesj-1224	52	29	at	at	ADP
cuesj-1224	52	30	p	p	NOUN
cuesj-1224	52	31	≤	≤	NUM
cuesj-1224	52	32	0.05	0.05	NUM
cuesj-1224	52	33	.	.	PUNCT
cuesj-1224	53	1	results	result	VERB
cuesj-1224	53	2	the	the	DET
cuesj-1224	53	3	age	age	NOUN
cuesj-1224	53	4	of	of	ADP
cuesj-1224	53	5	studied	study	VERB
cuesj-1224	53	6	subjects	subject	NOUN
cuesj-1224	53	7	ranged	range	VERB
cuesj-1224	53	8	between	between	ADP
cuesj-1224	53	9	ages	age	NOUN
cuesj-1224	53	10	30	30	NUM
cuesj-1224	53	11	and	and	CCONJ
cuesj-1224	53	12	78	78	NUM
cuesj-1224	53	13	,	,	PUNCT
cuesj-1224	53	14	in	in	ADP
cuesj-1224	53	15	a	a	DET
cuesj-1224	53	16	gender	gender	NOUN
cuesj-1224	53	17	ratio	ratio	NOUN
cuesj-1224	53	18	of	of	ADP
cuesj-1224	53	19	(	(	PUNCT
cuesj-1224	53	20	83:60	83:60	NUM
cuesj-1224	53	21	)	)	PUNCT
cuesj-1224	53	22	female	female	NOUN
cuesj-1224	53	23	to	to	ADP
cuesj-1224	53	24	male	male	NOUN
cuesj-1224	53	25	.	.	PUNCT
cuesj-1224	54	1	the	the	DET
cuesj-1224	54	2	majority	majority	NOUN
cuesj-1224	54	3	of	of	ADP
cuesj-1224	54	4	the	the	DET
cuesj-1224	54	5	patients	patient	NOUN
cuesj-1224	54	6	in	in	ADP
cuesj-1224	54	7	the	the	DET
cuesj-1224	54	8	study	study	NOUN
cuesj-1224	54	9	were	be	AUX
cuesj-1224	54	10	illiterate	illiterate	ADJ
cuesj-1224	54	11	,	,	PUNCT
cuesj-1224	54	12	in	in	ADP
cuesj-1224	54	13	an	an	DET
cuesj-1224	54	14	illiterate	illiterate	ADJ
cuesj-1224	54	15	to	to	PART
cuesj-1224	54	16	literate	literate	ADJ
cuesj-1224	54	17	ratio	ratio	NOUN
cuesj-1224	54	18	of	of	ADP
cuesj-1224	54	19	(	(	PUNCT
cuesj-1224	54	20	80:63	80:63	NUM
cuesj-1224	54	21	)	)	PUNCT
cuesj-1224	54	22	.	.	PUNCT
cuesj-1224	55	1	the	the	DET
cuesj-1224	55	2	majority	majority	NOUN
cuesj-1224	55	3	of	of	ADP
cuesj-1224	55	4	the	the	DET
cuesj-1224	55	5	patients	patient	NOUN
cuesj-1224	55	6	were	be	AUX
cuesj-1224	55	7	non	non	NOUN
cuesj-1224	55	8	-	-	NOUN
cuesj-1224	55	9	smokers	smoker	NOUN
cuesj-1224	55	10	in	in	ADP
cuesj-1224	55	11	a	a	DET
cuesj-1224	55	12	ratio	ratio	NOUN
cuesj-1224	55	13	of	of	ADP
cuesj-1224	55	14	(	(	PUNCT
cuesj-1224	55	15	77:66	77:66	NUM
cuesj-1224	55	16	)	)	PUNCT
cuesj-1224	55	17	non	non	ADJ
cuesj-1224	55	18	-	-	ADJ
cuesj-1224	55	19	smoker	smoker	ADJ
cuesj-1224	55	20	to	to	PART
cuesj-1224	55	21	smoker	smoker	ADV
cuesj-1224	55	22	presented	present	VERB
cuesj-1224	55	23	in	in	ADP
cuesj-1224	55	24	table	table	NOUN
cuesj-1224	55	25	1	1	NUM
cuesj-1224	55	26	.	.	PUNCT
cuesj-1224	56	1	in	in	ADP
cuesj-1224	56	2	table	table	NOUN
cuesj-1224	56	3	2	2	NUM
cuesj-1224	56	4	biochemical	biochemical	ADJ
cuesj-1224	56	5	analysis	analysis	NOUN
cuesj-1224	56	6	has	have	AUX
cuesj-1224	56	7	shown	show	VERB
cuesj-1224	56	8	statistically	statistically	ADV
cuesj-1224	56	9	significant	significant	ADJ
cuesj-1224	56	10	differences	difference	NOUN
cuesj-1224	56	11	between	between	ADP
cuesj-1224	56	12	the	the	DET
cuesj-1224	56	13	treatment	treatment	NOUN
cuesj-1224	56	14	groups	group	NOUN
cuesj-1224	56	15	in	in	ADP
cuesj-1224	56	16	terms	term	NOUN
cuesj-1224	56	17	of	of	ADP
cuesj-1224	56	18	hba1c	hba1c	PROPN
cuesj-1224	56	19	,	,	PUNCT
cuesj-1224	56	20	total	total	ADJ
cuesj-1224	56	21	cholesterol	cholesterol	NOUN
cuesj-1224	56	22	(	(	PUNCT
cuesj-1224	56	23	tc	tc	NOUN
cuesj-1224	56	24	)	)	PUNCT
cuesj-1224	56	25	,	,	PUNCT
cuesj-1224	56	26	and	and	CCONJ
cuesj-1224	56	27	low	low	ADJ
cuesj-1224	56	28	-	-	PUNCT
cuesj-1224	56	29	density	density	NOUN
cuesj-1224	56	30	lipoprotein	lipoprotein	ADJ
cuesj-1224	56	31	(	(	PUNCT
cuesj-1224	56	32	ldl	ldl	NOUN
cuesj-1224	56	33	)	)	PUNCT
cuesj-1224	56	34	,	,	PUNCT
cuesj-1224	56	35	with	with	ADP
cuesj-1224	56	36	the	the	DET
cuesj-1224	56	37	group	group	NOUN
cuesj-1224	56	38	ii	ii	PROPN
cuesj-1224	56	39	(	(	PUNCT
cuesj-1224	56	40	glimepiride	glimepiride	NOUN
cuesj-1224	56	41	)	)	PUNCT
cuesj-1224	56	42	recording	recording	NOUN
cuesj-1224	56	43	the	the	DET
cuesj-1224	56	44	lowest	low	ADJ
cuesj-1224	56	45	hba1c	hba1c	ADJ
cuesj-1224	56	46	level	level	NOUN
cuesj-1224	56	47	(	(	PUNCT
cuesj-1224	56	48	6.35	6.35	NUM
cuesj-1224	56	49	)	)	PUNCT
cuesj-1224	56	50	,	,	PUNCT
cuesj-1224	56	51	and	and	CCONJ
cuesj-1224	56	52	group	group	NOUN
cuesj-1224	56	53	i	i	PRON
cuesj-1224	56	54	(	(	PUNCT
cuesj-1224	56	55	metformin	metformin	PROPN
cuesj-1224	56	56	)	)	PUNCT
cuesj-1224	56	57	the	the	DET
cuesj-1224	56	58	lowest	low	ADJ
cuesj-1224	56	59	triglycerides	triglyceride	NOUN
cuesj-1224	56	60	(	(	PUNCT
cuesj-1224	56	61	tg	tg	X
cuesj-1224	56	62	)	)	PUNCT
cuesj-1224	56	63	(	(	PUNCT
cuesj-1224	56	64	167	167	NUM
cuesj-1224	56	65	)	)	PUNCT
cuesj-1224	56	66	and	and	CCONJ
cuesj-1224	56	67	ldl	ldl	NOUN
cuesj-1224	56	68	(	(	PUNCT
cuesj-1224	56	69	126.5	126.5	NUM
cuesj-1224	56	70	)	)	PUNCT
cuesj-1224	56	71	levels	level	NOUN
cuesj-1224	56	72	among	among	ADP
cuesj-1224	56	73	the	the	DET
cuesj-1224	56	74	three	three	NUM
cuesj-1224	56	75	treatment	treatment	NOUN
cuesj-1224	56	76	groups	group	NOUN
cuesj-1224	56	77	.	.	PUNCT
cuesj-1224	57	1	table	table	NOUN
cuesj-1224	57	2	3	3	NUM
cuesj-1224	57	3	shows	show	NOUN
cuesj-1224	57	4	in	in	ADP
cuesj-1224	57	5	group	group	PROPN
cuesj-1224	57	6	ii	ii	PROPN
cuesj-1224	57	7	(	(	PUNCT
cuesj-1224	57	8	glimepiride	glimepiride	PROPN
cuesj-1224	57	9	)	)	PUNCT
cuesj-1224	57	10	,	,	PUNCT
cuesj-1224	57	11	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	57	12	was	be	AUX
cuesj-1224	57	13	more	more	ADV
cuesj-1224	57	14	prevalent	prevalent	ADJ
cuesj-1224	57	15	.	.	PUNCT
cuesj-1224	58	1	as	as	ADP
cuesj-1224	58	2	for	for	ADP
cuesj-1224	58	3	group	group	NOUN
cuesj-1224	58	4	i	i	PRON
cuesj-1224	58	5	(	(	PUNCT
cuesj-1224	58	6	metformin	metformin	PROPN
cuesj-1224	58	7	)	)	PUNCT
cuesj-1224	58	8	,	,	PUNCT
cuesj-1224	58	9	patients	patient	NOUN
cuesj-1224	58	10	experienced	experience	VERB
cuesj-1224	58	11	gastrointestinal	gastrointestinal	ADJ
cuesj-1224	58	12	(	(	PUNCT
cuesj-1224	58	13	gi	gi	NOUN
cuesj-1224	58	14	)	)	PUNCT
cuesj-1224	58	15	disturbances	disturbance	NOUN
cuesj-1224	58	16	such	such	ADJ
cuesj-1224	58	17	as	as	ADP
cuesj-1224	58	18	diarrhea	diarrhea	NOUN
cuesj-1224	58	19	,	,	PUNCT
cuesj-1224	58	20	flatulence	flatulence	NOUN
cuesj-1224	58	21	,	,	PUNCT
cuesj-1224	58	22	and	and	CCONJ
cuesj-1224	58	23	nausea	nausea	NOUN
cuesj-1224	58	24	most	most	ADJ
cuesj-1224	58	25	.	.	PUNCT
cuesj-1224	59	1	moreover	moreover	ADV
cuesj-1224	59	2	,	,	PUNCT
cuesj-1224	59	3	finally	finally	ADV
cuesj-1224	59	4	,	,	PUNCT
cuesj-1224	59	5	the	the	DET
cuesj-1224	59	6	majority	majority	NOUN
cuesj-1224	59	7	of	of	ADP
cuesj-1224	59	8	skin	skin	NOUN
cuesj-1224	59	9	sensitivity	sensitivity	NOUN
cuesj-1224	59	10	symptoms	symptom	NOUN
cuesj-1224	59	11	such	such	ADJ
cuesj-1224	59	12	as	as	ADP
cuesj-1224	59	13	pruritis	pruritis	NOUN
cuesj-1224	59	14	,	,	PUNCT
cuesj-1224	59	15	angioedema	angioedema	VERB
cuesj-1224	59	16	,	,	PUNCT
cuesj-1224	59	17	rash	rash	ADJ
cuesj-1224	59	18	,	,	PUNCT
cuesj-1224	59	19	and	and	CCONJ
cuesj-1224	59	20	urticaria	urticaria	NOUN
cuesj-1224	59	21	were	be	AUX
cuesj-1224	59	22	observed	observe	VERB
cuesj-1224	59	23	among	among	ADP
cuesj-1224	59	24	group	group	PROPN
cuesj-1224	59	25	ii	ii	PROPN
cuesj-1224	59	26	(	(	PUNCT
cuesj-1224	59	27	glimepiride	glimepiride	NOUN
cuesj-1224	59	28	)	)	PUNCT
cuesj-1224	59	29	and	and	CCONJ
cuesj-1224	59	30	group	group	NOUN
cuesj-1224	59	31	iii	iii	PROPN
cuesj-1224	59	32	(	(	PUNCT
cuesj-1224	59	33	sitagliptin	sitagliptin	NOUN
cuesj-1224	59	34	)	)	PUNCT
cuesj-1224	59	35	participants	participant	NOUN
cuesj-1224	59	36	.	.	PUNCT
cuesj-1224	60	1	discussion	discussion	NOUN
cuesj-1224	60	2	this	this	DET
cuesj-1224	60	3	study	study	NOUN
cuesj-1224	60	4	was	be	AUX
cuesj-1224	60	5	carried	carry	VERB
cuesj-1224	60	6	out	out	ADP
cuesj-1224	60	7	to	to	PART
cuesj-1224	60	8	determine	determine	VERB
cuesj-1224	60	9	,	,	PUNCT
cuesj-1224	60	10	in	in	ADP
cuesj-1224	60	11	terms	term	NOUN
cuesj-1224	60	12	of	of	ADP
cuesj-1224	60	13	various	various	ADJ
cuesj-1224	60	14	parameters	parameter	NOUN
cuesj-1224	60	15	,	,	PUNCT
cuesj-1224	60	16	the	the	DET
cuesj-1224	60	17	effects	effect	NOUN
cuesj-1224	60	18	of	of	ADP
cuesj-1224	60	19	metformin	metformin	NOUN
cuesj-1224	60	20	,	,	PUNCT
cuesj-1224	60	21	sitagliptin	sitagliptin	NOUN
cuesj-1224	60	22	,	,	PUNCT
cuesj-1224	60	23	and	and	CCONJ
cuesj-1224	60	24	table	table	NOUN
cuesj-1224	60	25	2	2	NUM
cuesj-1224	60	26	:	:	PUNCT
cuesj-1224	60	27	post	post	ADJ
cuesj-1224	60	28	-	-	ADJ
cuesj-1224	60	29	treatment	treatment	ADJ
cuesj-1224	60	30	comparison	comparison	NOUN
cuesj-1224	60	31	of	of	ADP
cuesj-1224	60	32	physical	physical	ADJ
cuesj-1224	60	33	and	and	CCONJ
cuesj-1224	60	34	chemical	chemical	NOUN
cuesj-1224	60	35	parameters	parameter	NOUN
cuesj-1224	60	36	in	in	ADP
cuesj-1224	60	37	the	the	DET
cuesj-1224	60	38	full	full	ADJ
cuesj-1224	60	39	analysis	analysis	NOUN
cuesj-1224	60	40	set	set	VERB
cuesj-1224	60	41	groups	group	NOUN
cuesj-1224	60	42	group	group	NOUN
cuesj-1224	60	43	i	i	PRON
cuesj-1224	60	44	(	(	PUNCT
cuesj-1224	60	45	metformin	metformin	PROPN
cuesj-1224	60	46	)	)	PUNCT
cuesj-1224	60	47	group	group	NOUN
cuesj-1224	60	48	ii	ii	PROPN
cuesj-1224	60	49	(	(	PUNCT
cuesj-1224	60	50	glimepiride	glimepiride	NOUN
cuesj-1224	60	51	)	)	PUNCT
cuesj-1224	60	52	group	group	NOUN
cuesj-1224	60	53	iii	iii	PROPN
cuesj-1224	60	54	(	(	PUNCT
cuesj-1224	60	55	sitagliptin	sitagliptin	NOUN
cuesj-1224	60	56	)	)	PUNCT
cuesj-1224	60	57	p	p	ADJ
cuesj-1224	60	58	-	-	PUNCT
cuesj-1224	60	59	value	value	NOUN
cuesj-1224	60	60	age	age	NOUN
cuesj-1224	60	61	57.40±8.97	57.40±8.97	PROPN
cuesj-1224	60	62	54.62±10.16	54.62±10.16	PROPN
cuesj-1224	60	63	54.49±10.74	54.49±10.74	NUM
cuesj-1224	60	64	0.278	0.278	NUM
cuesj-1224	60	65	bmi	bmi	NOUN
cuesj-1224	60	66	23.95±3.27	23.95±3.27	NUM
cuesj-1224	60	67	24.30±3.77	24.30±3.77	NUM
cuesj-1224	60	68	23.99±3.64	23.99±3.64	NUM
cuesj-1224	60	69	0.868	0.868	NUM
cuesj-1224	60	70	wc	wc	PROPN
cuesj-1224	60	71	35.50±3.85	35.50±3.85	NUM
cuesj-1224	60	72	37±4.88	37±4.88	NUM
cuesj-1224	60	73	36.49±4.60	36.49±4.60	NUM
cuesj-1224	60	74	0.245	0.245	NUM
cuesj-1224	60	75	hba1c	hba1c	PROPN
cuesj-1224	61	1	6.43±0.95	6.43±0.95	NUM
cuesj-1224	61	2	6.35±1.14	6.35±1.14	NUM
cuesj-1224	61	3	7.11±0.93	7.11±0.93	NUM
cuesj-1224	61	4	0.001	0.001	NUM
cuesj-1224	61	5	*	*	NUM
cuesj-1224	61	6	fbs	fb	VERB
cuesj-1224	61	7	178.58±56.59	178.58±56.59	NUM
cuesj-1224	61	8	155.28±38.69	155.28±38.69	NUM
cuesj-1224	61	9	165±57.00	165±57.00	NUM
cuesj-1224	61	10	0.081	0.081	NUM
cuesj-1224	61	11	sbp	sbp	NOUN
cuesj-1224	61	12	135.84±9.47	135.84±9.47	NUM
cuesj-1224	61	13	140.93±12.57	140.93±12.57	NUM
cuesj-1224	61	14	137.46±10.39	137.46±10.39	NUM
cuesj-1224	61	15	0.080	0.080	NUM
cuesj-1224	61	16	dbp	dbp	PROPN
cuesj-1224	61	17	85.98±4.77	85.98±4.77	NUM
cuesj-1224	61	18	88.93±16.27	88.93±16.27	NUM
cuesj-1224	61	19	86.54±5.73	86.54±5.73	NUM
cuesj-1224	61	20	0.372	0.372	NUM
cuesj-1224	61	21	tc	tc	NUM
cuesj-1224	61	22	167±31.14	167±31.14	NUM
cuesj-1224	61	23	196.47±76.98	196.47±76.98	NUM
cuesj-1224	61	24	179.48±39.72	179.48±39.72	NUM
cuesj-1224	61	25	0.047	0.047	NUM
cuesj-1224	61	26	*	*	PUNCT
cuesj-1224	62	1	tg	tg	PROPN
cuesj-1224	62	2	178.71±67.31	178.71±67.31	NUM
cuesj-1224	62	3	168.63±50.06	168.63±50.06	NUM
cuesj-1224	62	4	181.11±68.75	181.11±68.75	NUM
cuesj-1224	62	5	0.593	0.593	NUM
cuesj-1224	62	6	ldl	ldl	NOUN
cuesj-1224	62	7	126.50±34.03	126.50±34.03	NUM
cuesj-1224	62	8	159.58±60.88	159.58±60.88	NUM
cuesj-1224	62	9	164.32±73.59	164.32±73.59	NUM
cuesj-1224	62	10	0.010	0.010	NUM
cuesj-1224	62	11	*	*	PUNCT
cuesj-1224	62	12	hdl	hdl	X
cuesj-1224	62	13	46.59±7.93	46.59±7.93	NUM
cuesj-1224	63	1	43.17±6.81	43.17±6.81	NOUN
cuesj-1224	63	2	47.02±13.81	47.02±13.81	NUM
cuesj-1224	63	3	0.141	0.141	NUM
cuesj-1224	63	4	creatinine	creatinine	NOUN
cuesj-1224	63	5	0.71±0.42	0.71±0.42	NUM
cuesj-1224	64	1	0.74±0.38	0.74±0.38	PROPN
cuesj-1224	64	2	0.65±0.33	0.65±0.33	NOUN
cuesj-1224	64	3	0.544	0.544	NUM
cuesj-1224	64	4	bilirubin	bilirubin	NOUN
cuesj-1224	64	5	8.78±14.62	8.78±14.62	NUM
cuesj-1224	64	6	4.20±6.59	4.20±6.59	NUM
cuesj-1224	64	7	4.79±12.61	4.79±12.61	NUM
cuesj-1224	64	8	0.176	0.176	NUM
cuesj-1224	64	9	urea	urea	NOUN
cuesj-1224	64	10	21.21±12.65	21.21±12.65	NUM
cuesj-1224	64	11	22.87±11.40	22.87±11.40	NUM
cuesj-1224	64	12	23.83±12.73	23.83±12.73	NUM
cuesj-1224	64	13	0.627	0.627	NUM
cuesj-1224	64	14	hb	hb	PROPN
cuesj-1224	64	15	16.58±14.92	16.58±14.92	NUM
cuesj-1224	64	16	14.18±1.40	14.18±1.40	NUM
cuesj-1224	64	17	13.99±1.20	13.99±1.20	NUM
cuesj-1224	64	18	0.310	0.310	NUM
cuesj-1224	64	19	the	the	DET
cuesj-1224	64	20	results	result	NOUN
cuesj-1224	64	21	were	be	AUX
cuesj-1224	64	22	expressed	express	VERB
cuesj-1224	64	23	as	as	ADP
cuesj-1224	64	24	number	number	NOUN
cuesj-1224	64	25	and	and	CCONJ
cuesj-1224	64	26	mean±standard	mean±standard	NOUN
cuesj-1224	64	27	deviation	deviation	NOUN
cuesj-1224	64	28	.	.	PUNCT
cuesj-1224	65	1	p	p	X
cuesj-1224	65	2	-	-	PUNCT
cuesj-1224	65	3	value	value	NOUN
cuesj-1224	65	4	was	be	AUX
cuesj-1224	65	5	calculated	calculate	VERB
cuesj-1224	65	6	by	by	ADP
cuesj-1224	65	7	using	use	VERB
cuesj-1224	65	8	one	one	NUM
cuesj-1224	65	9	-	-	PUNCT
cuesj-1224	65	10	way	way	NOUN
cuesj-1224	65	11	analysis	analysis	NOUN
cuesj-1224	65	12	of	of	ADP
cuesj-1224	65	13	variance	variance	NOUN
cuesj-1224	65	14	test	test	NOUN
cuesj-1224	65	15	for	for	ADP
cuesj-1224	65	16	category	category	NOUN
cuesj-1224	65	17	data	datum	NOUN
cuesj-1224	65	18	.	.	PUNCT
cuesj-1224	66	1	non	non	ADJ
cuesj-1224	66	2	-	-	ADJ
cuesj-1224	66	3	significant	significant	ADJ
cuesj-1224	66	4	(	(	PUNCT
cuesj-1224	66	5	n.s	n.s	PROPN
cuesj-1224	66	6	)	)	PUNCT
cuesj-1224	66	7	difference	difference	NOUN
cuesj-1224	66	8	(	(	PUNCT
cuesj-1224	66	9	p>0.05	p>0.05	NOUN
cuesj-1224	66	10	)	)	PUNCT
cuesj-1224	66	11	.	.	PUNCT
cuesj-1224	67	1	*	*	PUNCT
cuesj-1224	67	2	significant	significant	ADJ
cuesj-1224	67	3	difference	difference	NOUN
cuesj-1224	67	4	(	(	PUNCT
cuesj-1224	67	5	s	s	NOUN
cuesj-1224	67	6	)	)	PUNCT
cuesj-1224	67	7	(	(	PUNCT
cuesj-1224	67	8	p≤0.05	p≤0.05	NOUN
cuesj-1224	67	9	)	)	PUNCT
cuesj-1224	67	10	.	.	PUNCT
cuesj-1224	68	1	bmi	bmi	PROPN
cuesj-1224	68	2	:	:	PUNCT
cuesj-1224	68	3	body	body	NOUN
cuesj-1224	68	4	mass	mass	PROPN
cuesj-1224	68	5	index	index	PROPN
cuesj-1224	68	6	,	,	PUNCT
cuesj-1224	68	7	hba1c	hba1c	PROPN
cuesj-1224	68	8	:	:	PUNCT
cuesj-1224	68	9	hemoglobin	hemoglobin	PROPN
cuesj-1224	68	10	a1c	a1c	PROPN
cuesj-1224	68	11	,	,	PUNCT
cuesj-1224	68	12	fbs	fbs	PROPN
cuesj-1224	68	13	:	:	PUNCT
cuesj-1224	68	14	fasting	fast	VERB
cuesj-1224	68	15	blood	blood	NOUN
cuesj-1224	68	16	sugar	sugar	NOUN
cuesj-1224	68	17	,	,	PUNCT
cuesj-1224	68	18	tc	tc	NUM
cuesj-1224	68	19	:	:	PUNCT
cuesj-1224	68	20	total	total	ADJ
cuesj-1224	68	21	cholesterol	cholesterol	NOUN
cuesj-1224	68	22	,	,	PUNCT
cuesj-1224	68	23	tg	tg	PRON
cuesj-1224	68	24	:	:	PUNCT
cuesj-1224	68	25	triglyceride	triglyceride	ADJ
cuesj-1224	68	26	,	,	PUNCT
cuesj-1224	68	27	sbp	sbp	PROPN
cuesj-1224	68	28	:	:	PUNCT
cuesj-1224	68	29	systolic	systolic	ADJ
cuesj-1224	68	30	blood	blood	NOUN
cuesj-1224	68	31	pressure	pressure	NOUN
cuesj-1224	68	32	,	,	PUNCT
cuesj-1224	68	33	dbp	dbp	PROPN
cuesj-1224	68	34	:	:	PUNCT
cuesj-1224	68	35	diastolic	diastolic	ADJ
cuesj-1224	68	36	blood	blood	NOUN
cuesj-1224	68	37	pressure	pressure	NOUN
cuesj-1224	68	38	,	,	PUNCT
cuesj-1224	68	39	ldl	ldl	NOUN
cuesj-1224	68	40	:	:	PUNCT
cuesj-1224	68	41	low	low	ADJ
cuesj-1224	68	42	-	-	PUNCT
cuesj-1224	68	43	density	density	NOUN
cuesj-1224	68	44	lipoprotein	lipoprotein	ADJ
cuesj-1224	68	45	,	,	PUNCT
cuesj-1224	68	46	hdl	hdl	NOUN
cuesj-1224	68	47	:	:	PUNCT
cuesj-1224	68	48	high	high	ADJ
cuesj-1224	68	49	-	-	PUNCT
cuesj-1224	68	50	density	density	NOUN
cuesj-1224	68	51	lipoprotein	lipoprotein	ADJ
cuesj-1224	68	52	table	table	NOUN
cuesj-1224	68	53	3	3	NUM
cuesj-1224	68	54	:	:	PUNCT
cuesj-1224	69	1	safety	safety	NOUN
cuesj-1224	69	2	parameters	parameter	NOUN
cuesj-1224	69	3	observed	observe	VERB
cuesj-1224	69	4	in	in	ADP
cuesj-1224	69	5	the	the	DET
cuesj-1224	69	6	three	three	NUM
cuesj-1224	69	7	study	study	NOUN
cuesj-1224	69	8	groups	group	NOUN
cuesj-1224	69	9	safety	safety	NOUN
cuesj-1224	69	10	parameters	parameter	NOUN
cuesj-1224	69	11	group	group	NOUN
cuesj-1224	69	12	i	i	PRON
cuesj-1224	69	13	(	(	PUNCT
cuesj-1224	69	14	metformin	metformin	PROPN
cuesj-1224	69	15	)	)	PUNCT
cuesj-1224	69	16	group	group	NOUN
cuesj-1224	69	17	ii	ii	PROPN
cuesj-1224	69	18	(	(	PUNCT
cuesj-1224	69	19	glimepiride	glimepiride	NOUN
cuesj-1224	69	20	)	)	PUNCT
cuesj-1224	69	21	group	group	NOUN
cuesj-1224	69	22	iii	iii	PROPN
cuesj-1224	69	23	(	(	PUNCT
cuesj-1224	69	24	sitagliptin	sitagliptin	NOUN
cuesj-1224	69	25	)	)	PUNCT
cuesj-1224	69	26	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	69	27	14	14	NUM
cuesj-1224	69	28	18	18	NUM
cuesj-1224	69	29	14	14	NUM
cuesj-1224	69	30	pruritis	pruritis	ADJ
cuesj-1224	69	31	20	20	NUM
cuesj-1224	69	32	29	29	NUM
cuesj-1224	69	33	26	26	NUM
cuesj-1224	69	34	angioedema	angioedema	NOUN
cuesj-1224	69	35	1	1	NUM
cuesj-1224	69	36	8	8	NUM
cuesj-1224	69	37	11	11	NUM
cuesj-1224	69	38	rash	rash	NOUN
cuesj-1224	69	39	22	22	NUM
cuesj-1224	69	40	32	32	NUM
cuesj-1224	69	41	32	32	NUM
cuesj-1224	69	42	urticaria	urticaria	NOUN
cuesj-1224	69	43	2	2	NUM
cuesj-1224	69	44	15	15	NUM
cuesj-1224	69	45	13	13	NUM
cuesj-1224	69	46	diarrhea	diarrhea	NOUN
cuesj-1224	69	47	33	33	NUM
cuesj-1224	69	48	28	28	NUM
cuesj-1224	69	49	15	15	NUM
cuesj-1224	69	50	nausea	nausea	NOUN
cuesj-1224	69	51	32	32	NUM
cuesj-1224	69	52	22	22	NUM
cuesj-1224	69	53	26	26	NUM
cuesj-1224	69	54	flatulence	flatulence	NOUN
cuesj-1224	69	55	28	28	NUM
cuesj-1224	69	56	16	16	NUM
cuesj-1224	69	57	13	13	NUM
cuesj-1224	69	58	constipation	constipation	NOUN
cuesj-1224	69	59	8	8	NUM
cuesj-1224	69	60	11	11	NUM
cuesj-1224	69	61	21	21	NUM
cuesj-1224	69	62	arthralgia	arthralgia	NOUN
cuesj-1224	69	63	27	27	NUM
cuesj-1224	69	64	22	22	NUM
cuesj-1224	69	65	32	32	NUM
cuesj-1224	69	66	myalgia	myalgia	NOUN
cuesj-1224	69	67	24	24	NUM
cuesj-1224	69	68	22	22	NUM
cuesj-1224	69	69	23	23	NUM
cuesj-1224	69	70	yassen	yassen	NOUN
cuesj-1224	69	71	,	,	PUNCT
cuesj-1224	69	72	et	et	PROPN
cuesj-1224	69	73	al	al	PROPN
cuesj-1224	69	74	.	.	PUNCT
cuesj-1224	69	75	:	:	PUNCT
cuesj-1224	70	1	efficacy	efficacy	NOUN
cuesj-1224	70	2	and	and	CCONJ
cuesj-1224	70	3	safety	safety	NOUN
cuesj-1224	70	4	of	of	ADP
cuesj-1224	70	5	metformin	metformin	PROPN
cuesj-1224	70	6	,	,	PUNCT
cuesj-1224	70	7	sitagliptin	sitagliptin	NOUN
cuesj-1224	70	8	,	,	PUNCT
cuesj-1224	70	9	and	and	CCONJ
cuesj-1224	70	10	glimepiride	glimepiride	NOUN
cuesj-1224	70	11	in	in	ADP
cuesj-1224	70	12	type	type	NOUN
cuesj-1224	70	13	2	2	NUM
cuesj-1224	70	14	diabetes	diabetes	NOUN
cuesj-1224	70	15	107	107	NUM
cuesj-1224	70	16	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	70	17	cuesj	cuesj	ADJ
cuesj-1224	70	18	2024	2024	NUM
cuesj-1224	70	19	,	,	PUNCT
cuesj-1224	70	20	8	8	NUM
cuesj-1224	70	21	(	(	PUNCT
cuesj-1224	70	22	2	2	NUM
cuesj-1224	70	23	):	):	PUNCT
cuesj-1224	70	24	104	104	NUM
cuesj-1224	70	25	-	-	SYM
cuesj-1224	70	26	109	109	NUM
cuesj-1224	70	27	glimepiride	glimepiride	NOUN
cuesj-1224	70	28	(	(	PUNCT
cuesj-1224	70	29	taken	take	VERB
cuesj-1224	70	30	respectively	respectively	ADV
cuesj-1224	70	31	in	in	ADP
cuesj-1224	70	32	fixed	fix	VERB
cuesj-1224	70	33	dosages	dosage	NOUN
cuesj-1224	70	34	of	of	ADP
cuesj-1224	70	35	500	500	NUM
cuesj-1224	70	36	mg	mg	NOUN
cuesj-1224	70	37	,	,	PUNCT
cuesj-1224	70	38	100	100	NUM
cuesj-1224	70	39	mg	mg	NOUN
cuesj-1224	70	40	,	,	PUNCT
cuesj-1224	70	41	and	and	CCONJ
cuesj-1224	70	42	2	2	NUM
cuesj-1224	70	43	mg	mg	NUM
cuesj-1224	70	44	)	)	PUNCT
cuesj-1224	70	45	on	on	ADP
cuesj-1224	70	46	recently	recently	ADV
cuesj-1224	70	47	diagnosed	diagnose	VERB
cuesj-1224	70	48	type	type	NOUN
cuesj-1224	70	49	2	2	NUM
cuesj-1224	70	50	diabetic	diabetic	ADJ
cuesj-1224	70	51	patients	patient	NOUN
cuesj-1224	70	52	.	.	PUNCT
cuesj-1224	71	1	our	our	PRON
cuesj-1224	71	2	results	result	NOUN
cuesj-1224	71	3	show	show	VERB
cuesj-1224	71	4	that	that	DET
cuesj-1224	71	5	glimepiride	glimepiride	NOUN
cuesj-1224	71	6	as	as	ADP
cuesj-1224	71	7	an	an	DET
cuesj-1224	71	8	initial	initial	ADJ
cuesj-1224	71	9	treatment	treatment	NOUN
cuesj-1224	71	10	is	be	AUX
cuesj-1224	71	11	superior	superior	ADJ
cuesj-1224	71	12	to	to	ADP
cuesj-1224	71	13	others	other	NOUN
cuesj-1224	71	14	in	in	ADP
cuesj-1224	71	15	reducing	reduce	VERB
cuesj-1224	71	16	hba1c	hba1c	PROPN
cuesj-1224	71	17	and	and	CCONJ
cuesj-1224	71	18	fbs	fbs	PROPN
cuesj-1224	71	19	levels	level	NOUN
cuesj-1224	71	20	.	.	PUNCT
cuesj-1224	72	1	the	the	DET
cuesj-1224	72	2	current	current	ADJ
cuesj-1224	72	3	research	research	NOUN
cuesj-1224	72	4	indicates	indicate	VERB
cuesj-1224	72	5	that	that	SCONJ
cuesj-1224	72	6	t2	t2	NOUN
cuesj-1224	72	7	dm	dm	NOUN
cuesj-1224	72	8	is	be	AUX
cuesj-1224	72	9	more	more	ADV
cuesj-1224	72	10	frequent	frequent	ADJ
cuesj-1224	72	11	in	in	ADP
cuesj-1224	72	12	females	female	NOUN
cuesj-1224	72	13	(	(	PUNCT
cuesj-1224	72	14	male	male	ADJ
cuesj-1224	72	15	:	:	PUNCT
cuesj-1224	72	16	female	female	NOUN
cuesj-1224	72	17	=	=	NOUN
cuesj-1224	72	18	60:83	60:83	NUM
cuesj-1224	72	19	)	)	PUNCT
cuesj-1224	72	20	,	,	PUNCT
cuesj-1224	72	21	due	due	ADP
cuesj-1224	72	22	to	to	ADP
cuesj-1224	72	23	their	their	PRON
cuesj-1224	72	24	more	more	ADV
cuesj-1224	72	25	inactive	inactive	ADJ
cuesj-1224	72	26	and	and	CCONJ
cuesj-1224	72	27	diabetes	diabetes	NOUN
cuesj-1224	72	28	-	-	PUNCT
cuesj-1224	72	29	promoting	promote	VERB
cuesj-1224	72	30	lifestyle	lifestyle	NOUN
cuesj-1224	72	31	in	in	ADP
cuesj-1224	72	32	our	our	PRON
cuesj-1224	72	33	community	community	NOUN
cuesj-1224	72	34	,	,	PUNCT
cuesj-1224	72	35	which	which	PRON
cuesj-1224	72	36	is	be	AUX
cuesj-1224	72	37	akin	akin	ADJ
cuesj-1224	72	38	to	to	ADP
cuesj-1224	72	39	prior	prior	ADJ
cuesj-1224	72	40	researches.[16,17	researches.[16,17	PROPN
cuesj-1224	72	41	]	]	PUNCT
cuesj-1224	72	42	the	the	DET
cuesj-1224	72	43	age	age	NOUN
cuesj-1224	72	44	at	at	ADP
cuesj-1224	72	45	which	which	PRON
cuesj-1224	72	46	the	the	DET
cuesj-1224	72	47	disease	disease	NOUN
cuesj-1224	72	48	most	most	ADV
cuesj-1224	72	49	commonly	commonly	ADV
cuesj-1224	72	50	starts	start	VERB
cuesj-1224	72	51	is	be	AUX
cuesj-1224	72	52	in	in	ADP
cuesj-1224	72	53	between	between	ADP
cuesj-1224	72	54	(	(	PUNCT
cuesj-1224	72	55	30	30	NUM
cuesj-1224	72	56	and	and	CCONJ
cuesj-1224	72	57	77	77	NUM
cuesj-1224	72	58	)	)	PUNCT
cuesj-1224	72	59	years	year	NOUN
cuesj-1224	72	60	of	of	ADP
cuesj-1224	72	61	age	age	NOUN
cuesj-1224	72	62	.	.	PUNCT
cuesj-1224	73	1	conventionally	conventionally	ADV
cuesj-1224	73	2	,	,	PUNCT
cuesj-1224	73	3	thought	think	VERB
cuesj-1224	73	4	of	of	ADP
cuesj-1224	73	5	as	as	ADP
cuesj-1224	73	6	an	an	DET
cuesj-1224	73	7	ailment	ailment	NOUN
cuesj-1224	73	8	that	that	PRON
cuesj-1224	73	9	affects	affect	VERB
cuesj-1224	73	10	middle	middle	ADJ
cuesj-1224	73	11	age	age	NOUN
cuesj-1224	73	12	and	and	CCONJ
cuesj-1224	73	13	older	old	ADJ
cuesj-1224	73	14	people	people	NOUN
cuesj-1224	73	15	type	type	VERB
cuesj-1224	73	16	2	2	NUM
cuesj-1224	73	17	diabetes	diabetes	NOUN
cuesj-1224	73	18	is	be	AUX
cuesj-1224	73	19	now	now	ADV
cuesj-1224	73	20	being	be	AUX
cuesj-1224	73	21	diagnosed	diagnose	VERB
cuesj-1224	73	22	at	at	ADP
cuesj-1224	73	23	a	a	DET
cuesj-1224	73	24	younger	young	ADJ
cuesj-1224	73	25	age.[18	age.[18	NOUN
cuesj-1224	73	26	]	]	PUNCT
cuesj-1224	73	27	almost	almost	ADV
cuesj-1224	73	28	half	half	NOUN
cuesj-1224	73	29	of	of	ADP
cuesj-1224	73	30	the	the	DET
cuesj-1224	73	31	participants	participant	NOUN
cuesj-1224	73	32	(	(	PUNCT
cuesj-1224	73	33	46.2	46.2	NUM
cuesj-1224	73	34	%	%	NOUN
cuesj-1224	73	35	)	)	PUNCT
cuesj-1224	73	36	in	in	ADP
cuesj-1224	73	37	this	this	DET
cuesj-1224	73	38	study	study	NOUN
cuesj-1224	73	39	were	be	AUX
cuesj-1224	73	40	smokers	smoker	NOUN
cuesj-1224	73	41	;	;	PUNCT
cuesj-1224	73	42	other	other	ADJ
cuesj-1224	73	43	research	research	NOUN
cuesj-1224	73	44	has	have	AUX
cuesj-1224	73	45	shown	show	VERB
cuesj-1224	73	46	that	that	SCONJ
cuesj-1224	73	47	cigarette	cigarette	NOUN
cuesj-1224	73	48	smoking	smoking	NOUN
cuesj-1224	73	49	is	be	AUX
cuesj-1224	73	50	an	an	DET
cuesj-1224	73	51	important	important	ADJ
cuesj-1224	73	52	modifiable	modifiable	ADJ
cuesj-1224	73	53	risk	risk	NOUN
cuesj-1224	73	54	factor	factor	NOUN
cuesj-1224	73	55	for	for	ADP
cuesj-1224	73	56	t2dm.[19	t2dm.[19	NOUN
cuesj-1224	73	57	]	]	PUNCT
cuesj-1224	74	1	the	the	DET
cuesj-1224	74	2	total	total	ADJ
cuesj-1224	74	3	study	study	NOUN
cuesj-1224	74	4	period	period	NOUN
cuesj-1224	74	5	of	of	ADP
cuesj-1224	74	6	12	12	NUM
cuesj-1224	74	7	weeks	week	NOUN
cuesj-1224	74	8	showed	show	VERB
cuesj-1224	74	9	hba1c	hba1c	PROPN
cuesj-1224	74	10	for	for	SCONJ
cuesj-1224	74	11	all	all	DET
cuesj-1224	74	12	three	three	NUM
cuesj-1224	74	13	groups	group	NOUN
cuesj-1224	74	14	to	to	PART
cuesj-1224	74	15	be	be	AUX
cuesj-1224	74	16	significantly	significantly	ADV
cuesj-1224	74	17	different	different	ADJ
cuesj-1224	74	18	(	(	PUNCT
cuesj-1224	74	19	p	p	X
cuesj-1224	74	20	<	<	X
cuesj-1224	74	21	0.001	0.001	NUM
cuesj-1224	74	22	)	)	PUNCT
cuesj-1224	74	23	and	and	CCONJ
cuesj-1224	74	24	significant	significant	ADJ
cuesj-1224	74	25	differences	difference	NOUN
cuesj-1224	74	26	in	in	ADP
cuesj-1224	74	27	tc	tc	NOUN
cuesj-1224	74	28	and	and	CCONJ
cuesj-1224	74	29	ldl	ldl	VERB
cuesj-1224	74	30	with	with	ADP
cuesj-1224	74	31	p	p	NOUN
cuesj-1224	74	32	-	-	PUNCT
cuesj-1224	74	33	values	value	NOUN
cuesj-1224	74	34	(	(	PUNCT
cuesj-1224	74	35	0.047	0.047	NUM
cuesj-1224	74	36	)	)	PUNCT
cuesj-1224	74	37	and	and	CCONJ
cuesj-1224	74	38	(	(	PUNCT
cuesj-1224	74	39	0.010	0.010	NUM
cuesj-1224	74	40	)	)	PUNCT
cuesj-1224	74	41	,	,	PUNCT
cuesj-1224	74	42	respectively	respectively	ADV
cuesj-1224	74	43	.	.	PUNCT
cuesj-1224	75	1	the	the	DET
cuesj-1224	75	2	antidiabetic	antidiabetic	ADJ
cuesj-1224	75	3	medicines	medicine	NOUN
cuesj-1224	75	4	being	be	AUX
cuesj-1224	75	5	studied	study	VERB
cuesj-1224	75	6	have	have	VERB
cuesj-1224	75	7	several	several	ADJ
cuesj-1224	75	8	mechanisms	mechanism	NOUN
cuesj-1224	75	9	of	of	ADP
cuesj-1224	75	10	action	action	NOUN
cuesj-1224	75	11	.	.	PUNCT
cuesj-1224	76	1	metformin	metformin	NOUN
cuesj-1224	76	2	monotherapy	monotherapy	NOUN
cuesj-1224	76	3	has	have	AUX
cuesj-1224	76	4	been	be	AUX
cuesj-1224	76	5	shown	show	VERB
cuesj-1224	76	6	to	to	PART
cuesj-1224	76	7	reduce	reduce	VERB
cuesj-1224	76	8	mean	mean	NOUN
cuesj-1224	76	9	hba1c	hba1c	PROPN
cuesj-1224	76	10	by	by	ADP
cuesj-1224	76	11	1.3	1.3	NUM
cuesj-1224	76	12	%	%	NOUN
cuesj-1224	76	13	after	after	ADP
cuesj-1224	76	14	29	29	NUM
cuesj-1224	76	15	weeks	week	NOUN
cuesj-1224	76	16	,	,	PUNCT
cuesj-1224	76	17	compared	compare	VERB
cuesj-1224	76	18	to	to	ADP
cuesj-1224	76	19	a	a	DET
cuesj-1224	76	20	0.4	0.4	NUM
cuesj-1224	76	21	%	%	NOUN
cuesj-1224	76	22	increase	increase	NOUN
cuesj-1224	76	23	in	in	ADP
cuesj-1224	76	24	the	the	DET
cuesj-1224	76	25	placebo	placebo	NOUN
cuesj-1224	76	26	group.[20	group.[20	NOUN
cuesj-1224	76	27	]	]	PUNCT
cuesj-1224	76	28	to	to	PART
cuesj-1224	76	29	suggest	suggest	VERB
cuesj-1224	76	30	the	the	DET
cuesj-1224	76	31	mechanism	mechanism	NOUN
cuesj-1224	76	32	of	of	ADP
cuesj-1224	76	33	action	action	NOUN
cuesj-1224	76	34	of	of	ADP
cuesj-1224	76	35	metformin	metformin	NOUN
cuesj-1224	76	36	,	,	PUNCT
cuesj-1224	76	37	131	131	NUM
cuesj-1224	76	38	fasting	fast	VERB
cuesj-1224	76	39	blood	blood	NOUN
cuesj-1224	76	40	metabolites	metabolite	NOUN
cuesj-1224	76	41	were	be	AUX
cuesj-1224	76	42	studied	study	VERB
cuesj-1224	76	43	by	by	ADP
cuesj-1224	76	44	xu	xu	PROPN
cuesj-1224	76	45	et	et	NOUN
cuesj-1224	76	46	al.[20	al.[20	NOUN
cuesj-1224	76	47	]	]	PUNCT
cuesj-1224	76	48	in	in	ADP
cuesj-1224	76	49	three	three	NUM
cuesj-1224	76	50	separate	separate	ADJ
cuesj-1224	76	51	cross	cross	ADJ
cuesj-1224	76	52	-	-	ADJ
cuesj-1224	76	53	sectional	sectional	ADJ
cuesj-1224	76	54	cohort	cohort	NOUN
cuesj-1224	76	55	studies	study	NOUN
cuesj-1224	76	56	.	.	PUNCT
cuesj-1224	77	1	when	when	SCONJ
cuesj-1224	77	2	type	type	NOUN
cuesj-1224	77	3	2	2	NUM
cuesj-1224	77	4	diabetes	diabetes	NOUN
cuesj-1224	77	5	patients	patient	NOUN
cuesj-1224	77	6	using	use	VERB
cuesj-1224	77	7	metformin	metformin	NOUN
cuesj-1224	77	8	were	be	AUX
cuesj-1224	77	9	compared	compare	VERB
cuesj-1224	77	10	to	to	ADP
cuesj-1224	77	11	control	control	VERB
cuesj-1224	77	12	groups	group	NOUN
cuesj-1224	77	13	,	,	PUNCT
cuesj-1224	77	14	the	the	DET
cuesj-1224	77	15	amounts	amount	NOUN
cuesj-1224	77	16	of	of	ADP
cuesj-1224	77	17	three	three	NUM
cuesj-1224	77	18	metabolites	metabolite	NOUN
cuesj-1224	77	19	(	(	PUNCT
cuesj-1224	77	20	acylalkyl	acylalkyl	PROPN
cuesj-1224	77	21	phosphatidylcholines	phosphatidylcholine	NOUN
cuesj-1224	77	22	)	)	PUNCT
cuesj-1224	77	23	were	be	AUX
cuesj-1224	77	24	shown	show	VERB
cuesj-1224	77	25	to	to	PART
cuesj-1224	77	26	be	be	AUX
cuesj-1224	77	27	lower	low	ADJ
cuesj-1224	77	28	in	in	ADP
cuesj-1224	77	29	the	the	DET
cuesj-1224	77	30	metformin	metformin	NOUN
cuesj-1224	77	31	-	-	PUNCT
cuesj-1224	77	32	treated	treat	VERB
cuesj-1224	77	33	patients	patient	NOUN
cuesj-1224	77	34	.	.	PUNCT
cuesj-1224	78	1	lower	low	ADJ
cuesj-1224	78	2	plasma	plasma	NOUN
cuesj-1224	78	3	amounts	amount	NOUN
cuesj-1224	78	4	of	of	ADP
cuesj-1224	78	5	ldl	ldl	NOUN
cuesj-1224	78	6	cholesterol	cholesterol	NOUN
cuesj-1224	78	7	were	be	AUX
cuesj-1224	78	8	associated	associate	VERB
cuesj-1224	78	9	with	with	ADP
cuesj-1224	78	10	the	the	DET
cuesj-1224	78	11	lowering	lowering	NOUN
cuesj-1224	78	12	of	of	ADP
cuesj-1224	78	13	these	these	DET
cuesj-1224	78	14	metabolites	metabolite	NOUN
cuesj-1224	78	15	.	.	PUNCT
cuesj-1224	79	1	one	one	NUM
cuesj-1224	79	2	of	of	ADP
cuesj-1224	79	3	the	the	DET
cuesj-1224	79	4	most	most	ADV
cuesj-1224	79	5	effective	effective	ADJ
cuesj-1224	79	6	oral	oral	ADJ
cuesj-1224	79	7	antidiabetic	antidiabetic	ADJ
cuesj-1224	79	8	medications	medication	NOUN
cuesj-1224	79	9	,	,	PUNCT
cuesj-1224	79	10	sulfonylureas	sulfonylureas	PROPN
cuesj-1224	79	11	,	,	PUNCT
cuesj-1224	79	12	has	have	AUX
cuesj-1224	79	13	been	be	AUX
cuesj-1224	79	14	used	use	VERB
cuesj-1224	79	15	to	to	PART
cuesj-1224	79	16	treat	treat	VERB
cuesj-1224	79	17	t2	t2	NOUN
cuesj-1224	79	18	dm	dm	PROPN
cuesj-1224	79	19	since	since	SCONJ
cuesj-1224	79	20	1950.[21	1950.[21	PROPN
cuesj-1224	79	21	]	]	PUNCT
cuesj-1224	79	22	in	in	ADP
cuesj-1224	79	23	indian	indian	ADJ
cuesj-1224	79	24	clinical	clinical	ADJ
cuesj-1224	79	25	settings	setting	NOUN
cuesj-1224	79	26	,	,	PUNCT
cuesj-1224	79	27	sulfonylureas	sulfonylureas	PROPN
cuesj-1224	79	28	,	,	PUNCT
cuesj-1224	79	29	especially	especially	ADV
cuesj-1224	79	30	modern	modern	ADJ
cuesj-1224	79	31	ones	one	NOUN
cuesj-1224	79	32	such	such	ADJ
cuesj-1224	79	33	as	as	ADP
cuesj-1224	79	34	glimepiride	glimepiride	NOUN
cuesj-1224	79	35	,	,	PUNCT
cuesj-1224	79	36	are	be	AUX
cuesj-1224	79	37	commonly	commonly	ADV
cuesj-1224	79	38	used	use	VERB
cuesj-1224	79	39	as	as	ADP
cuesj-1224	79	40	the	the	DET
cuesj-1224	79	41	initial	initial	ADJ
cuesj-1224	79	42	complementary	complementary	ADJ
cuesj-1224	79	43	treatment	treatment	NOUN
cuesj-1224	79	44	to	to	ADP
cuesj-1224	79	45	metformin	metformin	NOUN
cuesj-1224	79	46	because	because	SCONJ
cuesj-1224	79	47	of	of	ADP
cuesj-1224	79	48	its	its	PRON
cuesj-1224	79	49	superior	superior	ADJ
cuesj-1224	79	50	effectiveness	effectiveness	NOUN
cuesj-1224	79	51	,	,	PUNCT
cuesj-1224	79	52	safety	safety	NOUN
cuesj-1224	79	53	,	,	PUNCT
cuesj-1224	79	54	and	and	CCONJ
cuesj-1224	79	55	low	low	ADJ
cuesj-1224	79	56	cost.[23	cost.[23	NOUN
cuesj-1224	79	57	]	]	PUNCT
cuesj-1224	79	58	glimepiride	glimepiride	NOUN
cuesj-1224	79	59	exhibits	exhibit	VERB
cuesj-1224	79	60	distinctive	distinctive	ADJ
cuesj-1224	79	61	binding	bind	VERB
cuesj-1224	79	62	properties	property	NOUN
cuesj-1224	79	63	with	with	ADP
cuesj-1224	79	64	the	the	DET
cuesj-1224	79	65	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	79	66	receptor	receptor	NOUN
cuesj-1224	79	67	1	1	NUM
cuesj-1224	79	68	(	(	PUNCT
cuesj-1224	79	69	sur1	sur1	PROPN
cuesj-1224	79	70	)	)	PUNCT
cuesj-1224	79	71	,	,	PUNCT
cuesj-1224	79	72	leading	lead	VERB
cuesj-1224	79	73	to	to	ADP
cuesj-1224	79	74	rapid	rapid	ADJ
cuesj-1224	79	75	attachment	attachment	NOUN
cuesj-1224	79	76	and	and	CCONJ
cuesj-1224	79	77	detachment	detachment	NOUN
cuesj-1224	79	78	.	.	PUNCT
cuesj-1224	80	1	glimepiride	glimepiride	NOUN
cuesj-1224	80	2	increases	increase	VERB
cuesj-1224	80	3	insulin	insulin	NOUN
cuesj-1224	80	4	sensitivity	sensitivity	NOUN
cuesj-1224	80	5	and	and	CCONJ
cuesj-1224	80	6	enhances	enhance	VERB
cuesj-1224	80	7	glucose	glucose	NOUN
cuesj-1224	80	8	consumption	consumption	NOUN
cuesj-1224	80	9	through	through	ADP
cuesj-1224	80	10	glucose	glucose	NOUN
cuesj-1224	80	11	transporter	transporter	NOUN
cuesj-1224	80	12	four	four	NUM
cuesj-1224	80	13	due	due	ADP
cuesj-1224	80	14	to	to	ADP
cuesj-1224	80	15	its	its	PRON
cuesj-1224	80	16	extrapancreatic	extrapancreatic	ADJ
cuesj-1224	80	17	effects.[24	effects.[24	NOUN
cuesj-1224	80	18	]	]	PUNCT
cuesj-1224	80	19	our	our	PRON
cuesj-1224	80	20	study	study	NOUN
cuesj-1224	80	21	showed	show	VERB
cuesj-1224	80	22	that	that	SCONJ
cuesj-1224	80	23	hba1c	hba1c	PROPN
cuesj-1224	80	24	was	be	AUX
cuesj-1224	80	25	6.35	6.35	NUM
cuesj-1224	80	26	±	±	NUM
cuesj-1224	80	27	1.14	1.14	NUM
cuesj-1224	80	28	,	,	PUNCT
cuesj-1224	80	29	which	which	PRON
cuesj-1224	80	30	means	mean	VERB
cuesj-1224	80	31	it	it	PRON
cuesj-1224	80	32	was	be	AUX
cuesj-1224	80	33	well	well	ADV
cuesj-1224	80	34	controlled	control	VERB
cuesj-1224	80	35	by	by	ADP
cuesj-1224	80	36	the	the	DET
cuesj-1224	80	37	glimepiride	glimepiride	NOUN
cuesj-1224	80	38	monotherapy	monotherapy	NOUN
cuesj-1224	80	39	.	.	PUNCT
cuesj-1224	81	1	as	as	ADP
cuesj-1224	81	2	for	for	ADP
cuesj-1224	81	3	ldl	ldl	NOUN
cuesj-1224	81	4	levels	level	NOUN
cuesj-1224	81	5	,	,	PUNCT
cuesj-1224	81	6	the	the	DET
cuesj-1224	81	7	results	result	NOUN
cuesj-1224	81	8	showed	show	VERB
cuesj-1224	81	9	a	a	DET
cuesj-1224	81	10	significant	significant	ADJ
cuesj-1224	81	11	difference	difference	NOUN
cuesj-1224	81	12	between	between	ADP
cuesj-1224	81	13	the	the	DET
cuesj-1224	81	14	three	three	NUM
cuesj-1224	81	15	treatment	treatment	NOUN
cuesj-1224	81	16	groups	group	NOUN
cuesj-1224	81	17	.	.	PUNCT
cuesj-1224	82	1	a	a	DET
cuesj-1224	82	2	metaanalysis	metaanalysis	NOUN
cuesj-1224	82	3	,	,	PUNCT
cuesj-1224	82	4	incorporating	incorporate	VERB
cuesj-1224	82	5	trial	trial	NOUN
cuesj-1224	82	6	sequence	sequence	NOUN
cuesj-1224	82	7	analysis	analysis	NOUN
cuesj-1224	82	8	of	of	ADP
cuesj-1224	82	9	randomized	randomized	ADJ
cuesj-1224	82	10	clinical	clinical	ADJ
cuesj-1224	82	11	trials	trial	NOUN
cuesj-1224	82	12	,	,	PUNCT
cuesj-1224	82	13	concluded	conclude	VERB
cuesj-1224	82	14	that	that	SCONJ
cuesj-1224	82	15	second	second	ADJ
cuesj-1224	82	16	and	and	CCONJ
cuesj-1224	82	17	third	third	ADJ
cuesj-1224	82	18	-	-	PUNCT
cuesj-1224	82	19	generation	generation	NOUN
cuesj-1224	82	20	sulfonylureas	sulfonylurea	NOUN
cuesj-1224	82	21	,	,	PUNCT
cuesj-1224	82	22	such	such	ADJ
cuesj-1224	82	23	as	as	ADP
cuesj-1224	82	24	glimepiride	glimepiride	NOUN
cuesj-1224	82	25	,	,	PUNCT
cuesj-1224	82	26	did	do	AUX
cuesj-1224	82	27	not	not	PART
cuesj-1224	82	28	show	show	VERB
cuesj-1224	82	29	an	an	DET
cuesj-1224	82	30	association	association	NOUN
cuesj-1224	82	31	with	with	ADP
cuesj-1224	82	32	higher	high	ADJ
cuesj-1224	82	33	general	general	ADJ
cuesj-1224	82	34	and	and	CCONJ
cuesj-1224	82	35	cardiovascular	cardiovascular	ADJ
cuesj-1224	82	36	mortality	mortality	NOUN
cuesj-1224	82	37	,	,	PUNCT
cuesj-1224	82	38	myocardial	myocardial	ADJ
cuesj-1224	82	39	infarction	infarction	NOUN
cuesj-1224	82	40	,	,	PUNCT
cuesj-1224	82	41	or	or	CCONJ
cuesj-1224	82	42	stroke.[25	stroke.[25	PROPN
cuesj-1224	82	43	]	]	PUNCT
cuesj-1224	82	44	in	in	ADP
cuesj-1224	82	45	contrast	contrast	NOUN
cuesj-1224	82	46	to	to	ADP
cuesj-1224	82	47	studies	study	NOUN
cuesj-1224	82	48	by	by	ADP
cuesj-1224	82	49	salpeter	salpeter	NOUN
cuesj-1224	82	50	and	and	CCONJ
cuesj-1224	82	51	kim	kim	PROPN
cuesj-1224	82	52	,	,	PUNCT
cuesj-1224	82	53	which	which	PRON
cuesj-1224	82	54	found	find	VERB
cuesj-1224	82	55	that	that	SCONJ
cuesj-1224	82	56	newly	newly	ADV
cuesj-1224	82	57	diagnosed	diagnose	VERB
cuesj-1224	82	58	type	type	NOUN
cuesj-1224	82	59	2	2	NUM
cuesj-1224	82	60	diabetic	diabetic	ADJ
cuesj-1224	82	61	patients	patient	NOUN
cuesj-1224	82	62	on	on	ADP
cuesj-1224	82	63	metformin	metformin	NOUN
cuesj-1224	82	64	had	have	VERB
cuesj-1224	82	65	statistically	statistically	ADV
cuesj-1224	82	66	significant	significant	ADJ
cuesj-1224	82	67	differences	difference	NOUN
cuesj-1224	82	68	in	in	ADP
cuesj-1224	82	69	lipid	lipid	ADJ
cuesj-1224	82	70	profiles	profile	NOUN
cuesj-1224	82	71	at	at	ADP
cuesj-1224	82	72	baseline	baseline	NOUN
cuesj-1224	82	73	,	,	PUNCT
cuesj-1224	82	74	the	the	DET
cuesj-1224	82	75	current	current	ADJ
cuesj-1224	82	76	study	study	NOUN
cuesj-1224	82	77	supported	support	VERB
cuesj-1224	82	78	this	this	DET
cuesj-1224	82	79	research	research	NOUN
cuesj-1224	82	80	and	and	CCONJ
cuesj-1224	82	81	showed	show	VERB
cuesj-1224	82	82	that	that	SCONJ
cuesj-1224	82	83	metformin	metformin	NOUN
cuesj-1224	82	84	,	,	PUNCT
cuesj-1224	82	85	decreased	decrease	VERB
cuesj-1224	82	86	tc	tc	NUM
cuesj-1224	82	87	,	,	PUNCT
cuesj-1224	82	88	ldl	ldl	NOUN
cuesj-1224	82	89	-	-	PUNCT
cuesj-1224	82	90	c	c	NOUN
cuesj-1224	82	91	,	,	PUNCT
cuesj-1224	82	92	and	and	CCONJ
cuesj-1224	82	93	tg	tg	PROPN
cuesj-1224	82	94	levels	level	NOUN
cuesj-1224	82	95	in	in	ADP
cuesj-1224	82	96	a	a	DET
cuesj-1224	82	97	non	non	ADJ
cuesj-1224	82	98	-	-	ADJ
cuesj-1224	82	99	significant	significant	ADJ
cuesj-1224	82	100	way.[26,27	way.[26,27	NOUN
cuesj-1224	82	101	]	]	PUNCT
cuesj-1224	82	102	dpp-4	dpp-4	NUM
cuesj-1224	82	103	antagonists	antagonist	NOUN
cuesj-1224	82	104	promote	promote	VERB
cuesj-1224	82	105	insulin	insulin	NOUN
cuesj-1224	82	106	secretion	secretion	NOUN
cuesj-1224	82	107	by	by	ADP
cuesj-1224	82	108	deactivating	deactivate	VERB
cuesj-1224	82	109	incretins	incretin	NOUN
cuesj-1224	82	110	such	such	ADJ
cuesj-1224	82	111	as	as	ADP
cuesj-1224	82	112	glp-1	glp-1	NOUN
cuesj-1224	82	113	and	and	CCONJ
cuesj-1224	82	114	gastric	gastric	ADJ
cuesj-1224	82	115	inhibitory	inhibitory	ADJ
cuesj-1224	82	116	polypeptide	polypeptide	ADJ
cuesj-1224	82	117	which	which	PRON
cuesj-1224	82	118	is	be	AUX
cuesj-1224	82	119	a	a	DET
cuesj-1224	82	120	different	different	ADJ
cuesj-1224	82	121	mechanism	mechanism	NOUN
cuesj-1224	82	122	than	than	ADP
cuesj-1224	82	123	traditional	traditional	ADJ
cuesj-1224	82	124	hypoglycemic	hypoglycemic	ADJ
cuesj-1224	82	125	drugs.[28	drugs.[28	NOUN
cuesj-1224	82	126	]	]	PUNCT
cuesj-1224	82	127	according	accord	VERB
cuesj-1224	82	128	to	to	ADP
cuesj-1224	82	129	one	one	NUM
cuesj-1224	82	130	research	research	NOUN
cuesj-1224	82	131	,	,	PUNCT
cuesj-1224	82	132	sitagliptin	sitagliptin	NOUN
cuesj-1224	82	133	,	,	PUNCT
cuesj-1224	82	134	used	use	VERB
cuesj-1224	82	135	as	as	ADP
cuesj-1224	82	136	a	a	DET
cuesj-1224	82	137	single	single	ADJ
cuesj-1224	82	138	medication	medication	NOUN
cuesj-1224	82	139	,	,	PUNCT
cuesj-1224	82	140	reduced	reduce	VERB
cuesj-1224	82	141	both	both	PRON
cuesj-1224	82	142	hba1c	hba1c	ADJ
cuesj-1224	82	143	level	level	NOUN
cuesj-1224	82	144	and	and	CCONJ
cuesj-1224	82	145	fasting	fast	VERB
cuesj-1224	82	146	blood	blood	NOUN
cuesj-1224	82	147	glucose	glucose	NOUN
cuesj-1224	82	148	levels.[29	levels.[29	NOUN
cuesj-1224	82	149	]	]	X
cuesj-1224	82	150	certain	certain	ADJ
cuesj-1224	82	151	clinical	clinical	ADJ
cuesj-1224	82	152	studies	study	NOUN
cuesj-1224	82	153	have	have	AUX
cuesj-1224	82	154	shown	show	VERB
cuesj-1224	82	155	a	a	DET
cuesj-1224	82	156	5	5	NUM
cuesj-1224	82	157	%	%	NOUN
cuesj-1224	82	158	drop	drop	NOUN
cuesj-1224	82	159	in	in	ADP
cuesj-1224	82	160	ldl	ldl	NOUN
cuesj-1224	82	161	-	-	PUNCT
cuesj-1224	82	162	c	c	NOUN
cuesj-1224	82	163	and	and	CCONJ
cuesj-1224	82	164	fasting	fast	VERB
cuesj-1224	82	165	tc	tc	NUM
cuesj-1224	82	166	post	post	ADJ
cuesj-1224	82	167	-	-	ADJ
cuesj-1224	82	168	sitagliptin	sitagliptin	ADJ
cuesj-1224	82	169	treatment	treatment	NOUN
cuesj-1224	82	170	.	.	PUNCT
cuesj-1224	83	1	although	although	SCONJ
cuesj-1224	83	2	a	a	DET
cuesj-1224	83	3	different	different	ADJ
cuesj-1224	83	4	trial	trial	NOUN
cuesj-1224	83	5	did	do	AUX
cuesj-1224	83	6	not	not	PART
cuesj-1224	83	7	find	find	VERB
cuesj-1224	83	8	a	a	DET
cuesj-1224	83	9	significant	significant	ADJ
cuesj-1224	83	10	drop	drop	NOUN
cuesj-1224	83	11	in	in	ADP
cuesj-1224	83	12	fasting	fast	VERB
cuesj-1224	83	13	tg	tg	PRON
cuesj-1224	83	14	,	,	PUNCT
cuesj-1224	83	15	postprandial	postprandial	ADJ
cuesj-1224	83	16	tg	tg	PRON
cuesj-1224	83	17	was	be	AUX
cuesj-1224	83	18	lowered	lower	VERB
cuesj-1224	83	19	by	by	ADP
cuesj-1224	83	20	around	around	ADP
cuesj-1224	83	21	9.5%.[30	9.5%.[30	NUM
cuesj-1224	83	22	]	]	X
cuesj-1224	83	23	oral	oral	ADJ
cuesj-1224	83	24	hypoglycemic	hypoglycemic	ADJ
cuesj-1224	83	25	drugs	drug	NOUN
cuesj-1224	83	26	were	be	AUX
cuesj-1224	83	27	found	find	VERB
cuesj-1224	83	28	to	to	PART
cuesj-1224	83	29	be	be	AUX
cuesj-1224	83	30	a	a	DET
cuesj-1224	83	31	common	common	ADJ
cuesj-1224	83	32	cause	cause	NOUN
cuesj-1224	83	33	of	of	ADP
cuesj-1224	83	34	side	side	NOUN
cuesj-1224	83	35	effects	effect	NOUN
cuesj-1224	83	36	,	,	PUNCT
cuesj-1224	83	37	particularly	particularly	ADV
cuesj-1224	83	38	gi	gi	ADP
cuesj-1224	83	39	side	side	NOUN
cuesj-1224	83	40	effects	effect	NOUN
cuesj-1224	83	41	;	;	PUNCT
cuesj-1224	83	42	however	however	ADV
cuesj-1224	83	43	,	,	PUNCT
cuesj-1224	83	44	the	the	DET
cuesj-1224	83	45	mechanism	mechanism	NOUN
cuesj-1224	83	46	underlying	underlie	VERB
cuesj-1224	83	47	these	these	DET
cuesj-1224	83	48	side	side	NOUN
cuesj-1224	83	49	effects	effect	NOUN
cuesj-1224	83	50	remained	remain	VERB
cuesj-1224	83	51	controversial	controversial	ADJ
cuesj-1224	83	52	,	,	PUNCT
cuesj-1224	83	53	and	and	CCONJ
cuesj-1224	83	54	conflicting	conflicting	ADJ
cuesj-1224	83	55	study	study	NOUN
cuesj-1224	83	56	results	result	NOUN
cuesj-1224	83	57	were	be	AUX
cuesj-1224	83	58	reported	report	VERB
cuesj-1224	83	59	;	;	PUNCT
cuesj-1224	83	60	additionally	additionally	ADV
cuesj-1224	83	61	,	,	PUNCT
cuesj-1224	83	62	these	these	DET
cuesj-1224	83	63	symptoms	symptom	NOUN
cuesj-1224	83	64	were	be	AUX
cuesj-1224	83	65	common	common	ADJ
cuesj-1224	83	66	in	in	ADP
cuesj-1224	83	67	both	both	CCONJ
cuesj-1224	83	68	diabetic	diabetic	ADJ
cuesj-1224	83	69	patients	patient	NOUN
cuesj-1224	83	70	and	and	CCONJ
cuesj-1224	83	71	normal	normal	ADJ
cuesj-1224	83	72	community	community	NOUN
cuesj-1224	83	73	members	member	NOUN
cuesj-1224	83	74	,	,	PUNCT
cuesj-1224	83	75	making	make	VERB
cuesj-1224	83	76	the	the	DET
cuesj-1224	83	77	relationship	relationship	NOUN
cuesj-1224	83	78	difficult	difficult	ADJ
cuesj-1224	83	79	to	to	PART
cuesj-1224	83	80	establish	establish	VERB
cuesj-1224	83	81	;	;	PUNCT
cuesj-1224	83	82	and	and	CCONJ
cuesj-1224	83	83	even	even	ADV
cuesj-1224	83	84	in	in	ADP
cuesj-1224	83	85	patients	patient	NOUN
cuesj-1224	83	86	with	with	ADP
cuesj-1224	83	87	diabetes	diabetes	NOUN
cuesj-1224	83	88	,	,	PUNCT
cuesj-1224	83	89	there	there	PRON
cuesj-1224	83	90	was	be	VERB
cuesj-1224	83	91	a	a	DET
cuesj-1224	83	92	significant	significant	ADJ
cuesj-1224	83	93	interindividual	interindividual	ADJ
cuesj-1224	83	94	variation	variation	NOUN
cuesj-1224	83	95	in	in	ADP
cuesj-1224	83	96	the	the	DET
cuesj-1224	83	97	frequency	frequency	NOUN
cuesj-1224	83	98	and	and	CCONJ
cuesj-1224	83	99	severity	severity	NOUN
cuesj-1224	83	100	of	of	ADP
cuesj-1224	83	101	these	these	DET
cuesj-1224	83	102	side	side	NOUN
cuesj-1224	83	103	effects	effect	NOUN
cuesj-1224	83	104	,	,	PUNCT
cuesj-1224	83	105	which	which	PRON
cuesj-1224	83	106	may	may	AUX
cuesj-1224	83	107	have	have	AUX
cuesj-1224	83	108	prevented	prevent	VERB
cuesj-1224	83	109	a	a	DET
cuesj-1224	83	110	genetic	genetic	ADJ
cuesj-1224	83	111	predisposition.[31	predisposition.[31	NOUN
cuesj-1224	83	112	]	]	PUNCT
cuesj-1224	83	113	patients	patient	NOUN
cuesj-1224	83	114	taking	take	VERB
cuesj-1224	83	115	metformin	metformin	NOUN
cuesj-1224	83	116	tablets	tablet	NOUN
cuesj-1224	83	117	commonly	commonly	ADV
cuesj-1224	83	118	report	report	VERB
cuesj-1224	83	119	gi	gi	NOUN
cuesj-1224	83	120	side	side	NOUN
cuesj-1224	83	121	effects	effect	NOUN
cuesj-1224	83	122	as	as	ADP
cuesj-1224	83	123	their	their	PRON
cuesj-1224	83	124	biggest	big	ADJ
cuesj-1224	83	125	issue	issue	NOUN
cuesj-1224	83	126	.	.	PUNCT
cuesj-1224	84	1	metformin	metformin	NOUN
cuesj-1224	84	2	is	be	AUX
cuesj-1224	84	3	commonly	commonly	ADV
cuesj-1224	84	4	linked	link	VERB
cuesj-1224	84	5	to	to	PART
cuesj-1224	84	6	gi	gi	VERB
cuesj-1224	84	7	side	side	NOUN
cuesj-1224	84	8	effects	effect	NOUN
cuesj-1224	84	9	such	such	ADJ
cuesj-1224	84	10	as	as	ADP
cuesj-1224	84	11	diarrhea	diarrhea	NOUN
cuesj-1224	84	12	,	,	PUNCT
cuesj-1224	84	13	nausea	nausea	NOUN
cuesj-1224	84	14	,	,	PUNCT
cuesj-1224	84	15	and	and	CCONJ
cuesj-1224	84	16	vomiting	vomiting	NOUN
cuesj-1224	84	17	.	.	PUNCT
cuesj-1224	85	1	it	it	PRON
cuesj-1224	85	2	was	be	AUX
cuesj-1224	85	3	noted	note	VERB
cuesj-1224	85	4	,	,	PUNCT
cuesj-1224	85	5	meanwhile	meanwhile	ADV
cuesj-1224	85	6	,	,	PUNCT
cuesj-1224	85	7	that	that	SCONJ
cuesj-1224	85	8	some	some	DET
cuesj-1224	85	9	patients	patient	NOUN
cuesj-1224	85	10	would	would	AUX
cuesj-1224	85	11	stop	stop	VERB
cuesj-1224	85	12	their	their	PRON
cuesj-1224	85	13	treatment	treatment	NOUN
cuesj-1224	85	14	since	since	SCONJ
cuesj-1224	85	15	the	the	DET
cuesj-1224	85	16	cost	cost	NOUN
cuesj-1224	85	17	of	of	ADP
cuesj-1224	85	18	their	their	PRON
cuesj-1224	85	19	medications	medication	NOUN
cuesj-1224	85	20	is	be	AUX
cuesj-1224	85	21	increasing.[32	increasing.[32	PROPN
cuesj-1224	85	22	]	]	PUNCT
cuesj-1224	85	23	in	in	ADP
cuesj-1224	85	24	our	our	PRON
cuesj-1224	85	25	study	study	NOUN
cuesj-1224	85	26	,	,	PUNCT
cuesj-1224	85	27	metformin	metformin	PROPN
cuesj-1224	85	28	drug	drug	NOUN
cuesj-1224	85	29	used	use	VERB
cuesj-1224	85	30	had	have	AUX
cuesj-1224	85	31	gi	gi	VERB
cuesj-1224	85	32	side	side	NOUN
cuesj-1224	85	33	effects	effect	NOUN
cuesj-1224	85	34	in	in	ADP
cuesj-1224	85	35	a	a	DET
cuesj-1224	85	36	frequency	frequency	NOUN
cuesj-1224	85	37	of	of	ADP
cuesj-1224	85	38	(	(	PUNCT
cuesj-1224	85	39	diarrhea	diarrhea	PROPN
cuesj-1224	85	40	,	,	PUNCT
cuesj-1224	85	41	n	n	NOUN
cuesj-1224	85	42	=	=	NUM
cuesj-1224	85	43	33	33	NUM
cuesj-1224	85	44	and	and	CCONJ
cuesj-1224	85	45	nausea	nausea	NOUN
cuesj-1224	85	46	,	,	PUNCT
cuesj-1224	85	47	n	n	NOUN
cuesj-1224	85	48	=	=	SYM
cuesj-1224	85	49	32	32	NUM
cuesj-1224	85	50	cases	case	NOUN
cuesj-1224	85	51	)	)	PUNCT
cuesj-1224	85	52	.	.	PUNCT
cuesj-1224	86	1	study	study	NOUN
cuesj-1224	86	2	done	do	VERB
cuesj-1224	86	3	by	by	ADP
cuesj-1224	86	4	mccreight	mccreight	PROPN
cuesj-1224	86	5	has	have	AUX
cuesj-1224	86	6	shown	show	VERB
cuesj-1224	86	7	that	that	SCONJ
cuesj-1224	86	8	patients	patient	NOUN
cuesj-1224	86	9	using	use	VERB
cuesj-1224	86	10	metformin	metformin	NOUN
cuesj-1224	86	11	tablets	tablet	NOUN
cuesj-1224	86	12	typically	typically	ADV
cuesj-1224	86	13	complain	complain	VERB
cuesj-1224	86	14	about	about	ADP
cuesj-1224	86	15	gi	gi	INTJ
cuesj-1224	86	16	adverse	adverse	ADJ
cuesj-1224	86	17	effects.[33	effects.[33	PROPN
cuesj-1224	86	18	]	]	PUNCT
cuesj-1224	86	19	according	accord	VERB
cuesj-1224	86	20	to	to	ADP
cuesj-1224	86	21	current	current	ADJ
cuesj-1224	86	22	literature	literature	NOUN
cuesj-1224	86	23	,	,	PUNCT
cuesj-1224	86	24	the	the	DET
cuesj-1224	86	25	most	most	ADV
cuesj-1224	86	26	prevalent	prevalent	ADJ
cuesj-1224	86	27	gi	gi	NOUN
cuesj-1224	86	28	side	side	NOUN
cuesj-1224	86	29	effects	effect	NOUN
cuesj-1224	86	30	of	of	ADP
cuesj-1224	86	31	metformin	metformin	NOUN
cuesj-1224	86	32	include	include	VERB
cuesj-1224	86	33	diarrhea	diarrhea	NOUN
cuesj-1224	86	34	,	,	PUNCT
cuesj-1224	86	35	nausea	nausea	NOUN
cuesj-1224	86	36	,	,	PUNCT
cuesj-1224	86	37	and	and	CCONJ
cuesj-1224	86	38	vomiting	vomiting	NOUN
cuesj-1224	86	39	(	(	PUNCT
cuesj-1224	86	40	with	with	ADP
cuesj-1224	86	41	a	a	DET
cuesj-1224	86	42	prevalence	prevalence	NOUN
cuesj-1224	86	43	of	of	ADP
cuesj-1224	86	44	2–63	2–63	NUM
cuesj-1224	86	45	%	%	NOUN
cuesj-1224	86	46	)	)	PUNCT
cuesj-1224	86	47	.	.	PUNCT
cuesj-1224	87	1	sulfonylureas	sulfonylureas	PROPN
cuesj-1224	87	2	function	function	PROPN
cuesj-1224	87	3	on	on	ADP
cuesj-1224	87	4	the	the	DET
cuesj-1224	87	5	atp	atp	PROPN
cuesj-1224	87	6	-	-	PUNCT
cuesj-1224	87	7	k	k	PROPN
cuesj-1224	87	8	channel	channel	NOUN
cuesj-1224	87	9	in	in	ADP
cuesj-1224	87	10	the	the	DET
cuesj-1224	87	11	pancreatic	pancreatic	ADJ
cuesj-1224	87	12	beta	beta	NOUN
cuesj-1224	87	13	cells	cell	NOUN
cuesj-1224	87	14	to	to	PART
cuesj-1224	87	15	promote	promote	VERB
cuesj-1224	87	16	the	the	DET
cuesj-1224	87	17	release	release	NOUN
cuesj-1224	87	18	of	of	ADP
cuesj-1224	87	19	insulin	insulin	NOUN
cuesj-1224	87	20	,	,	PUNCT
cuesj-1224	87	21	hence	hence	ADV
cuesj-1224	87	22	lowering	lower	VERB
cuesj-1224	87	23	hyperglycemia	hyperglycemia	NOUN
cuesj-1224	87	24	associated	associate	VERB
cuesj-1224	87	25	with	with	ADP
cuesj-1224	87	26	diabetes	diabetes	NOUN
cuesj-1224	87	27	.	.	PUNCT
cuesj-1224	88	1	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	88	2	is	be	AUX
cuesj-1224	88	3	a	a	DET
cuesj-1224	88	4	frequent	frequent	ADJ
cuesj-1224	88	5	adverse	adverse	ADJ
cuesj-1224	88	6	effect	effect	NOUN
cuesj-1224	88	7	of	of	ADP
cuesj-1224	88	8	sulfonylureas	sulfonylurea	NOUN
cuesj-1224	88	9	that	that	PRON
cuesj-1224	88	10	,	,	PUNCT
cuesj-1224	88	11	if	if	SCONJ
cuesj-1224	88	12	ignored	ignore	VERB
cuesj-1224	88	13	,	,	PUNCT
cuesj-1224	88	14	can	can	AUX
cuesj-1224	88	15	result	result	VERB
cuesj-1224	88	16	in	in	ADP
cuesj-1224	88	17	altered	altered	ADJ
cuesj-1224	88	18	mental	mental	ADJ
cuesj-1224	88	19	state	state	NOUN
cuesj-1224	88	20	,	,	PUNCT
cuesj-1224	88	21	convulsions	convulsion	NOUN
cuesj-1224	88	22	,	,	PUNCT
cuesj-1224	88	23	coma	coma	NOUN
cuesj-1224	88	24	,	,	PUNCT
cuesj-1224	88	25	or	or	CCONJ
cuesj-1224	88	26	even	even	ADV
cuesj-1224	88	27	death	death	NOUN
cuesj-1224	88	28	.	.	PUNCT
cuesj-1224	89	1	within	within	ADP
cuesj-1224	89	2	6	6	NUM
cuesj-1224	89	3	months	month	NOUN
cuesj-1224	89	4	of	of	ADP
cuesj-1224	89	5	starting	start	VERB
cuesj-1224	89	6	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	89	7	therapy	therapy	NOUN
cuesj-1224	89	8	,	,	PUNCT
cuesj-1224	89	9	20	20	NUM
cuesj-1224	89	10	%	%	NOUN
cuesj-1224	89	11	of	of	ADP
cuesj-1224	89	12	patients	patient	NOUN
cuesj-1224	89	13	are	be	AUX
cuesj-1224	89	14	thought	think	VERB
cuesj-1224	89	15	to	to	PART
cuesj-1224	89	16	develop	develop	VERB
cuesj-1224	89	17	hypoglycemia.[34	hypoglycemia.[34	PROPN
cuesj-1224	89	18	]	]	X
cuesj-1224	89	19	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	89	20	was	be	AUX
cuesj-1224	89	21	one	one	NUM
cuesj-1224	89	22	of	of	ADP
cuesj-1224	89	23	the	the	DET
cuesj-1224	89	24	common	common	ADJ
cuesj-1224	89	25	side	side	NOUN
cuesj-1224	89	26	effects	effect	NOUN
cuesj-1224	89	27	of	of	ADP
cuesj-1224	89	28	glimepiride	glimepiride	NOUN
cuesj-1224	89	29	in	in	ADP
cuesj-1224	89	30	this	this	DET
cuesj-1224	89	31	study	study	NOUN
cuesj-1224	89	32	which	which	PRON
cuesj-1224	89	33	accounts	account	VERB
cuesj-1224	89	34	as	as	ADP
cuesj-1224	89	35	(	(	PUNCT
cuesj-1224	89	36	n	n	NOUN
cuesj-1224	89	37	=	=	NUM
cuesj-1224	89	38	18	18	NUM
cuesj-1224	89	39	)	)	PUNCT
cuesj-1224	89	40	of	of	ADP
cuesj-1224	89	41	using	use	VERB
cuesj-1224	89	42	this	this	DET
cuesj-1224	89	43	antidiabetic	antidiabetic	ADJ
cuesj-1224	89	44	drug	drug	NOUN
cuesj-1224	89	45	as	as	ADP
cuesj-1224	89	46	monotherapy	monotherapy	NOUN
cuesj-1224	89	47	.	.	PUNCT
cuesj-1224	90	1	the	the	DET
cuesj-1224	90	2	fact	fact	NOUN
cuesj-1224	90	3	that	that	SCONJ
cuesj-1224	90	4	glimepiride	glimepiride	NOUN
cuesj-1224	90	5	has	have	AUX
cuesj-1224	90	6	two	two	NUM
cuesj-1224	90	7	mechanisms	mechanism	NOUN
cuesj-1224	90	8	of	of	ADP
cuesj-1224	90	9	action	action	NOUN
cuesj-1224	90	10	leads	lead	VERB
cuesj-1224	90	11	to	to	ADP
cuesj-1224	90	12	a	a	DET
cuesj-1224	90	13	dramatic	dramatic	ADJ
cuesj-1224	90	14	decrease	decrease	NOUN
cuesj-1224	90	15	in	in	ADP
cuesj-1224	90	16	blood	blood	NOUN
cuesj-1224	90	17	sugar	sugar	NOUN
cuesj-1224	90	18	levels	level	NOUN
cuesj-1224	90	19	while	while	SCONJ
cuesj-1224	90	20	posing	pose	VERB
cuesj-1224	90	21	little	little	ADJ
cuesj-1224	90	22	risk	risk	NOUN
cuesj-1224	90	23	of	of	ADP
cuesj-1224	90	24	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	90	25	or	or	CCONJ
cuesj-1224	90	26	increased	increase	VERB
cuesj-1224	90	27	body	body	NOUN
cuesj-1224	90	28	weight.[23	weight.[23	PROPN
cuesj-1224	90	29	]	]	PUNCT
cuesj-1224	90	30	study	study	NOUN
cuesj-1224	90	31	done	do	VERB
cuesj-1224	90	32	by	by	ADP
cuesj-1224	90	33	pranarka	pranarka	NOUN
cuesj-1224	90	34	had	have	AUX
cuesj-1224	90	35	shown	show	VERB
cuesj-1224	90	36	that	that	SCONJ
cuesj-1224	90	37	the	the	DET
cuesj-1224	90	38	kir	kir	PROPN
cuesj-1224	90	39	channel	channel	NOUN
cuesj-1224	90	40	gets	get	AUX
cuesj-1224	90	41	blocked	block	VERB
cuesj-1224	90	42	when	when	SCONJ
cuesj-1224	90	43	the	the	DET
cuesj-1224	90	44	ligand	ligand	ADJ
cuesj-1224	90	45	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	90	46	binds	bind	VERB
cuesj-1224	90	47	to	to	ADP
cuesj-1224	90	48	sur1	sur1	NOUN
cuesj-1224	90	49	,	,	PUNCT
cuesj-1224	90	50	causing	cause	VERB
cuesj-1224	90	51	membrane	membrane	NOUN
cuesj-1224	90	52	depolarization	depolarization	NOUN
cuesj-1224	90	53	.	.	PUNCT
cuesj-1224	91	1	this	this	PRON
cuesj-1224	91	2	opens	open	VERB
cuesj-1224	91	3	voltage	voltage	NOUN
cuesj-1224	91	4	-	-	PUNCT
cuesj-1224	91	5	dependent	dependent	ADJ
cuesj-1224	91	6	calcium	calcium	NOUN
cuesj-1224	91	7	channels	channel	NOUN
cuesj-1224	91	8	and	and	CCONJ
cuesj-1224	91	9	allows	allow	VERB
cuesj-1224	91	10	calcium	calcium	NOUN
cuesj-1224	91	11	to	to	PART
cuesj-1224	91	12	enter	enter	VERB
cuesj-1224	91	13	the	the	DET
cuesj-1224	91	14	cell	cell	NOUN
cuesj-1224	91	15	.	.	PUNCT
cuesj-1224	92	1	the	the	DET
cuesj-1224	92	2	release	release	NOUN
cuesj-1224	92	3	of	of	ADP
cuesj-1224	92	4	insulin	insulin	NOUN
cuesj-1224	92	5	is	be	AUX
cuesj-1224	92	6	triggered	trigger	VERB
cuesj-1224	92	7	by	by	ADP
cuesj-1224	92	8	the	the	DET
cuesj-1224	92	9	increased	increase	VERB
cuesj-1224	92	10	intracellular	intracellular	ADJ
cuesj-1224	92	11	calcium	calcium	NOUN
cuesj-1224	92	12	levels	level	NOUN
cuesj-1224	92	13	.	.	PUNCT
cuesj-1224	93	1	it	it	PRON
cuesj-1224	93	2	acts	act	VERB
cuesj-1224	93	3	as	as	ADP
cuesj-1224	93	4	a	a	DET
cuesj-1224	93	5	direct	direct	ADJ
cuesj-1224	93	6	secretagogue	secretagogue	NOUN
cuesj-1224	93	7	,	,	PUNCT
cuesj-1224	93	8	but	but	CCONJ
cuesj-1224	93	9	it	it	PRON
cuesj-1224	93	10	also	also	ADV
cuesj-1224	93	11	enhances	enhance	VERB
cuesj-1224	93	12	secretion	secretion	NOUN
cuesj-1224	93	13	of	of	ADP
cuesj-1224	93	14	insulin	insulin	NOUN
cuesj-1224	93	15	indirectly	indirectly	ADV
cuesj-1224	93	16	in	in	ADP
cuesj-1224	93	17	response	response	NOUN
cuesj-1224	93	18	to	to	ADP
cuesj-1224	93	19	fuels	fuel	NOUN
cuesj-1224	93	20	like	like	ADP
cuesj-1224	93	21	glucose.[35	glucose.[35	NOUN
cuesj-1224	93	22	]	]	PUNCT
cuesj-1224	93	23	in	in	ADP
cuesj-1224	93	24	this	this	DET
cuesj-1224	93	25	study	study	NOUN
cuesj-1224	93	26	,	,	PUNCT
cuesj-1224	93	27	pruritis	pruritis	ADJ
cuesj-1224	93	28	side	side	NOUN
cuesj-1224	93	29	effect	effect	NOUN
cuesj-1224	93	30	was	be	AUX
cuesj-1224	93	31	mostly	mostly	ADV
cuesj-1224	93	32	induced	induce	VERB
cuesj-1224	93	33	by	by	ADP
cuesj-1224	93	34	glimepiride	glimepiride	NOUN
cuesj-1224	93	35	(	(	PUNCT
cuesj-1224	93	36	n	n	NOUN
cuesj-1224	93	37	=	=	NUM
cuesj-1224	93	38	29	29	NUM
cuesj-1224	93	39	)	)	PUNCT
cuesj-1224	93	40	.	.	PUNCT
cuesj-1224	94	1	the	the	DET
cuesj-1224	94	2	antidiabetic	antidiabetic	ADJ
cuesj-1224	94	3	sulfonylurea	sulfonylurea	PROPN
cuesj-1224	94	4	drug	drug	NOUN
cuesj-1224	94	5	glimepiride	glimepiride	NOUN
cuesj-1224	94	6	generally	generally	ADV
cuesj-1224	94	7	is	be	AUX
cuesj-1224	94	8	well	well	ADV
cuesj-1224	94	9	tolerated	tolerate	VERB
cuesj-1224	94	10	.	.	PUNCT
cuesj-1224	95	1	glimepiride	glimepiride	NOUN
cuesj-1224	95	2	-	-	PUNCT
cuesj-1224	95	3	related	relate	VERB
cuesj-1224	95	4	skin	skin	NOUN
cuesj-1224	95	5	side	side	NOUN
cuesj-1224	95	6	effects	effect	NOUN
cuesj-1224	95	7	are	be	AUX
cuesj-1224	95	8	uncommon	uncommon	ADJ
cuesj-1224	95	9	and	and	CCONJ
cuesj-1224	95	10	might	might	AUX
cuesj-1224	95	11	include	include	VERB
cuesj-1224	95	12	rash	rash	NOUN
cuesj-1224	95	13	,	,	PUNCT
cuesj-1224	95	14	pruritis	pruritis	NOUN
cuesj-1224	95	15	,	,	PUNCT
cuesj-1224	95	16	photosensitivity	photosensitivity	NOUN
cuesj-1224	95	17	,	,	PUNCT
cuesj-1224	95	18	and	and	CCONJ
cuesj-1224	95	19	lichenoid	lichenoid	PROPN
cuesj-1224	95	20	eruption	eruption	NOUN
cuesj-1224	95	21	.	.	PUNCT
cuesj-1224	96	1	according	accord	VERB
cuesj-1224	96	2	yassen	yassen	PROPN
cuesj-1224	96	3	,	,	PUNCT
cuesj-1224	96	4	et	et	PROPN
cuesj-1224	96	5	al	al	PROPN
cuesj-1224	96	6	.	.	PUNCT
cuesj-1224	96	7	:	:	PUNCT
cuesj-1224	97	1	efficacy	efficacy	NOUN
cuesj-1224	97	2	and	and	CCONJ
cuesj-1224	97	3	safety	safety	NOUN
cuesj-1224	97	4	of	of	ADP
cuesj-1224	97	5	metformin	metformin	PROPN
cuesj-1224	97	6	,	,	PUNCT
cuesj-1224	97	7	sitagliptin	sitagliptin	NOUN
cuesj-1224	97	8	,	,	PUNCT
cuesj-1224	97	9	and	and	CCONJ
cuesj-1224	97	10	glimepiride	glimepiride	NOUN
cuesj-1224	97	11	in	in	ADP
cuesj-1224	97	12	type	type	NOUN
cuesj-1224	97	13	2	2	NUM
cuesj-1224	97	14	diabetes	diabetes	NOUN
cuesj-1224	97	15	108	108	NUM
cuesj-1224	97	16	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	97	17	cuesj	cuesj	NOUN
cuesj-1224	97	18	2024	2024	NUM
cuesj-1224	97	19	,	,	PUNCT
cuesj-1224	97	20	8	8	NUM
cuesj-1224	97	21	(	(	PUNCT
cuesj-1224	97	22	2	2	NUM
cuesj-1224	97	23	):	):	PUNCT
cuesj-1224	97	24	104	104	NUM
cuesj-1224	97	25	-	-	SYM
cuesj-1224	97	26	109	109	NUM
cuesj-1224	97	27	to	to	ADP
cuesj-1224	97	28	a	a	DET
cuesj-1224	97	29	number	number	NOUN
cuesj-1224	97	30	of	of	ADP
cuesj-1224	97	31	studies	study	NOUN
cuesj-1224	97	32	,	,	PUNCT
cuesj-1224	97	33	it	it	PRON
cuesj-1224	97	34	is	be	AUX
cuesj-1224	97	35	doubtful	doubtful	ADJ
cuesj-1224	97	36	that	that	SCONJ
cuesj-1224	97	37	sulfonamide	sulfonamide	NOUN
cuesj-1224	97	38	antimicrobials	antimicrobial	NOUN
cuesj-1224	97	39	(	(	PUNCT
cuesj-1224	97	40	such	such	ADJ
cuesj-1224	97	41	as	as	ADP
cuesj-1224	97	42	sulfamethoxazole	sulfamethoxazole	NOUN
cuesj-1224	97	43	-	-	PUNCT
cuesj-1224	97	44	trimethoprim	trimethoprim	NOUN
cuesj-1224	97	45	[	[	X
cuesj-1224	97	46	smx	smx	X
cuesj-1224	97	47	-	-	PUNCT
cuesj-1224	97	48	tmp	tmp	NOUN
cuesj-1224	97	49	]	]	PUNCT
cuesj-1224	97	50	)	)	PUNCT
cuesj-1224	97	51	and	and	CCONJ
cuesj-1224	97	52	sulfonamide	sulfonamide	VERB
cuesj-1224	97	53	non	non	NOUN
cuesj-1224	97	54	-	-	NOUN
cuesj-1224	97	55	antimicrobials	antimicrobial	NOUN
cuesj-1224	97	56	,	,	PUNCT
cuesj-1224	97	57	including	include	VERB
cuesj-1224	97	58	the	the	DET
cuesj-1224	97	59	antidiabetic	antidiabetic	ADJ
cuesj-1224	97	60	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	97	61	drug	drug	NOUN
cuesj-1224	97	62	;	;	PUNCT
cuesj-1224	97	63	glimepiride	glimepiride	NOUN
cuesj-1224	97	64	,	,	PUNCT
cuesj-1224	97	65	will	will	AUX
cuesj-1224	97	66	work	work	VERB
cuesj-1224	97	67	in	in	ADP
cuesj-1224	97	68	harmony	harmony	NOUN
cuesj-1224	97	69	.	.	PUNCT
cuesj-1224	98	1	here	here	ADV
cuesj-1224	98	2	,	,	PUNCT
cuesj-1224	98	3	this	this	DET
cuesj-1224	98	4	research	research	NOUN
cuesj-1224	98	5	describes	describe	VERB
cuesj-1224	98	6	a	a	DET
cuesj-1224	98	7	case	case	NOUN
cuesj-1224	98	8	of	of	ADP
cuesj-1224	98	9	neonatal	neonatal	ADJ
cuesj-1224	98	10	toxic	toxic	ADJ
cuesj-1224	98	11	epidermal	epidermal	ADJ
cuesj-1224	98	12	necrolysis	necrolysis	NOUN
cuesj-1224	98	13	in	in	ADP
cuesj-1224	98	14	a	a	DET
cuesj-1224	98	15	patient	patient	NOUN
cuesj-1224	98	16	who	who	PRON
cuesj-1224	98	17	had	have	VERB
cuesj-1224	98	18	a	a	DET
cuesj-1224	98	19	medical	medical	ADJ
cuesj-1224	98	20	history	history	NOUN
cuesj-1224	98	21	of	of	ADP
cuesj-1224	98	22	smx	smx	NOUN
cuesj-1224	98	23	-	-	PUNCT
cuesj-1224	98	24	tmp	tmp	NOUN
cuesj-1224	98	25	hypersensitivity	hypersensitivity	NOUN
cuesj-1224	98	26	,	,	PUNCT
cuesj-1224	98	27	most	most	ADV
cuesj-1224	98	28	likely	likely	ADJ
cuesj-1224	98	29	due	due	ADP
cuesj-1224	98	30	to	to	ADP
cuesj-1224	98	31	glimepiride.[36	glimepiride.[36	PROPN
cuesj-1224	98	32	]	]	PUNCT
cuesj-1224	98	33	this	this	DET
cuesj-1224	98	34	case	case	NOUN
cuesj-1224	98	35	emphasizes	emphasize	VERB
cuesj-1224	98	36	an	an	DET
cuesj-1224	98	37	uncommon	uncommon	ADJ
cuesj-1224	98	38	adverse	adverse	ADJ
cuesj-1224	98	39	reaction	reaction	NOUN
cuesj-1224	98	40	associated	associate	VERB
cuesj-1224	98	41	with	with	ADP
cuesj-1224	98	42	the	the	DET
cuesj-1224	98	43	administration	administration	NOUN
cuesj-1224	98	44	of	of	ADP
cuesj-1224	98	45	the	the	DET
cuesj-1224	98	46	dpp-4	dpp-4	ADJ
cuesj-1224	98	47	inhibitor	inhibitor	NOUN
cuesj-1224	98	48	sitagliptin	sitagliptin	NOUN
cuesj-1224	98	49	.	.	PUNCT
cuesj-1224	99	1	thirty	thirty	NUM
cuesj-1224	99	2	-	-	PUNCT
cuesj-1224	99	3	three	three	NUM
cuesj-1224	99	4	instances	instance	NOUN
cuesj-1224	99	5	of	of	ADP
cuesj-1224	99	6	joint	joint	ADJ
cuesj-1224	99	7	pain	pain	NOUN
cuesj-1224	99	8	associated	associate	VERB
cuesj-1224	99	9	with	with	ADP
cuesj-1224	99	10	dpp-4	dpp-4	ADJ
cuesj-1224	99	11	inhibitors	inhibitor	NOUN
cuesj-1224	99	12	were	be	AUX
cuesj-1224	99	13	found	find	VERB
cuesj-1224	99	14	by	by	ADP
cuesj-1224	99	15	the	the	DET
cuesj-1224	99	16	u.s	u.s	PROPN
cuesj-1224	99	17	.	.	PROPN
cuesj-1224	99	18	fda	fda	PROPN
cuesj-1224	99	19	.	.	PUNCT
cuesj-1224	99	20	sitagliptin	sitagliptin	PROPN
cuesj-1224	99	21	is	be	AUX
cuesj-1224	99	22	widely	widely	ADV
cuesj-1224	99	23	used	use	VERB
cuesj-1224	99	24	in	in	ADP
cuesj-1224	99	25	type	type	NOUN
cuesj-1224	99	26	2	2	NUM
cuesj-1224	99	27	d.m	d.m	PROPN
cuesj-1224	99	28	.	.	PUNCT
cuesj-1224	99	29	;	;	PUNCT
cuesj-1224	99	30	the	the	DET
cuesj-1224	99	31	side	side	ADJ
cuesj-1224	99	32	effect	effect	NOUN
cuesj-1224	99	33	rash	rash	NOUN
cuesj-1224	99	34	(	(	PUNCT
cuesj-1224	99	35	n	n	NOUN
cuesj-1224	99	36	=	=	SYM
cuesj-1224	99	37	32	32	NUM
cuesj-1224	99	38	)	)	PUNCT
cuesj-1224	99	39	cases	case	NOUN
cuesj-1224	99	40	have	have	AUX
cuesj-1224	99	41	been	be	AUX
cuesj-1224	99	42	reported	report	VERB
cuesj-1224	99	43	in	in	ADP
cuesj-1224	99	44	this	this	DET
cuesj-1224	99	45	study	study	NOUN
cuesj-1224	99	46	.	.	PUNCT
cuesj-1224	100	1	study	study	NOUN
cuesj-1224	100	2	done	do	VERB
cuesj-1224	100	3	by	by	ADP
cuesj-1224	100	4	sargın	sargın	PROPN
cuesj-1224	100	5	,	,	PUNCT
cuesj-1224	100	6	describe	describe	VERB
cuesj-1224	100	7	a	a	DET
cuesj-1224	100	8	case	case	NOUN
cuesj-1224	100	9	there	there	PRON
cuesj-1224	100	10	have	have	AUX
cuesj-1224	100	11	been	be	AUX
cuesj-1224	100	12	reports	report	NOUN
cuesj-1224	100	13	of	of	ADP
cuesj-1224	100	14	hypersensitivity	hypersensitivity	NOUN
cuesj-1224	100	15	reactions	reaction	NOUN
cuesj-1224	100	16	and	and	CCONJ
cuesj-1224	100	17	widespread	widespread	ADJ
cuesj-1224	100	18	skin	skin	NOUN
cuesj-1224	100	19	eruptions	eruption	NOUN
cuesj-1224	100	20	associated	associate	VERB
cuesj-1224	100	21	with	with	ADP
cuesj-1224	100	22	sitagliptin	sitagliptin	NOUN
cuesj-1224	100	23	and	and	CCONJ
cuesj-1224	100	24	its	its	PRON
cuesj-1224	100	25	metabolites	metabolite	NOUN
cuesj-1224	100	26	are	be	AUX
cuesj-1224	100	27	extremely	extremely	ADV
cuesj-1224	100	28	rare.[37	rare.[37	NOUN
cuesj-1224	100	29	]	]	PUNCT
cuesj-1224	100	30	finally	finally	ADV
cuesj-1224	100	31	,	,	PUNCT
cuesj-1224	100	32	the	the	DET
cuesj-1224	100	33	present	present	ADJ
cuesj-1224	100	34	study	study	NOUN
cuesj-1224	100	35	had	have	VERB
cuesj-1224	100	36	some	some	DET
cuesj-1224	100	37	limitations	limitation	NOUN
cuesj-1224	100	38	,	,	PUNCT
cuesj-1224	100	39	the	the	DET
cuesj-1224	100	40	most	most	ADV
cuesj-1224	100	41	protuberant	protuberant	ADJ
cuesj-1224	100	42	one	one	PRON
cuesj-1224	100	43	being	be	AUX
cuesj-1224	100	44	the	the	DET
cuesj-1224	100	45	rather	rather	ADV
cuesj-1224	100	46	small	small	ADJ
cuesj-1224	100	47	number	number	NOUN
cuesj-1224	100	48	of	of	ADP
cuesj-1224	100	49	patients	patient	NOUN
cuesj-1224	100	50	,	,	PUNCT
cuesj-1224	100	51	which	which	PRON
cuesj-1224	100	52	was	be	AUX
cuesj-1224	100	53	due	due	ADJ
cuesj-1224	100	54	to	to	ADP
cuesj-1224	100	55	restrictions	restriction	NOUN
cuesj-1224	100	56	on	on	ADP
cuesj-1224	100	57	resources	resource	NOUN
cuesj-1224	100	58	and	and	CCONJ
cuesj-1224	100	59	financing	financing	NOUN
cuesj-1224	100	60	.	.	PUNCT
cuesj-1224	101	1	conclusion	conclusion	NOUN
cuesj-1224	101	2	despite	despite	SCONJ
cuesj-1224	101	3	the	the	DET
cuesj-1224	101	4	study	study	NOUN
cuesj-1224	101	5	being	be	AUX
cuesj-1224	101	6	brief	brief	ADJ
cuesj-1224	101	7	,	,	PUNCT
cuesj-1224	101	8	both	both	CCONJ
cuesj-1224	101	9	glimepiride	glimepiride	NOUN
cuesj-1224	101	10	and	and	CCONJ
cuesj-1224	101	11	sitagliptin	sitagliptin	NOUN
cuesj-1224	101	12	were	be	AUX
cuesj-1224	101	13	well	well	ADV
cuesj-1224	101	14	received	receive	VERB
cuesj-1224	101	15	with	with	ADP
cuesj-1224	101	16	no	no	DET
cuesj-1224	101	17	significant	significant	ADJ
cuesj-1224	101	18	variations	variation	NOUN
cuesj-1224	101	19	in	in	ADP
cuesj-1224	101	20	weight	weight	NOUN
cuesj-1224	101	21	across	across	ADP
cuesj-1224	101	22	groups	group	NOUN
cuesj-1224	101	23	and	and	CCONJ
cuesj-1224	101	24	a	a	DET
cuesj-1224	101	25	low	low	ADJ
cuesj-1224	101	26	likelihood	likelihood	NOUN
cuesj-1224	101	27	of	of	ADP
cuesj-1224	101	28	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	101	29	.	.	PUNCT
cuesj-1224	102	1	considering	consider	VERB
cuesj-1224	102	2	the	the	DET
cuesj-1224	102	3	good	good	ADJ
cuesj-1224	102	4	efficacy	efficacy	NOUN
cuesj-1224	102	5	,	,	PUNCT
cuesj-1224	102	6	safe	safe	ADJ
cuesj-1224	102	7	profile	profile	NOUN
cuesj-1224	102	8	,	,	PUNCT
cuesj-1224	102	9	low	low	ADJ
cuesj-1224	102	10	risk	risk	NOUN
cuesj-1224	102	11	of	of	ADP
cuesj-1224	102	12	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	102	13	,	,	PUNCT
cuesj-1224	102	14	lack	lack	NOUN
cuesj-1224	102	15	of	of	ADP
cuesj-1224	102	16	weight	weight	NOUN
cuesj-1224	102	17	change	change	NOUN
cuesj-1224	102	18	,	,	PUNCT
cuesj-1224	102	19	additional	additional	ADJ
cuesj-1224	102	20	extrapancreatic	extrapancreatic	ADJ
cuesj-1224	102	21	action	action	NOUN
cuesj-1224	102	22	,	,	PUNCT
cuesj-1224	102	23	and	and	CCONJ
cuesj-1224	102	24	low	low	ADJ
cuesj-1224	102	25	cost	cost	NOUN
cuesj-1224	102	26	,	,	PUNCT
cuesj-1224	102	27	glimepiride	glimepiride	NOUN
cuesj-1224	102	28	remains	remain	VERB
cuesj-1224	102	29	a	a	DET
cuesj-1224	102	30	sensible	sensible	ADJ
cuesj-1224	102	31	choice	choice	NOUN
cuesj-1224	102	32	as	as	ADP
cuesj-1224	102	33	a	a	DET
cuesj-1224	102	34	supplement	supplement	NOUN
cuesj-1224	102	35	to	to	PART
cuesj-1224	102	36	metformin	metformin	NOUN
cuesj-1224	102	37	in	in	ADP
cuesj-1224	102	38	patients	patient	NOUN
cuesj-1224	102	39	with	with	ADP
cuesj-1224	102	40	type	type	NOUN
cuesj-1224	102	41	2	2	NUM
cuesj-1224	102	42	diabetes	diabetes	NOUN
cuesj-1224	102	43	.	.	PUNCT
cuesj-1224	103	1	contemporary	contemporary	ADJ
cuesj-1224	103	2	sulfonylureas	sulfonylurea	NOUN
cuesj-1224	103	3	such	such	ADJ
cuesj-1224	103	4	as	as	ADP
cuesj-1224	103	5	glimepiride	glimepiride	NOUN
cuesj-1224	103	6	remain	remain	VERB
cuesj-1224	103	7	a	a	DET
cuesj-1224	103	8	significant	significant	ADJ
cuesj-1224	103	9	choice	choice	NOUN
cuesj-1224	103	10	as	as	ADP
cuesj-1224	103	11	a	a	DET
cuesj-1224	103	12	second	second	ADJ
cuesj-1224	103	13	-	-	PUNCT
cuesj-1224	103	14	line	line	NOUN
cuesj-1224	103	15	treatment	treatment	NOUN
cuesj-1224	103	16	following	follow	VERB
cuesj-1224	103	17	metformin	metformin	NOUN
cuesj-1224	103	18	among	among	ADP
cuesj-1224	103	19	the	the	DET
cuesj-1224	103	20	latest	late	ADJ
cuesj-1224	103	21	antidiabetic	antidiabetic	ADJ
cuesj-1224	103	22	medications	medication	NOUN
cuesj-1224	103	23	.	.	PUNCT
cuesj-1224	104	1	acknowledgment	acknowledgment	NOUN
cuesj-1224	104	2	we	we	PRON
cuesj-1224	104	3	would	would	AUX
cuesj-1224	104	4	like	like	VERB
cuesj-1224	104	5	to	to	PART
cuesj-1224	104	6	express	express	VERB
cuesj-1224	104	7	our	our	PRON
cuesj-1224	104	8	deep	deep	ADJ
cuesj-1224	104	9	gratitude	gratitude	NOUN
cuesj-1224	104	10	to	to	ADP
cuesj-1224	104	11	the	the	DET
cuesj-1224	104	12	layla	layla	PROPN
cuesj-1224	104	13	qasim	qasim	PROPN
cuesj-1224	104	14	diabetes	diabetes	PROPN
cuesj-1224	104	15	center	center	PROPN
cuesj-1224	104	16	in	in	ADP
cuesj-1224	104	17	erbil	erbil	PROPN
cuesj-1224	104	18	for	for	ADP
cuesj-1224	104	19	their	their	PRON
cuesj-1224	104	20	cooperation	cooperation	NOUN
cuesj-1224	104	21	;	;	PUNCT
cuesj-1224	104	22	without	without	ADP
cuesj-1224	104	23	them	they	PRON
cuesj-1224	104	24	,	,	PUNCT
cuesj-1224	104	25	this	this	DET
cuesj-1224	104	26	research	research	NOUN
cuesj-1224	104	27	would	would	AUX
cuesj-1224	104	28	not	not	PART
cuesj-1224	104	29	have	have	AUX
cuesj-1224	104	30	been	be	AUX
cuesj-1224	104	31	possible	possible	ADJ
cuesj-1224	104	32	.	.	PUNCT
cuesj-1224	105	1	references	reference	NOUN
cuesj-1224	105	2	[	[	X
cuesj-1224	105	3	1	1	NUM
cuesj-1224	105	4	]	]	PUNCT
cuesj-1224	105	5	h.	h.	PROPN
cuesj-1224	105	6	wang	wang	PROPN
cuesj-1224	105	7	,	,	PUNCT
cuesj-1224	105	8	j.	j.	PROPN
cuesj-1224	105	9	kuang	kuang	PROPN
cuesj-1224	105	10	and	and	CCONJ
cuesj-1224	105	11	y.	y.	PROPN
cuesj-1224	105	12	luo	luo	PROPN
cuesj-1224	105	13	.	.	PUNCT
cuesj-1224	106	1	insulin	insulin	NOUN
cuesj-1224	106	2	sensitivity	sensitivity	NOUN
cuesj-1224	106	3	and	and	CCONJ
cuesj-1224	106	4	pancreatic	pancreatic	ADJ
cuesj-1224	106	5	islet	islet	NOUN
cuesj-1224	106	6	in	in	ADP
cuesj-1224	106	7	patients	patient	NOUN
cuesj-1224	106	8	with	with	ADP
cuesj-1224	106	9	newly	newly	ADV
cuesj-1224	106	10	diagnosed	diagnose	VERB
cuesj-1224	106	11	type	type	NOUN
cuesj-1224	106	12	2	2	NUM
cuesj-1224	106	13	diabetes	diabetes	NOUN
cuesj-1224	106	14	mellitus	mellitus	NOUN
cuesj-1224	106	15	.	.	PUNCT
cuesj-1224	107	1	α	α	PROPN
cuesj-1224	107	2	and	and	CCONJ
cuesj-1224	107	3	β	β	X
cuesj-1224	107	4	effect	effect	NOUN
cuesj-1224	107	5	of	of	ADP
cuesj-1224	107	6	cell	cell	NOUN
cuesj-1224	107	7	function	function	NOUN
cuesj-1224	107	8	.	.	PUNCT
cuesj-1224	108	1	chinese	chinese	ADJ
cuesj-1224	108	2	journal	journal	PROPN
cuesj-1224	108	3	of	of	ADP
cuesj-1224	108	4	diabetes	diabetes	NOUN
cuesj-1224	108	5	,	,	PUNCT
cuesj-1224	108	6	vol	vol	NOUN
cuesj-1224	108	7	.	.	PROPN
cuesj-1224	108	8	12	12	NUM
cuesj-1224	108	9	,	,	PUNCT
cuesj-1224	108	10	pp	pp	ADJ
cuesj-1224	108	11	.	.	PUNCT
cuesj-1224	109	1	382	382	NUM
cuesj-1224	109	2	-	-	SYM
cuesj-1224	109	3	386	386	NUM
cuesj-1224	109	4	,	,	PUNCT
cuesj-1224	109	5	2020	2020	NUM
cuesj-1224	109	6	.	.	PUNCT
cuesj-1224	110	1	[	[	X
cuesj-1224	110	2	2	2	NUM
cuesj-1224	110	3	]	]	PUNCT
cuesj-1224	110	4	r.	r.	PROPN
cuesj-1224	110	5	hwaiz	hwaiz	PROPN
cuesj-1224	110	6	and	and	CCONJ
cuesj-1224	110	7	h.	h.	PROPN
cuesj-1224	110	8	sabri	sabri	PROPN
cuesj-1224	110	9	.	.	PUNCT
cuesj-1224	111	1	inhibition	inhibition	NOUN
cuesj-1224	111	2	of	of	ADP
cuesj-1224	111	3	rac	rac	NOUN
cuesj-1224	111	4	1	1	NUM
cuesj-1224	111	5	protect	protect	NOUN
cuesj-1224	111	6	against	against	ADP
cuesj-1224	111	7	platelet	platelet	NOUN
cuesj-1224	111	8	induced	induce	VERB
cuesj-1224	111	9	liver	liver	NOUN
cuesj-1224	111	10	and	and	CCONJ
cuesj-1224	111	11	kidney	kidney	NOUN
cuesj-1224	111	12	‎injury	‎injury	PROPN
cuesj-1224	111	13	in	in	ADP
cuesj-1224	111	14	diabetes	diabetes	NOUN
cuesj-1224	111	15	mellitus	mellitus	NOUN
cuesj-1224	111	16	.	.	PUNCT
cuesj-1224	112	1	cihan	cihan	VERB
cuesj-1224	112	2	university	university	NOUN
cuesj-1224	112	3	-	-	PUNCT
cuesj-1224	112	4	erbil	erbil	PROPN
cuesj-1224	112	5	scientific	scientific	ADJ
cuesj-1224	112	6	journal	journal	NOUN
cuesj-1224	112	7	,	,	PUNCT
cuesj-1224	112	8	vol	vol	NOUN
cuesj-1224	112	9	.	.	PROPN
cuesj-1224	113	1	7	7	NUM
cuesj-1224	113	2	,	,	PUNCT
cuesj-1224	113	3	no	no	INTJ
cuesj-1224	113	4	.	.	NOUN
cuesj-1224	113	5	1	1	NUM
cuesj-1224	113	6	,	,	PUNCT
cuesj-1224	113	7	pp	pp	ADJ
cuesj-1224	113	8	.	.	PUNCT
cuesj-1224	114	1	29	29	NUM
cuesj-1224	114	2	-	-	SYM
cuesj-1224	114	3	34	34	NUM
cuesj-1224	114	4	,	,	PUNCT
cuesj-1224	114	5	2023	2023	NUM
cuesj-1224	114	6	.	.	PUNCT
cuesj-1224	115	1	[	[	X
cuesj-1224	115	2	3	3	NUM
cuesj-1224	115	3	]	]	PUNCT
cuesj-1224	115	4	a.	a.	NOUN
cuesj-1224	115	5	hussein	hussein	PROPN
cuesj-1224	115	6	,	,	PUNCT
cuesj-1224	115	7	r.	r.	PROPN
cuesj-1224	115	8	salahalddin	salahalddin	PROPN
cuesj-1224	115	9	,	,	PUNCT
cuesj-1224	115	10	z.	z.	PROPN
cuesj-1224	115	11	taha	taha	PROPN
cuesj-1224	115	12	,	,	PUNCT
cuesj-1224	115	13	h.	h.	PROPN
cuesj-1224	115	14	majeed	majeed	PROPN
cuesj-1224	115	15	,	,	PUNCT
cuesj-1224	115	16	a.	a.	NOUN
cuesj-1224	115	17	muhialdin	muhialdin	NOUN
cuesj-1224	115	18	and	and	CCONJ
cuesj-1224	115	19	r.	r.	PROPN
cuesj-1224	115	20	faraj	faraj	PROPN
cuesj-1224	115	21	.	.	PUNCT
cuesj-1224	116	1	a	a	DET
cuesj-1224	116	2	comparison	comparison	NOUN
cuesj-1224	116	3	of	of	ADP
cuesj-1224	116	4	chemical	chemical	NOUN
cuesj-1224	116	5	compounds	compound	NOUN
cuesj-1224	116	6	between	between	ADP
cuesj-1224	116	7	antidiabetic	antidiabetic	ADJ
cuesj-1224	116	8	drug	drug	NOUN
cuesj-1224	116	9	and	and	CCONJ
cuesj-1224	116	10	some	some	DET
cuesj-1224	116	11	medicinal	medicinal	ADJ
cuesj-1224	116	12	plants	plant	NOUN
cuesj-1224	116	13	.	.	PUNCT
cuesj-1224	117	1	cihan	cihan	VERB
cuesj-1224	117	2	university	university	NOUN
cuesj-1224	117	3	-	-	PUNCT
cuesj-1224	117	4	erbil	erbil	PROPN
cuesj-1224	117	5	scientific	scientific	ADJ
cuesj-1224	117	6	journal	journal	NOUN
cuesj-1224	117	7	,	,	PUNCT
cuesj-1224	117	8	vol	vol	NOUN
cuesj-1224	117	9	.	.	PROPN
cuesj-1224	117	10	6	6	NUM
cuesj-1224	117	11	,	,	PUNCT
cuesj-1224	117	12	no	no	INTJ
cuesj-1224	117	13	.	.	NOUN
cuesj-1224	117	14	2	2	NUM
cuesj-1224	117	15	,	,	PUNCT
cuesj-1224	117	16	pp	pp	ADJ
cuesj-1224	117	17	.	.	PUNCT
cuesj-1224	118	1	99	99	NUM
cuesj-1224	118	2	-	-	SYM
cuesj-1224	118	3	102	102	NUM
cuesj-1224	118	4	,	,	PUNCT
cuesj-1224	118	5	2022	2022	NUM
cuesj-1224	118	6	.	.	PUNCT
cuesj-1224	119	1	[	[	X
cuesj-1224	119	2	4	4	X
cuesj-1224	119	3	]	]	PUNCT
cuesj-1224	119	4	s.	s.	PROPN
cuesj-1224	119	5	r.	r.	PROPN
cuesj-1224	119	6	choudhury	choudhury	PROPN
cuesj-1224	119	7	,	,	PUNCT
cuesj-1224	119	8	a.	a.	PROPN
cuesj-1224	119	9	datta	datta	PROPN
cuesj-1224	119	10	and	and	CCONJ
cuesj-1224	119	11	s.	s.	PROPN
cuesj-1224	119	12	chanda	chanda	PROPN
cuesj-1224	119	13	.	.	PUNCT
cuesj-1224	120	1	overview	overview	NOUN
cuesj-1224	120	2	of	of	ADP
cuesj-1224	120	3	current	current	ADJ
cuesj-1224	120	4	and	and	CCONJ
cuesj-1224	120	5	upcoming	upcoming	ADJ
cuesj-1224	120	6	strategies	strategy	NOUN
cuesj-1224	120	7	implied	imply	VERB
cuesj-1224	120	8	for	for	ADP
cuesj-1224	120	9	the	the	DET
cuesj-1224	120	10	therapy	therapy	NOUN
cuesj-1224	120	11	of	of	ADP
cuesj-1224	120	12	type	type	NOUN
cuesj-1224	120	13	2	2	NUM
cuesj-1224	120	14	diabetes	diabetes	NOUN
cuesj-1224	120	15	mellitus	mellitus	NOUN
cuesj-1224	120	16	.	.	PUNCT
cuesj-1224	121	1	current	current	ADJ
cuesj-1224	121	2	diabetes	diabetes	NOUN
cuesj-1224	121	3	reviews	review	NOUN
cuesj-1224	121	4	,	,	PUNCT
cuesj-1224	121	5	vol	vol	NOUN
cuesj-1224	121	6	.	.	PROPN
cuesj-1224	121	7	10	10	NUM
cuesj-1224	121	8	,	,	PUNCT
cuesj-1224	121	9	pp	pp	ADJ
cuesj-1224	121	10	.	.	PUNCT
cuesj-1224	122	1	275	275	NUM
cuesj-1224	122	2	-	-	SYM
cuesj-1224	122	3	282	282	NUM
cuesj-1224	122	4	,	,	PUNCT
cuesj-1224	122	5	2014	2014	NUM
cuesj-1224	122	6	.	.	PUNCT
cuesj-1224	123	1	[	[	X
cuesj-1224	123	2	5	5	X
cuesj-1224	123	3	]	]	PUNCT
cuesj-1224	123	4	e.	e.	PROPN
cuesj-1224	123	5	montanya	montanya	PROPN
cuesj-1224	123	6	and	and	CCONJ
cuesj-1224	123	7	g.	g.	PROPN
cuesj-1224	123	8	sesti	sesti	PROPN
cuesj-1224	123	9	.	.	PUNCT
cuesj-1224	124	1	a	a	DET
cuesj-1224	124	2	review	review	NOUN
cuesj-1224	124	3	of	of	ADP
cuesj-1224	124	4	efficacy	efficacy	NOUN
cuesj-1224	124	5	and	and	CCONJ
cuesj-1224	124	6	safety	safety	NOUN
cuesj-1224	124	7	data	datum	NOUN
cuesj-1224	124	8	regarding	regard	VERB
cuesj-1224	124	9	the	the	DET
cuesj-1224	124	10	use	use	NOUN
cuesj-1224	124	11	of	of	ADP
cuesj-1224	124	12	liraglutide	liraglutide	NOUN
cuesj-1224	124	13	.	.	PUNCT
cuesj-1224	125	1	diabetes	diabetes	NOUN
cuesj-1224	125	2	care	care	NOUN
cuesj-1224	125	3	,	,	PUNCT
cuesj-1224	125	4	vol	vol	NOUN
cuesj-1224	125	5	.	.	PROPN
cuesj-1224	126	1	32	32	NUM
cuesj-1224	126	2	,	,	PUNCT
cuesj-1224	126	3	pp	pp	ADJ
cuesj-1224	126	4	.	.	PUNCT
cuesj-1224	127	1	193203	193203	NUM
cuesj-1224	127	2	,	,	PUNCT
cuesj-1224	127	3	2009	2009	NUM
cuesj-1224	127	4	.	.	PUNCT
cuesj-1224	128	1	[	[	X
cuesj-1224	128	2	6	6	NUM
cuesj-1224	128	3	]	]	PUNCT
cuesj-1224	128	4	w.	w.	PROPN
cuesj-1224	128	5	a.	a.	NOUN
cuesj-1224	128	6	nuffer	nuffer	PROPN
cuesj-1224	128	7	and	and	CCONJ
cuesj-1224	128	8	j.	j.	PROPN
cuesj-1224	128	9	m.	m.	PROPN
cuesj-1224	128	10	trujillo	trujillo	PROPN
cuesj-1224	128	11	.	.	PUNCT
cuesj-1224	128	12	liraglutide	liraglutide	PROPN
cuesj-1224	128	13	:	:	PUNCT
cuesj-1224	128	14	a	a	DET
cuesj-1224	128	15	new	new	ADJ
cuesj-1224	128	16	option	option	NOUN
cuesj-1224	128	17	for	for	ADP
cuesj-1224	128	18	the	the	DET
cuesj-1224	128	19	treatment	treatment	NOUN
cuesj-1224	128	20	of	of	ADP
cuesj-1224	128	21	obesity	obesity	NOUN
cuesj-1224	128	22	.	.	PUNCT
cuesj-1224	129	1	pharmacotherapy	pharmacotherapy	NOUN
cuesj-1224	129	2	:	:	PUNCT
cuesj-1224	129	3	the	the	DET
cuesj-1224	129	4	journal	journal	NOUN
cuesj-1224	129	5	of	of	ADP
cuesj-1224	129	6	human	human	ADJ
cuesj-1224	129	7	pharmacology	pharmacology	NOUN
cuesj-1224	129	8	and	and	CCONJ
cuesj-1224	129	9	drug	drug	NOUN
cuesj-1224	129	10	therapy	therapy	NOUN
cuesj-1224	129	11	,	,	PUNCT
cuesj-1224	129	12	vol	vol	NOUN
cuesj-1224	129	13	.	.	PROPN
cuesj-1224	129	14	35	35	NUM
cuesj-1224	129	15	,	,	PUNCT
cuesj-1224	129	16	no	no	INTJ
cuesj-1224	129	17	.	.	NOUN
cuesj-1224	129	18	10	10	NUM
cuesj-1224	129	19	,	,	PUNCT
cuesj-1224	129	20	pp	pp	ADJ
cuesj-1224	129	21	.	.	PUNCT
cuesj-1224	130	1	926	926	NUM
cuesj-1224	130	2	-	-	SYM
cuesj-1224	130	3	934	934	NUM
cuesj-1224	130	4	,	,	PUNCT
cuesj-1224	130	5	2015	2015	NUM
cuesj-1224	130	6	.	.	PUNCT
cuesj-1224	131	1	[	[	X
cuesj-1224	131	2	7	7	NUM
cuesj-1224	131	3	]	]	PUNCT
cuesj-1224	131	4	a.	a.	NOUN
cuesj-1224	131	5	j.	j.	PROPN
cuesj-1224	131	6	scheen	scheen	PROPN
cuesj-1224	131	7	and	and	CCONJ
cuesj-1224	131	8	n.	n.	PROPN
cuesj-1224	131	9	paquot	paquot	PROPN
cuesj-1224	131	10	.	.	PUNCT
cuesj-1224	132	1	gliptin	gliptin	PROPN
cuesj-1224	132	2	versus	versus	ADP
cuesj-1224	132	3	a	a	DET
cuesj-1224	132	4	sulphonylurea	sulphonylurea	NOUN
cuesj-1224	132	5	as	as	ADP
cuesj-1224	132	6	add	add	NOUN
cuesj-1224	132	7	-	-	PUNCT
cuesj-1224	132	8	on	on	NOUN
cuesj-1224	132	9	to	to	ADP
cuesj-1224	132	10	metformin	metformin	NOUN
cuesj-1224	132	11	.	.	PUNCT
cuesj-1224	133	1	lancet	lancet	PROPN
cuesj-1224	133	2	(	(	PUNCT
cuesj-1224	133	3	london	london	PROPN
cuesj-1224	133	4	,	,	PUNCT
cuesj-1224	133	5	england	england	PROPN
cuesj-1224	133	6	)	)	PUNCT
cuesj-1224	133	7	,	,	PUNCT
cuesj-1224	133	8	vol	vol	NOUN
cuesj-1224	133	9	.	.	PROPN
cuesj-1224	133	10	380	380	NUM
cuesj-1224	133	11	,	,	PUNCT
cuesj-1224	133	12	no	no	INTJ
cuesj-1224	133	13	.	.	NOUN
cuesj-1224	133	14	9840	9840	NUM
cuesj-1224	133	15	,	,	PUNCT
cuesj-1224	133	16	pp	pp	ADJ
cuesj-1224	133	17	.	.	PUNCT
cuesj-1224	134	1	450	450	NUM
cuesj-1224	134	2	-	-	SYM
cuesj-1224	134	3	452	452	NUM
cuesj-1224	134	4	,	,	PUNCT
cuesj-1224	134	5	2012	2012	NUM
cuesj-1224	134	6	.	.	PUNCT
cuesj-1224	135	1	[	[	X
cuesj-1224	135	2	8	8	NUM
cuesj-1224	135	3	]	]	X
cuesj-1224	135	4	n.	n.	PROPN
cuesj-1224	135	5	m.	m.	PROPN
cuesj-1224	135	6	pham	pham	PROPN
cuesj-1224	135	7	,	,	PUNCT
cuesj-1224	135	8	v.	v.	CCONJ
cuesj-1224	135	9	v.	v.	CCONJ
cuesj-1224	135	10	do	do	AUX
cuesj-1224	135	11	and	and	CCONJ
cuesj-1224	135	12	a.	a.	PROPN
cuesj-1224	135	13	h.	h.	PROPN
cuesj-1224	135	14	lee	lee	PROPN
cuesj-1224	135	15	.	.	PUNCT
cuesj-1224	136	1	polyphenol	polyphenol	NOUN
cuesj-1224	136	2	-	-	PUNCT
cuesj-1224	136	3	rich	rich	ADJ
cuesj-1224	136	4	foods	food	NOUN
cuesj-1224	136	5	and	and	CCONJ
cuesj-1224	136	6	risk	risk	NOUN
cuesj-1224	136	7	of	of	ADP
cuesj-1224	136	8	gestational	gestational	ADJ
cuesj-1224	136	9	diabetes	diabetes	NOUN
cuesj-1224	136	10	:	:	PUNCT
cuesj-1224	136	11	a	a	DET
cuesj-1224	136	12	systematic	systematic	ADJ
cuesj-1224	136	13	review	review	NOUN
cuesj-1224	136	14	and	and	CCONJ
cuesj-1224	136	15	meta	meta	ADJ
cuesj-1224	136	16	-	-	PUNCT
cuesj-1224	136	17	analysis	analysis	NOUN
cuesj-1224	136	18	.	.	PUNCT
cuesj-1224	137	1	european	european	ADJ
cuesj-1224	137	2	journal	journal	PROPN
cuesj-1224	137	3	of	of	ADP
cuesj-1224	137	4	clinical	clinical	ADJ
cuesj-1224	137	5	nutrition	nutrition	NOUN
cuesj-1224	137	6	,	,	PUNCT
cuesj-1224	137	7	vol	vol	NOUN
cuesj-1224	137	8	.	.	PROPN
cuesj-1224	137	9	73	73	NUM
cuesj-1224	137	10	,	,	PUNCT
cuesj-1224	137	11	pp	pp	ADJ
cuesj-1224	137	12	.	.	PUNCT
cuesj-1224	138	1	647	647	NUM
cuesj-1224	138	2	-	-	SYM
cuesj-1224	138	3	656	656	NUM
cuesj-1224	138	4	,	,	PUNCT
cuesj-1224	138	5	2019	2019	NUM
cuesj-1224	138	6	.	.	PUNCT
cuesj-1224	139	1	[	[	X
cuesj-1224	139	2	9	9	NUM
cuesj-1224	139	3	]	]	PUNCT
cuesj-1224	139	4	b.	b.	PROPN
cuesj-1224	139	5	viollet	viollet	PROPN
cuesj-1224	139	6	,	,	PUNCT
cuesj-1224	139	7	b.	b.	PROPN
cuesj-1224	139	8	guigas	guigas	PROPN
cuesj-1224	139	9	,	,	PUNCT
cuesj-1224	139	10	n.	n.	PROPN
cuesj-1224	139	11	s.	s.	PROPN
cuesj-1224	139	12	garcia	garcia	PROPN
cuesj-1224	139	13	,	,	PUNCT
cuesj-1224	139	14	j.	j.	PROPN
cuesj-1224	139	15	leclerc	leclerc	PROPN
cuesj-1224	139	16	,	,	PUNCT
cuesj-1224	139	17	m.	m.	NOUN
cuesj-1224	139	18	foretz	foretz	PROPN
cuesj-1224	139	19	and	and	CCONJ
cuesj-1224	139	20	f.	f.	PROPN
cuesj-1224	139	21	andreelli	andreelli	PROPN
cuesj-1224	139	22	.	.	PUNCT
cuesj-1224	140	1	cellular	cellular	ADJ
cuesj-1224	140	2	and	and	CCONJ
cuesj-1224	140	3	molecular	molecular	ADJ
cuesj-1224	140	4	mechanisms	mechanism	NOUN
cuesj-1224	140	5	of	of	ADP
cuesj-1224	140	6	metformin	metformin	NOUN
cuesj-1224	140	7	:	:	PUNCT
cuesj-1224	140	8	an	an	DET
cuesj-1224	140	9	overview	overview	NOUN
cuesj-1224	140	10	.	.	PUNCT
cuesj-1224	141	1	clinical	clinical	ADJ
cuesj-1224	141	2	science	science	NOUN
cuesj-1224	141	3	,	,	PUNCT
cuesj-1224	141	4	vol	vol	NOUN
cuesj-1224	141	5	.	.	PROPN
cuesj-1224	141	6	122	122	NUM
cuesj-1224	141	7	,	,	PUNCT
cuesj-1224	141	8	no	no	INTJ
cuesj-1224	141	9	.	.	NOUN
cuesj-1224	141	10	6	6	NUM
cuesj-1224	141	11	,	,	PUNCT
cuesj-1224	141	12	pp	pp	ADJ
cuesj-1224	141	13	.	.	PUNCT
cuesj-1224	142	1	253	253	NUM
cuesj-1224	142	2	-	-	SYM
cuesj-1224	142	3	270	270	NUM
cuesj-1224	142	4	,	,	PUNCT
cuesj-1224	142	5	2012	2012	NUM
cuesj-1224	142	6	.	.	PUNCT
cuesj-1224	143	1	[	[	X
cuesj-1224	143	2	10	10	NUM
cuesj-1224	143	3	]	]	X
cuesj-1224	143	4	e.	e.	PROPN
cuesj-1224	143	5	sanchez	sanchez	PROPN
cuesj-1224	143	6	-	-	PUNCT
cuesj-1224	143	7	rangel	rangel	PROPN
cuesj-1224	143	8	and	and	CCONJ
cuesj-1224	143	9	s.	s.	PROPN
cuesj-1224	143	10	e.	e.	PROPN
cuesj-1224	143	11	inzucchi	inzucchi	PROPN
cuesj-1224	143	12	.	.	PUNCT
cuesj-1224	144	1	metformin	metformin	NOUN
cuesj-1224	144	2	:	:	PUNCT
cuesj-1224	144	3	clinical	clinical	ADJ
cuesj-1224	144	4	use	use	NOUN
cuesj-1224	144	5	in	in	ADP
cuesj-1224	144	6	type	type	NOUN
cuesj-1224	144	7	2	2	NUM
cuesj-1224	144	8	diabetes	diabetes	NOUN
cuesj-1224	144	9	.	.	PUNCT
cuesj-1224	145	1	diabetologia	diabetologia	NOUN
cuesj-1224	145	2	,	,	PUNCT
cuesj-1224	145	3	vol	vol	NOUN
cuesj-1224	145	4	.	.	PROPN
cuesj-1224	145	5	60	60	NUM
cuesj-1224	145	6	,	,	PUNCT
cuesj-1224	145	7	pp	pp	ADJ
cuesj-1224	145	8	.	.	PUNCT
cuesj-1224	146	1	1586	1586	NUM
cuesj-1224	146	2	-	-	SYM
cuesj-1224	146	3	1593	1593	NUM
cuesj-1224	146	4	,	,	PUNCT
cuesj-1224	146	5	2017	2017	NUM
cuesj-1224	146	6	.	.	PUNCT
cuesj-1224	147	1	[	[	X
cuesj-1224	147	2	11	11	NUM
cuesj-1224	147	3	]	]	X
cuesj-1224	147	4	i.	i.	NOUN
cuesj-1224	147	5	vardarli	vardarli	PROPN
cuesj-1224	147	6	,	,	PUNCT
cuesj-1224	147	7	e.	e.	PROPN
cuesj-1224	147	8	arndt	arndt	PROPN
cuesj-1224	147	9	,	,	PUNCT
cuesj-1224	147	10	c.	c.	PROPN
cuesj-1224	147	11	f.	f.	PROPN
cuesj-1224	147	12	deacon	deacon	PROPN
cuesj-1224	147	13	,	,	PUNCT
cuesj-1224	147	14	j.	j.	PROPN
cuesj-1224	147	15	j.	j.	PROPN
cuesj-1224	147	16	holst	holst	PROPN
cuesj-1224	147	17	and	and	CCONJ
cuesj-1224	147	18	m.	m.	NOUN
cuesj-1224	147	19	a.	a.	NOUN
cuesj-1224	147	20	nauck	nauck	PROPN
cuesj-1224	147	21	.	.	PUNCT
cuesj-1224	148	1	effects	effect	NOUN
cuesj-1224	148	2	of	of	ADP
cuesj-1224	148	3	sitagliptin	sitagliptin	NOUN
cuesj-1224	148	4	and	and	CCONJ
cuesj-1224	148	5	metformin	metformin	NOUN
cuesj-1224	148	6	treatment	treatment	NOUN
cuesj-1224	148	7	on	on	ADP
cuesj-1224	148	8	incretin	incretin	ADJ
cuesj-1224	148	9	hormone	hormone	NOUN
cuesj-1224	148	10	and	and	CCONJ
cuesj-1224	148	11	insulin	insulin	NOUN
cuesj-1224	148	12	secretory	secretory	ADJ
cuesj-1224	148	13	responses	response	NOUN
cuesj-1224	148	14	to	to	ADP
cuesj-1224	148	15	oral	oral	ADJ
cuesj-1224	148	16	and	and	CCONJ
cuesj-1224	148	17	‘	'	PUNCT
cuesj-1224	148	18	isoglycemic	isoglycemic	ADJ
cuesj-1224	148	19	’	'	PUNCT
cuesj-1224	148	20	intravenous	intravenous	ADJ
cuesj-1224	148	21	glucose	glucose	NOUN
cuesj-1224	148	22	.	.	PUNCT
cuesj-1224	149	1	diabetes	diabetes	NOUN
cuesj-1224	149	2	,	,	PUNCT
cuesj-1224	149	3	vol	vol	NOUN
cuesj-1224	149	4	.	.	PROPN
cuesj-1224	149	5	63	63	NUM
cuesj-1224	149	6	,	,	PUNCT
cuesj-1224	149	7	no	no	INTJ
cuesj-1224	149	8	.	.	NOUN
cuesj-1224	149	9	2	2	NUM
cuesj-1224	149	10	,	,	PUNCT
cuesj-1224	149	11	pp	pp	ADJ
cuesj-1224	149	12	.	.	PUNCT
cuesj-1224	150	1	663	663	NUM
cuesj-1224	150	2	-	-	SYM
cuesj-1224	150	3	674	674	NUM
cuesj-1224	150	4	,	,	PUNCT
cuesj-1224	150	5	2014	2014	NUM
cuesj-1224	150	6	.	.	PUNCT
cuesj-1224	151	1	[	[	X
cuesj-1224	151	2	12	12	NUM
cuesj-1224	151	3	]	]	PUNCT
cuesj-1224	151	4	r.	r.	PROPN
cuesj-1224	151	5	mahaseth	mahaseth	PROPN
cuesj-1224	151	6	.	.	PUNCT
cuesj-1224	152	1	incretin	incretin	NOUN
cuesj-1224	152	2	system	system	NOUN
cuesj-1224	152	3	:	:	PUNCT
cuesj-1224	152	4	recent	recent	ADJ
cuesj-1224	152	5	advances	advance	NOUN
cuesj-1224	152	6	in	in	ADP
cuesj-1224	152	7	glucagon	glucagon	NOUN
cuesj-1224	152	8	like	like	ADP
cuesj-1224	152	9	peptide-1	peptide-1	PROPN
cuesj-1224	152	10	and	and	CCONJ
cuesj-1224	152	11	dipeptidyl	dipeptidyl	VERB
cuesj-1224	152	12	peptidase-4	peptidase-4	NOUN
cuesj-1224	152	13	inhibitors	inhibitor	NOUN
cuesj-1224	152	14	.	.	PUNCT
cuesj-1224	153	1	journal	journal	NOUN
cuesj-1224	153	2	of	of	ADP
cuesj-1224	153	3	patan	patan	PROPN
cuesj-1224	153	4	academy	academy	PROPN
cuesj-1224	153	5	of	of	ADP
cuesj-1224	153	6	health	health	PROPN
cuesj-1224	153	7	sciences	sciences	PROPN
cuesj-1224	153	8	,	,	PUNCT
cuesj-1224	153	9	vol	vol	NOUN
cuesj-1224	153	10	.	.	PROPN
cuesj-1224	153	11	1	1	NUM
cuesj-1224	153	12	,	,	PUNCT
cuesj-1224	153	13	no	no	INTJ
cuesj-1224	153	14	.	.	NOUN
cuesj-1224	153	15	1	1	NUM
cuesj-1224	153	16	,	,	PUNCT
cuesj-1224	153	17	pp	pp	ADJ
cuesj-1224	153	18	.	.	PUNCT
cuesj-1224	154	1	36	36	NUM
cuesj-1224	154	2	-	-	SYM
cuesj-1224	154	3	42	42	NUM
cuesj-1224	154	4	,	,	PUNCT
cuesj-1224	154	5	2014	2014	NUM
cuesj-1224	154	6	.	.	PUNCT
cuesj-1224	155	1	[	[	X
cuesj-1224	155	2	13	13	NUM
cuesj-1224	155	3	]	]	PUNCT
cuesj-1224	155	4	m.	m.	NOUN
cuesj-1224	155	5	elashoff	elashoff	NOUN
cuesj-1224	155	6	,	,	PUNCT
cuesj-1224	155	7	a.	a.	PROPN
cuesj-1224	155	8	v.	v.	PROPN
cuesj-1224	155	9	matveyenko	matveyenko	PROPN
cuesj-1224	155	10	,	,	PUNCT
cuesj-1224	155	11	b.	b.	PROPN
cuesj-1224	155	12	gier	gier	PROPN
cuesj-1224	155	13	,	,	PUNCT
cuesj-1224	155	14	r.	r.	PROPN
cuesj-1224	155	15	elashoff	elashoff	PROPN
cuesj-1224	155	16	and	and	CCONJ
cuesj-1224	155	17	p.	p.	PROPN
cuesj-1224	155	18	c.	c.	PROPN
cuesj-1224	155	19	butler	butler	PROPN
cuesj-1224	155	20	.	.	PUNCT
cuesj-1224	156	1	pancreatitis	pancreatitis	PROPN
cuesj-1224	156	2	,	,	PUNCT
cuesj-1224	156	3	pancreatic	pancreatic	NOUN
cuesj-1224	156	4	,	,	PUNCT
cuesj-1224	156	5	and	and	CCONJ
cuesj-1224	156	6	thyroid	thyroid	NOUN
cuesj-1224	156	7	cancer	cancer	NOUN
cuesj-1224	156	8	with	with	ADP
cuesj-1224	156	9	glucagon	glucagon	NOUN
cuesj-1224	156	10	-	-	PUNCT
cuesj-1224	156	11	like	like	ADJ
cuesj-1224	156	12	peptide-1	peptide-1	NOUN
cuesj-1224	156	13	-	-	PUNCT
cuesj-1224	156	14	based	base	VERB
cuesj-1224	156	15	therapies	therapy	NOUN
cuesj-1224	156	16	.	.	PUNCT
cuesj-1224	157	1	gastroenterology	gastroenterology	NOUN
cuesj-1224	157	2	,	,	PUNCT
cuesj-1224	157	3	vol	vol	NOUN
cuesj-1224	157	4	.	.	PROPN
cuesj-1224	157	5	141	141	NUM
cuesj-1224	157	6	,	,	PUNCT
cuesj-1224	157	7	pp	pp	ADJ
cuesj-1224	157	8	.	.	PUNCT
cuesj-1224	157	9	150156	150156	NUM
cuesj-1224	157	10	,	,	PUNCT
cuesj-1224	157	11	2011	2011	NUM
cuesj-1224	157	12	.	.	PUNCT
cuesj-1224	158	1	[	[	X
cuesj-1224	158	2	14	14	NUM
cuesj-1224	158	3	]	]	X
cuesj-1224	158	4	s.	s.	PROPN
cuesj-1224	158	5	kalra	kalra	PROPN
cuesj-1224	158	6	,	,	PUNCT
cuesj-1224	158	7	s.	s.	PROPN
cuesj-1224	158	8	bahendeka	bahendeka	PROPN
cuesj-1224	158	9	,	,	PUNCT
cuesj-1224	158	10	r.	r.	PROPN
cuesj-1224	158	11	sahay	sahay	PROPN
cuesj-1224	158	12	,	,	PUNCT
cuesj-1224	158	13	s.	s.	PROPN
cuesj-1224	158	14	ghosh	ghosh	PROPN
cuesj-1224	158	15	,	,	PUNCT
cuesj-1224	158	16	m.	m.	NOUN
cuesj-1224	158	17	fariduddin	fariduddin	NOUN
cuesj-1224	158	18	,	,	PUNCT
cuesj-1224	158	19	a.	a.	NOUN
cuesj-1224	158	20	orabi	orabi	PROPN
cuesj-1224	158	21	,	,	PUNCT
cuesj-1224	158	22	k.	k.	PROPN
cuesj-1224	158	23	ramaiya	ramaiya	PROPN
cuesj-1224	158	24	,	,	PUNCT
cuesj-1224	158	25	s.	s.	PROPN
cuesj-1224	158	26	al	al	PROPN
cuesj-1224	158	27	shammari	shammari	PROPN
cuesj-1224	158	28	,	,	PUNCT
cuesj-1224	158	29	d.	d.	PROPN
cuesj-1224	158	30	shrestha	shrestha	PROPN
cuesj-1224	158	31	,	,	PUNCT
cuesj-1224	158	32	k.	k.	PROPN
cuesj-1224	158	33	shaikh	shaikh	PROPN
cuesj-1224	158	34	,	,	PUNCT
cuesj-1224	158	35	s.	s.	PROPN
cuesj-1224	158	36	abhayaratna	abhayaratna	PROPN
cuesj-1224	158	37	,	,	PUNCT
cuesj-1224	159	1	p.	p.	PROPN
cuesj-1224	159	2	k.	k.	PROPN
cuesj-1224	159	3	shrestha	shrestha	PROPN
cuesj-1224	159	4	,	,	PUNCT
cuesj-1224	159	5	a.	a.	PROPN
cuesj-1224	159	6	mahalingam	mahalingam	PROPN
cuesj-1224	159	7	,	,	PUNCT
cuesj-1224	159	8	m.	m.	PROPN
cuesj-1224	159	9	askheta	askheta	PROPN
cuesj-1224	159	10	,	,	PUNCT
cuesj-1224	159	11	a.	a.	NOUN
cuesj-1224	159	12	a.	a.	PROPN
cuesj-1224	159	13	a.	a.	PROPN
cuesj-1224	159	14	rahim	rahim	PROPN
cuesj-1224	159	15	.	.	PROPN
cuesj-1224	159	16	,	,	PUNCT
cuesj-1224	160	1	a.	a.	PROPN
cuesj-1224	160	2	k.	k.	PROPN
cuesj-1224	160	3	das	das	PROPN
cuesj-1224	160	4	.	.	PUNCT
cuesj-1224	161	1	consensus	consensus	NOUN
cuesj-1224	161	2	recommendations	recommendation	NOUN
cuesj-1224	161	3	on	on	ADP
cuesj-1224	161	4	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	161	5	and	and	CCONJ
cuesj-1224	161	6	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	161	7	combinations	combination	NOUN
cuesj-1224	161	8	in	in	ADP
cuesj-1224	161	9	the	the	DET
cuesj-1224	161	10	management	management	NOUN
cuesj-1224	161	11	of	of	ADP
cuesj-1224	161	12	type	type	NOUN
cuesj-1224	161	13	2	2	NUM
cuesj-1224	161	14	diabetes	diabetes	NOUN
cuesj-1224	161	15	mellitus	mellitus	PROPN
cuesj-1224	161	16	international	international	PROPN
cuesj-1224	161	17	task	task	PROPN
cuesj-1224	161	18	force	force	NOUN
cuesj-1224	161	19	.	.	PUNCT
cuesj-1224	162	1	indian	indian	ADJ
cuesj-1224	162	2	journal	journal	PROPN
cuesj-1224	162	3	of	of	ADP
cuesj-1224	162	4	endocrinology	endocrinology	NOUN
cuesj-1224	162	5	and	and	CCONJ
cuesj-1224	162	6	metabolism	metabolism	NOUN
cuesj-1224	162	7	,	,	PUNCT
cuesj-1224	162	8	vol	vol	NOUN
cuesj-1224	162	9	.	.	PROPN
cuesj-1224	162	10	22	22	NUM
cuesj-1224	162	11	,	,	PUNCT
cuesj-1224	162	12	pp	pp	ADJ
cuesj-1224	162	13	.	.	PUNCT
cuesj-1224	163	1	132	132	NUM
cuesj-1224	163	2	-	-	SYM
cuesj-1224	163	3	157	157	NUM
cuesj-1224	163	4	,	,	PUNCT
cuesj-1224	163	5	2018	2018	NUM
cuesj-1224	163	6	.	.	PUNCT
cuesj-1224	164	1	[	[	X
cuesj-1224	164	2	15	15	NUM
cuesj-1224	164	3	]	]	X
cuesj-1224	164	4	m.	m.	NOUN
cuesj-1224	164	5	anjoom	anjoom	PROPN
cuesj-1224	164	6	,	,	PUNCT
cuesj-1224	164	7	s.	s.	PROPN
cuesj-1224	164	8	b.	b.	PROPN
cuesj-1224	164	9	dutta	dutta	PROPN
cuesj-1224	164	10	,	,	PUNCT
cuesj-1224	164	11	m.	m.	NOUN
cuesj-1224	164	12	beg	beg	PROPN
cuesj-1224	164	13	,	,	PUNCT
cuesj-1224	164	14	a.	a.	PROPN
cuesj-1224	164	15	varma	varma	PROPN
cuesj-1224	164	16	,	,	PUNCT
cuesj-1224	164	17	s.	s.	PROPN
cuesj-1224	164	18	bawa	bawa	PROPN
cuesj-1224	164	19	and	and	CCONJ
cuesj-1224	164	20	r.	r.	PROPN
cuesj-1224	164	21	kant	kant	PROPN
cuesj-1224	164	22	.	.	PUNCT
cuesj-1224	165	1	comparative	comparative	ADJ
cuesj-1224	165	2	evaluation	evaluation	NOUN
cuesj-1224	165	3	of	of	ADP
cuesj-1224	165	4	combination	combination	NOUN
cuesj-1224	165	5	of	of	ADP
cuesj-1224	165	6	metformin	metformin	NOUN
cuesj-1224	165	7	and	and	CCONJ
cuesj-1224	165	8	glimepiride	glimepiride	NOUN
cuesj-1224	165	9	with	with	ADP
cuesj-1224	165	10	that	that	PRON
cuesj-1224	165	11	of	of	ADP
cuesj-1224	165	12	metformin	metformin	NOUN
cuesj-1224	165	13	and	and	CCONJ
cuesj-1224	165	14	sitagliptin	sitagliptin	NOUN
cuesj-1224	165	15	in	in	ADP
cuesj-1224	165	16	type	type	NOUN
cuesj-1224	165	17	2	2	NUM
cuesj-1224	165	18	diabetes	diabetes	NOUN
cuesj-1224	165	19	mellitus	mellitus	NOUN
cuesj-1224	165	20	with	with	ADP
cuesj-1224	165	21	respect	respect	NOUN
cuesj-1224	165	22	to	to	ADP
cuesj-1224	165	23	glycemic	glycemic	ADJ
cuesj-1224	165	24	targets	target	NOUN
cuesj-1224	165	25	.	.	PUNCT
cuesj-1224	166	1	international	international	ADJ
cuesj-1224	166	2	j	j	PROPN
cuesj-1224	166	3	of	of	ADP
cuesj-1224	166	4	medical	medical	ADJ
cuesj-1224	166	5	science	science	NOUN
cuesj-1224	166	6	and	and	CCONJ
cuesj-1224	166	7	public	public	ADJ
cuesj-1224	166	8	health	health	NOUN
cuesj-1224	166	9	,	,	PUNCT
cuesj-1224	166	10	vol	vol	NOUN
cuesj-1224	166	11	.	.	PROPN
cuesj-1224	166	12	4	4	NUM
cuesj-1224	166	13	,	,	PUNCT
cuesj-1224	166	14	no	no	INTJ
cuesj-1224	166	15	.	.	NOUN
cuesj-1224	166	16	4	4	NUM
cuesj-1224	166	17	,	,	PUNCT
cuesj-1224	166	18	pp	pp	ADJ
cuesj-1224	166	19	.	.	PUNCT
cuesj-1224	167	1	476	476	NUM
cuesj-1224	167	2	-	-	SYM
cuesj-1224	167	3	480	480	NUM
cuesj-1224	167	4	,	,	PUNCT
cuesj-1224	167	5	2015	2015	NUM
cuesj-1224	167	6	.	.	PUNCT
cuesj-1224	168	1	[	[	X
cuesj-1224	168	2	16	16	NUM
cuesj-1224	168	3	]	]	X
cuesj-1224	168	4	n.	n.	PROPN
cuesj-1224	168	5	mahmood	mahmood	PROPN
cuesj-1224	168	6	,	,	PUNCT
cuesj-1224	168	7	r.	r.	PROPN
cuesj-1224	168	8	yahya	yahya	PROPN
cuesj-1224	168	9	and	and	CCONJ
cuesj-1224	168	10	s.	s.	PROPN
cuesj-1224	168	11	aziz	aziz	PROPN
cuesj-1224	168	12	.	.	PROPN
cuesj-1224	168	13	apply	apply	VERB
cuesj-1224	168	14	binary	binary	ADJ
cuesj-1224	168	15	logistic	logistic	ADJ
cuesj-1224	168	16	regression	regression	NOUN
cuesj-1224	168	17	model	model	NOUN
cuesj-1224	168	18	to	to	PART
cuesj-1224	168	19	recognize	recognize	VERB
cuesj-1224	168	20	the	the	DET
cuesj-1224	168	21	risk	risk	NOUN
cuesj-1224	168	22	factors	factor	NOUN
cuesj-1224	168	23	of	of	ADP
cuesj-1224	168	24	diabetes	diabetes	NOUN
cuesj-1224	168	25	through	through	ADP
cuesj-1224	168	26	measuring	measure	VERB
cuesj-1224	168	27	glycated	glycate	VERB
cuesj-1224	168	28	hemoglobin	hemoglobin	NOUN
cuesj-1224	168	29	levels	level	NOUN
cuesj-1224	168	30	.	.	PUNCT
cuesj-1224	169	1	cihan	cihan	VERB
cuesj-1224	169	2	university	university	NOUN
cuesj-1224	169	3	-	-	PUNCT
cuesj-1224	169	4	erbil	erbil	PROPN
cuesj-1224	169	5	scientific	scientific	ADJ
cuesj-1224	169	6	journal	journal	NOUN
cuesj-1224	169	7	,	,	PUNCT
cuesj-1224	169	8	vol	vol	NOUN
cuesj-1224	169	9	.	.	PROPN
cuesj-1224	169	10	6	6	NUM
cuesj-1224	169	11	,	,	PUNCT
cuesj-1224	169	12	no	no	INTJ
cuesj-1224	169	13	.	.	NOUN
cuesj-1224	169	14	1	1	NUM
cuesj-1224	169	15	,	,	PUNCT
cuesj-1224	169	16	pp	pp	ADJ
cuesj-1224	169	17	.	.	PUNCT
cuesj-1224	170	1	7	7	NUM
cuesj-1224	170	2	-	-	SYM
cuesj-1224	170	3	11	11	NUM
cuesj-1224	170	4	,	,	PUNCT
cuesj-1224	170	5	2022	2022	NUM
cuesj-1224	170	6	.	.	PUNCT
cuesj-1224	171	1	[	[	X
cuesj-1224	171	2	17	17	NUM
cuesj-1224	171	3	]	]	X
cuesj-1224	171	4	d.	d.	PROPN
cuesj-1224	171	5	rahelic	rahelic	PROPN
cuesj-1224	171	6	.	.	PUNCT
cuesj-1224	172	1	7th	7th	ADJ
cuesj-1224	172	2	edition	edition	NOUN
cuesj-1224	172	3	of	of	ADP
cuesj-1224	172	4	idf	idf	PROPN
cuesj-1224	172	5	diabetes	diabetes	PROPN
cuesj-1224	172	6	atlas	atlas	PROPN
cuesj-1224	172	7	:	:	PUNCT
cuesj-1224	172	8	call	call	VERB
cuesj-1224	172	9	for	for	ADP
cuesj-1224	172	10	immediate	immediate	ADJ
cuesj-1224	172	11	action	action	NOUN
cuesj-1224	172	12	.	.	PUNCT
cuesj-1224	173	1	lijec	lijec	NOUN
cuesj-1224	173	2	vjesn	vjesn	NOUN
cuesj-1224	173	3	,	,	PUNCT
cuesj-1224	173	4	vol	vol	NOUN
cuesj-1224	173	5	.	.	PROPN
cuesj-1224	173	6	138	138	NUM
cuesj-1224	173	7	,	,	PUNCT
cuesj-1224	173	8	pp	pp	ADJ
cuesj-1224	173	9	.	.	PUNCT
cuesj-1224	174	1	57	57	NUM
cuesj-1224	174	2	-	-	SYM
cuesj-1224	174	3	58	58	NUM
cuesj-1224	174	4	,	,	PUNCT
cuesj-1224	174	5	2016	2016	NUM
cuesj-1224	174	6	.	.	PUNCT
cuesj-1224	175	1	[	[	X
cuesj-1224	175	2	18	18	NUM
cuesj-1224	175	3	]	]	PUNCT
cuesj-1224	175	4	a.	a.	NOUN
cuesj-1224	175	5	pan	pan	PROPN
cuesj-1224	175	6	,	,	PUNCT
cuesj-1224	175	7	y.	y.	PROPN
cuesj-1224	175	8	wang	wang	PROPN
cuesj-1224	175	9	,	,	PUNCT
cuesj-1224	175	10	m.	m.	NOUN
cuesj-1224	175	11	talaei	talaei	PROPN
cuesj-1224	175	12	,	,	PUNCT
cuesj-1224	175	13	f.	f.	PROPN
cuesj-1224	175	14	b.	b.	PROPN
cuesj-1224	175	15	hu	hu	PROPN
cuesj-1224	175	16	and	and	CCONJ
cuesj-1224	175	17	t.	t.	PROPN
cuesj-1224	175	18	wu	wu	PROPN
cuesj-1224	175	19	.	.	PUNCT
cuesj-1224	176	1	relation	relation	NOUN
cuesj-1224	176	2	of	of	ADP
cuesj-1224	176	3	active	active	ADJ
cuesj-1224	176	4	,	,	PUNCT
cuesj-1224	176	5	passive	passive	ADJ
cuesj-1224	176	6	,	,	PUNCT
cuesj-1224	176	7	and	and	CCONJ
cuesj-1224	176	8	quitting	quit	VERB
cuesj-1224	176	9	smoking	smoke	VERB
cuesj-1224	176	10	with	with	ADP
cuesj-1224	176	11	incident	incident	NOUN
cuesj-1224	176	12	type	type	NOUN
cuesj-1224	176	13	2	2	NUM
cuesj-1224	176	14	diabetes	diabetes	NOUN
cuesj-1224	176	15	:	:	PUNCT
cuesj-1224	176	16	a	a	DET
cuesj-1224	176	17	systematic	systematic	ADJ
cuesj-1224	176	18	review	review	NOUN
cuesj-1224	176	19	and	and	CCONJ
cuesj-1224	176	20	meta	meta	ADJ
cuesj-1224	176	21	-	-	PUNCT
cuesj-1224	176	22	analysis	analysis	NOUN
cuesj-1224	176	23	.	.	PUNCT
cuesj-1224	177	1	the	the	DET
cuesj-1224	177	2	lancet	lancet	PROPN
cuesj-1224	177	3	diabetes	diabetes	NOUN
cuesj-1224	177	4	and	and	CCONJ
cuesj-1224	177	5	endocrinology	endocrinology	NOUN
cuesj-1224	177	6	,	,	PUNCT
cuesj-1224	177	7	vol	vol	NOUN
cuesj-1224	177	8	.	.	PROPN
cuesj-1224	177	9	3	3	NUM
cuesj-1224	177	10	,	,	PUNCT
cuesj-1224	177	11	pp	pp	ADJ
cuesj-1224	177	12	.	.	PUNCT
cuesj-1224	178	1	958	958	NUM
cuesj-1224	178	2	-	-	SYM
cuesj-1224	178	3	967	967	NUM
cuesj-1224	178	4	,	,	PUNCT
cuesj-1224	178	5	2015	2015	NUM
cuesj-1224	178	6	.	.	PUNCT
cuesj-1224	179	1	[	[	X
cuesj-1224	179	2	19	19	NUM
cuesj-1224	179	3	]	]	X
cuesj-1224	179	4	c.	c.	PROPN
cuesj-1224	179	5	baker	baker	PROPN
cuesj-1224	179	6	,	,	PUNCT
cuesj-1224	179	7	c.	c.	PROPN
cuesj-1224	179	8	retzik	retzik	PROPN
cuesj-1224	179	9	-	-	PUNCT
cuesj-1224	179	10	stahr	stahr	NOUN
cuesj-1224	179	11	,	,	PUNCT
cuesj-1224	179	12	v.	v.	PROPN
cuesj-1224	179	13	singh	singh	PROPN
cuesj-1224	179	14	,	,	PUNCT
cuesj-1224	179	15	r.	r.	PROPN
cuesj-1224	179	16	plomondon	plomondon	PROPN
cuesj-1224	179	17	,	,	PUNCT
cuesj-1224	179	18	v.	v.	ADP
cuesj-1224	179	19	anderson	anderson	PROPN
cuesj-1224	179	20	and	and	CCONJ
cuesj-1224	179	21	n.	n.	PROPN
cuesj-1224	179	22	rasouli	rasouli	PROPN
cuesj-1224	179	23	.	.	PUNCT
cuesj-1224	180	1	should	should	AUX
cuesj-1224	180	2	metformin	metformin	VERB
cuesj-1224	180	3	remain	remain	VERB
cuesj-1224	180	4	the	the	DET
cuesj-1224	180	5	first	first	ADJ
cuesj-1224	180	6	-	-	PUNCT
cuesj-1224	180	7	line	line	NOUN
cuesj-1224	180	8	therapy	therapy	NOUN
cuesj-1224	180	9	for	for	ADP
cuesj-1224	180	10	treatment	treatment	NOUN
cuesj-1224	180	11	of	of	ADP
cuesj-1224	180	12	type	type	NOUN
cuesj-1224	180	13	2	2	NUM
cuesj-1224	180	14	diabetes	diabetes	NOUN
cuesj-1224	180	15	?	?	PUNCT
cuesj-1224	181	1	therapeutic	therapeutic	ADJ
cuesj-1224	181	2	advances	advance	NOUN
cuesj-1224	181	3	in	in	ADP
cuesj-1224	181	4	endocrinology	endocrinology	NOUN
cuesj-1224	181	5	and	and	CCONJ
cuesj-1224	181	6	metabolism	metabolism	NOUN
cuesj-1224	181	7	,	,	PUNCT
cuesj-1224	181	8	vol	vol	NOUN
cuesj-1224	181	9	.	.	PROPN
cuesj-1224	181	10	12	12	NUM
cuesj-1224	181	11	,	,	PUNCT
cuesj-1224	181	12	pp	pp	ADJ
cuesj-1224	181	13	.	.	PUNCT
cuesj-1224	182	1	1	1	NUM
cuesj-1224	182	2	-	-	SYM
cuesj-1224	182	3	13	13	NUM
cuesj-1224	182	4	,	,	PUNCT
cuesj-1224	182	5	2021	2021	NUM
cuesj-1224	182	6	.	.	PUNCT
cuesj-1224	183	1	[	[	X
cuesj-1224	183	2	20	20	NUM
cuesj-1224	183	3	]	]	PUNCT
cuesj-1224	183	4	t.	t.	PROPN
cuesj-1224	183	5	xu	xu	PROPN
cuesj-1224	183	6	,	,	PUNCT
cuesj-1224	183	7	s.	s.	PROPN
cuesj-1224	183	8	brandmaier	brandmaier	PROPN
cuesj-1224	183	9	,	,	PUNCT
cuesj-1224	183	10	a.	a.	PROPN
cuesj-1224	183	11	c.	c.	PROPN
cuesj-1224	183	12	messias	messias	PROPN
cuesj-1224	183	13	,	,	PUNCT
cuesj-1224	183	14	c.	c.	PROPN
cuesj-1224	183	15	herder	herder	NOUN
cuesj-1224	183	16	,	,	PUNCT
cuesj-1224	183	17	h.	h.	PROPN
cuesj-1224	183	18	h.	h.	PROPN
cuesj-1224	183	19	m.	m.	PROPN
cuesj-1224	183	20	draisma	draisma	PROPN
cuesj-1224	183	21	,	,	PUNCT
cuesj-1224	183	22	a.	a.	NOUN
cuesj-1224	183	23	demirkan	demirkan	PROPN
cuesj-1224	183	24	,	,	PUNCT
cuesj-1224	183	25	z.	z.	PROPN
cuesj-1224	183	26	yu	yu	PROPN
cuesj-1224	183	27	,	,	PUNCT
cuesj-1224	183	28	j.	j.	PROPN
cuesj-1224	183	29	s.	s.	PROPN
cuesj-1224	183	30	ried	rie	VERB
cuesj-1224	183	31	,	,	PUNCT
cuesj-1224	183	32	t.	t.	PROPN
cuesj-1224	183	33	haller	haller	PROPN
cuesj-1224	183	34	,	,	PUNCT
cuesj-1224	183	35	m.	m.	NOUN
cuesj-1224	183	36	heier	heier	NOUN
cuesj-1224	183	37	,	,	PUNCT
cuesj-1224	183	38	…	…	PUNCT
cuesj-1224	183	39	&	&	CCONJ
cuesj-1224	183	40	r.	r.	PROPN
cuesj-1224	183	41	wangsattler	wangsattler	PROPN
cuesj-1224	183	42	.	.	PUNCT
cuesj-1224	184	1	effects	effect	NOUN
cuesj-1224	184	2	of	of	ADP
cuesj-1224	184	3	metformin	metformin	NOUN
cuesj-1224	184	4	on	on	ADP
cuesj-1224	184	5	metabolite	metabolite	NOUN
cuesj-1224	184	6	profiles	profile	NOUN
cuesj-1224	184	7	and	and	CCONJ
cuesj-1224	184	8	ldl	ldl	VERB
cuesj-1224	184	9	cholesterol	cholesterol	NOUN
cuesj-1224	184	10	in	in	ADP
cuesj-1224	184	11	patients	patient	NOUN
cuesj-1224	184	12	with	with	ADP
cuesj-1224	184	13	type	type	NOUN
cuesj-1224	184	14	2	2	NUM
cuesj-1224	184	15	diabetes	diabetes	NOUN
cuesj-1224	184	16	.	.	PUNCT
cuesj-1224	185	1	diabetes	diabetes	NOUN
cuesj-1224	185	2	care	care	NOUN
cuesj-1224	185	3	,	,	PUNCT
cuesj-1224	185	4	vol	vol	NOUN
cuesj-1224	185	5	.	.	PROPN
cuesj-1224	186	1	38	38	NUM
cuesj-1224	186	2	,	,	PUNCT
cuesj-1224	186	3	pp	pp	ADJ
cuesj-1224	186	4	.	.	PUNCT
cuesj-1224	187	1	1858	1858	NUM
cuesj-1224	187	2	-	-	SYM
cuesj-1224	187	3	1867	1867	NUM
cuesj-1224	187	4	,	,	PUNCT
cuesj-1224	187	5	2015	2015	NUM
cuesj-1224	187	6	.	.	PUNCT
cuesj-1224	188	1	[	[	X
cuesj-1224	188	2	21	21	NUM
cuesj-1224	188	3	]	]	X
cuesj-1224	188	4	b.	b.	PROPN
cuesj-1224	188	5	m.	m.	PROPN
cuesj-1224	188	6	makkar	makkar	PROPN
cuesj-1224	188	7	,	,	PUNCT
cuesj-1224	188	8	d.	d.	PROPN
cuesj-1224	188	9	gupta	gupta	PROPN
cuesj-1224	188	10	and	and	CCONJ
cuesj-1224	188	11	a.	a.	NOUN
cuesj-1224	188	12	gainda	gainda	PROPN
cuesj-1224	188	13	.	.	PUNCT
cuesj-1224	189	1	clinical	clinical	ADJ
cuesj-1224	189	2	trials	trial	NOUN
cuesj-1224	189	3	to	to	ADP
cuesj-1224	189	4	clinical	clinical	ADJ
cuesj-1224	189	5	practice	practice	NOUN
cuesj-1224	189	6	:	:	PUNCT
cuesj-1224	189	7	role	role	NOUN
cuesj-1224	189	8	of	of	ADP
cuesj-1224	189	9	sulfonylureas	sulfonylurea	NOUN
cuesj-1224	189	10	in	in	ADP
cuesj-1224	189	11	today	today	NOUN
cuesj-1224	189	12	’s	’s	PART
cuesj-1224	189	13	practice	practice	NOUN
cuesj-1224	189	14	.	.	PUNCT
cuesj-1224	190	1	in	in	ADP
cuesj-1224	190	2	:	:	PUNCT
cuesj-1224	190	3	medicine	medicine	NOUN
cuesj-1224	190	4	update	update	NOUN
cuesj-1224	190	5	.	.	PUNCT
cuesj-1224	191	1	jaypee	jaypee	PROPN
cuesj-1224	191	2	brothers	brothers	PROPN
cuesj-1224	191	3	medical	medical	ADJ
cuesj-1224	191	4	publishers	publisher	NOUN
cuesj-1224	191	5	,	,	PUNCT
cuesj-1224	191	6	new	new	ADJ
cuesj-1224	191	7	delhi	delhi	PROPN
cuesj-1224	191	8	,	,	PUNCT
cuesj-1224	191	9	india	india	PROPN
cuesj-1224	191	10	,	,	PUNCT
cuesj-1224	191	11	pp	pp	ADJ
cuesj-1224	191	12	.	.	PUNCT
cuesj-1224	192	1	393	393	NUM
cuesj-1224	192	2	-	-	SYM
cuesj-1224	192	3	8	8	NUM
cuesj-1224	192	4	,	,	PUNCT
cuesj-1224	192	5	2013	2013	NUM
cuesj-1224	192	6	.	.	PUNCT
cuesj-1224	193	1	[	[	X
cuesj-1224	193	2	22	22	NUM
cuesj-1224	193	3	]	]	X
cuesj-1224	193	4	h.	h.	PROPN
cuesj-1224	193	5	thacker	thacker	PROPN
cuesj-1224	193	6	,	,	PUNCT
cuesj-1224	193	7	s.	s.	PROPN
cuesj-1224	193	8	shah	shah	PROPN
cuesj-1224	193	9	,	,	PUNCT
cuesj-1224	193	10	m.	m.	NOUN
cuesj-1224	193	11	chadha	chadha	PROPN
cuesj-1224	193	12	,	,	PUNCT
cuesj-1224	193	13	r.	r.	PROPN
cuesj-1224	193	14	kovil	kovil	PROPN
cuesj-1224	193	15	,	,	PUNCT
cuesj-1224	193	16	m.	m.	NOUN
cuesj-1224	193	17	chawla	chawla	PROPN
cuesj-1224	193	18	,	,	PUNCT
cuesj-1224	193	19	s.	s.	PROPN
cuesj-1224	193	20	gupta	gupta	PROPN
cuesj-1224	193	21	and	and	CCONJ
cuesj-1224	193	22	n.	n.	PROPN
cuesj-1224	193	23	wadhwa	wadhwa	PROPN
cuesj-1224	193	24	.	.	PUNCT
cuesj-1224	194	1	management	management	NOUN
cuesj-1224	194	2	of	of	ADP
cuesj-1224	194	3	type	type	NOUN
cuesj-1224	194	4	2	2	NUM
cuesj-1224	194	5	diabetes	diabetes	NOUN
cuesj-1224	194	6	in	in	ADP
cuesj-1224	194	7	western	western	ADJ
cuesj-1224	194	8	india	india	PROPN
cuesj-1224	194	9	:	:	PUNCT
cuesj-1224	194	10	attitudes	attitude	NOUN
cuesj-1224	194	11	and	and	CCONJ
cuesj-1224	194	12	practices	practice	NOUN
cuesj-1224	194	13	among	among	ADP
cuesj-1224	194	14	physicians	physician	NOUN
cuesj-1224	194	15	leading	lead	VERB
cuesj-1224	194	16	the	the	DET
cuesj-1224	194	17	forefront	forefront	NOUN
cuesj-1224	194	18	of	of	ADP
cuesj-1224	194	19	diabetes	diabetes	NOUN
cuesj-1224	194	20	care	care	NOUN
cuesj-1224	194	21	.	.	PUNCT
cuesj-1224	195	1	diabetes	diabetes	NOUN
cuesj-1224	195	2	,	,	PUNCT
cuesj-1224	195	3	vol	vol	NOUN
cuesj-1224	195	4	.	.	PROPN
cuesj-1224	195	5	65	65	NUM
cuesj-1224	195	6	,	,	PUNCT
cuesj-1224	195	7	pp	pp	ADJ
cuesj-1224	195	8	.	.	PUNCT
cuesj-1224	196	1	a556	a556	NUM
cuesj-1224	196	2	,	,	PUNCT
cuesj-1224	196	3	2016	2016	NUM
cuesj-1224	196	4	.	.	PUNCT
cuesj-1224	197	1	[	[	X
cuesj-1224	197	2	23	23	X
cuesj-1224	197	3	]	]	X
cuesj-1224	197	4	v.	v.	PROPN
cuesj-1224	197	5	j.	j.	PROPN
cuesj-1224	197	6	briscoe	briscoe	PROPN
cuesj-1224	197	7	,	,	PUNCT
cuesj-1224	197	8	m.	m.	PROPN
cuesj-1224	197	9	l.	l.	PROPN
cuesj-1224	197	10	griffith	griffith	PROPN
cuesj-1224	197	11	and	and	CCONJ
cuesj-1224	197	12	s.	s.	PROPN
cuesj-1224	197	13	n.	n.	PROPN
cuesj-1224	197	14	davis	davis	PROPN
cuesj-1224	197	15	.	.	PUNCT
cuesj-1224	198	1	the	the	DET
cuesj-1224	198	2	role	role	NOUN
cuesj-1224	198	3	of	of	ADP
cuesj-1224	198	4	glimepiride	glimepiride	NOUN
cuesj-1224	198	5	in	in	ADP
cuesj-1224	198	6	the	the	DET
cuesj-1224	198	7	treatment	treatment	NOUN
cuesj-1224	198	8	of	of	ADP
cuesj-1224	198	9	type	type	NOUN
cuesj-1224	198	10	2	2	NUM
cuesj-1224	198	11	diabetes	diabetes	NOUN
cuesj-1224	198	12	mellitus	mellitus	NOUN
cuesj-1224	198	13	.	.	PUNCT
cuesj-1224	199	1	expert	expert	ADJ
cuesj-1224	199	2	opinion	opinion	NOUN
cuesj-1224	199	3	on	on	ADP
cuesj-1224	199	4	drug	drug	NOUN
cuesj-1224	199	5	metabolism	metabolism	NOUN
cuesj-1224	199	6	and	and	CCONJ
cuesj-1224	199	7	toxicology	toxicology	NOUN
cuesj-1224	199	8	,	,	PUNCT
cuesj-1224	199	9	vol	vol	NOUN
cuesj-1224	199	10	.	.	PROPN
cuesj-1224	199	11	6	6	NUM
cuesj-1224	199	12	,	,	PUNCT
cuesj-1224	199	13	pp	pp	ADJ
cuesj-1224	199	14	.	.	PUNCT
cuesj-1224	200	1	225	225	NUM
cuesj-1224	200	2	-	-	SYM
cuesj-1224	200	3	235	235	NUM
cuesj-1224	200	4	,	,	PUNCT
cuesj-1224	200	5	2010	2010	NUM
cuesj-1224	200	6	.	.	PUNCT
cuesj-1224	201	1	yassen	yassen	PROPN
cuesj-1224	201	2	,	,	PUNCT
cuesj-1224	201	3	et	et	PROPN
cuesj-1224	201	4	al	al	PROPN
cuesj-1224	201	5	.	.	PUNCT
cuesj-1224	201	6	:	:	PUNCT
cuesj-1224	202	1	efficacy	efficacy	NOUN
cuesj-1224	202	2	and	and	CCONJ
cuesj-1224	202	3	safety	safety	NOUN
cuesj-1224	202	4	of	of	ADP
cuesj-1224	202	5	metformin	metformin	PROPN
cuesj-1224	202	6	,	,	PUNCT
cuesj-1224	202	7	sitagliptin	sitagliptin	NOUN
cuesj-1224	202	8	,	,	PUNCT
cuesj-1224	202	9	and	and	CCONJ
cuesj-1224	202	10	glimepiride	glimepiride	NOUN
cuesj-1224	202	11	in	in	ADP
cuesj-1224	202	12	type	type	NOUN
cuesj-1224	202	13	2	2	NUM
cuesj-1224	202	14	diabetes	diabetes	NOUN
cuesj-1224	202	15	109	109	NUM
cuesj-1224	202	16	http://journals.cihanuniversity.edu.iq/index.php/cuesj	http://journals.cihanuniversity.edu.iq/index.php/cuesj	ADJ
cuesj-1224	202	17	cuesj	cuesj	ADJ
cuesj-1224	202	18	2024	2024	NUM
cuesj-1224	202	19	,	,	PUNCT
cuesj-1224	202	20	8	8	NUM
cuesj-1224	202	21	(	(	PUNCT
cuesj-1224	202	22	2	2	NUM
cuesj-1224	202	23	):	):	PUNCT
cuesj-1224	202	24	104	104	NUM
cuesj-1224	202	25	-	-	SYM
cuesj-1224	202	26	109	109	NUM
cuesj-1224	203	1	[	[	SYM
cuesj-1224	203	2	24	24	NUM
cuesj-1224	203	3	]	]	X
cuesj-1224	203	4	d.	d.	PROPN
cuesj-1224	203	5	v.	v.	PROPN
cuesj-1224	203	6	rados	rados	PROPN
cuesj-1224	203	7	,	,	PUNCT
cuesj-1224	203	8	l.	l.	PROPN
cuesj-1224	203	9	c.	c.	PROPN
cuesj-1224	203	10	pinto	pinto	PROPN
cuesj-1224	203	11	,	,	PUNCT
cuesj-1224	203	12	l.	l.	PROPN
cuesj-1224	203	13	r.	r.	PROPN
cuesj-1224	203	14	remonti	remonti	PROPN
cuesj-1224	203	15	,	,	PUNCT
cuesj-1224	203	16	c.	c.	PROPN
cuesj-1224	203	17	b.	b.	PROPN
cuesj-1224	203	18	leitão	leitão	PROPN
cuesj-1224	203	19	and	and	CCONJ
cuesj-1224	203	20	j.	j.	PROPN
cuesj-1224	203	21	l.	l.	PROPN
cuesj-1224	203	22	gross	gross	PROPN
cuesj-1224	203	23	.	.	PUNCT
cuesj-1224	204	1	the	the	DET
cuesj-1224	204	2	association	association	NOUN
cuesj-1224	204	3	between	between	ADP
cuesj-1224	204	4	sulfonylurea	sulfonylurea	NOUN
cuesj-1224	204	5	use	use	NOUN
cuesj-1224	204	6	and	and	CCONJ
cuesj-1224	204	7	all	all	DET
cuesj-1224	204	8	cause	cause	NOUN
cuesj-1224	204	9	and	and	CCONJ
cuesj-1224	204	10	cardiovascular	cardiovascular	ADJ
cuesj-1224	204	11	mortality	mortality	NOUN
cuesj-1224	204	12	:	:	PUNCT
cuesj-1224	204	13	a	a	DET
cuesj-1224	204	14	meta	meta	ADJ
cuesj-1224	204	15	-	-	PUNCT
cuesj-1224	204	16	analysis	analysis	NOUN
cuesj-1224	204	17	with	with	ADP
cuesj-1224	204	18	trial	trial	NOUN
cuesj-1224	204	19	sequential	sequential	ADJ
cuesj-1224	204	20	analysis	analysis	NOUN
cuesj-1224	204	21	of	of	ADP
cuesj-1224	204	22	randomized	randomized	ADJ
cuesj-1224	204	23	clinical	clinical	ADJ
cuesj-1224	204	24	trials	trial	NOUN
cuesj-1224	204	25	.	.	PUNCT
cuesj-1224	205	1	plos	plos	PROPN
cuesj-1224	205	2	med	med	PROPN
cuesj-1224	205	3	,	,	PUNCT
cuesj-1224	205	4	vol	vol	NOUN
cuesj-1224	205	5	.	.	PROPN
cuesj-1224	205	6	13	13	NUM
cuesj-1224	205	7	,	,	PUNCT
cuesj-1224	205	8	p.	p.	NOUN
cuesj-1224	205	9	e1001992	e1001992	NOUN
cuesj-1224	205	10	,	,	PUNCT
cuesj-1224	205	11	2016	2016	NUM
cuesj-1224	205	12	.	.	PUNCT
cuesj-1224	206	1	[	[	X
cuesj-1224	206	2	25	25	NUM
cuesj-1224	206	3	]	]	X
cuesj-1224	206	4	s.	s.	PROPN
cuesj-1224	206	5	r.	r.	PROPN
cuesj-1224	206	6	salpeter	salpeter	PROPN
cuesj-1224	206	7	,	,	PUNCT
cuesj-1224	206	8	e.	e.	PROPN
cuesj-1224	206	9	greyber	greyber	PROPN
cuesj-1224	206	10	,	,	PUNCT
cuesj-1224	206	11	g.	g.	PROPN
cuesj-1224	206	12	a.	a.	PROPN
cuesj-1224	206	13	pasternak	pasternak	PROPN
cuesj-1224	206	14	and	and	CCONJ
cuesj-1224	206	15	e.	e.	PROPN
cuesj-1224	206	16	e.	e.	PROPN
cuesj-1224	206	17	salpeter	salpeter	PROPN
cuesj-1224	206	18	.	.	PUNCT
cuesj-1224	207	1	risk	risk	NOUN
cuesj-1224	207	2	of	of	ADP
cuesj-1224	207	3	fatal	fatal	ADJ
cuesj-1224	207	4	and	and	CCONJ
cuesj-1224	207	5	nonfatal	nonfatal	ADJ
cuesj-1224	207	6	lactic	lactic	ADJ
cuesj-1224	207	7	acidosis	acidosis	NOUN
cuesj-1224	207	8	with	with	ADP
cuesj-1224	207	9	metformin	metformin	NOUN
cuesj-1224	207	10	use	use	NOUN
cuesj-1224	207	11	in	in	ADP
cuesj-1224	207	12	type	type	NOUN
cuesj-1224	207	13	2	2	NUM
cuesj-1224	207	14	diabetes	diabetes	NOUN
cuesj-1224	207	15	mellitus	mellitus	NOUN
cuesj-1224	207	16	:	:	PUNCT
cuesj-1224	207	17	systematic	systematic	ADJ
cuesj-1224	207	18	review	review	NOUN
cuesj-1224	207	19	and	and	CCONJ
cuesj-1224	207	20	metaanalysis	metaanalysis	NOUN
cuesj-1224	207	21	.	.	PUNCT
cuesj-1224	208	1	archives	archive	NOUN
cuesj-1224	208	2	of	of	ADP
cuesj-1224	208	3	internal	internal	ADJ
cuesj-1224	208	4	medicine	medicine	NOUN
cuesj-1224	208	5	,	,	PUNCT
cuesj-1224	208	6	vol	vol	NOUN
cuesj-1224	208	7	.	.	PROPN
cuesj-1224	208	8	163	163	NUM
cuesj-1224	208	9	,	,	PUNCT
cuesj-1224	208	10	pp	pp	ADJ
cuesj-1224	208	11	.	.	PUNCT
cuesj-1224	208	12	2594	2594	NUM
cuesj-1224	208	13	,	,	PUNCT
cuesj-1224	208	14	2003	2003	NUM
cuesj-1224	208	15	.	.	PUNCT
cuesj-1224	209	1	[	[	X
cuesj-1224	209	2	26	26	NUM
cuesj-1224	209	3	]	]	PUNCT
cuesj-1224	209	4	h.	h.	PROPN
cuesj-1224	209	5	j.	j.	PROPN
cuesj-1224	209	6	kim	kim	PROPN
cuesj-1224	209	7	.	.	PUNCT
cuesj-1224	210	1	effects	effect	NOUN
cuesj-1224	210	2	of	of	ADP
cuesj-1224	210	3	rosiglitazone	rosiglitazone	NOUN
cuesj-1224	210	4	and	and	CCONJ
cuesj-1224	210	5	metformin	metformin	NOUN
cuesj-1224	210	6	on	on	ADP
cuesj-1224	210	7	inflammatory	inflammatory	ADJ
cuesj-1224	210	8	markers	marker	NOUN
cuesj-1224	210	9	and	and	CCONJ
cuesj-1224	210	10	adipokines	adipokine	NOUN
cuesj-1224	210	11	:	:	PUNCT
cuesj-1224	210	12	decrease	decrease	NOUN
cuesj-1224	210	13	in	in	ADP
cuesj-1224	210	14	interleukin-18	interleukin-18	PROPN
cuesj-1224	210	15	is	be	AUX
cuesj-1224	210	16	an	an	DET
cuesj-1224	210	17	independent	independent	ADJ
cuesj-1224	210	18	factor	factor	NOUN
cuesj-1224	210	19	for	for	ADP
cuesj-1224	210	20	the	the	DET
cuesj-1224	210	21	improvement	improvement	NOUN
cuesj-1224	210	22	of	of	ADP
cuesj-1224	210	23	homeostasis	homeostasis	NOUN
cuesj-1224	210	24	model	model	NOUN
cuesj-1224	210	25	assessment	assessment	NOUN
cuesj-1224	210	26	-	-	PUNCT
cuesj-1224	210	27	beta	beta	NOUN
cuesj-1224	210	28	in	in	ADP
cuesj-1224	210	29	type	type	NOUN
cuesj-1224	210	30	2	2	NUM
cuesj-1224	210	31	diabetes	diabetes	NOUN
cuesj-1224	210	32	mellitus	mellitus	NOUN
cuesj-1224	210	33	.	.	PUNCT
cuesj-1224	211	1	clinical	clinical	ADJ
cuesj-1224	211	2	endocrinology	endocrinology	NOUN
cuesj-1224	211	3	.	.	PUNCT
cuesj-1224	212	1	(	(	PUNCT
cuesj-1224	212	2	oxford	oxford	PROPN
cuesj-1224	212	3	)	)	PUNCT
cuesj-1224	212	4	,	,	PUNCT
cuesj-1224	212	5	vol	vol	NOUN
cuesj-1224	212	6	.	.	PROPN
cuesj-1224	213	1	66	66	NUM
cuesj-1224	213	2	,	,	PUNCT
cuesj-1224	213	3	no	no	INTJ
cuesj-1224	213	4	.	.	NOUN
cuesj-1224	213	5	2	2	NUM
cuesj-1224	213	6	,	,	PUNCT
cuesj-1224	213	7	pp	pp	ADJ
cuesj-1224	213	8	.	.	PUNCT
cuesj-1224	214	1	282	282	NUM
cuesj-1224	214	2	,	,	PUNCT
cuesj-1224	214	3	2007	2007	NUM
cuesj-1224	214	4	.	.	PUNCT
cuesj-1224	215	1	[	[	X
cuesj-1224	215	2	27	27	NUM
cuesj-1224	215	3	]	]	X
cuesj-1224	215	4	h.	h.	PROPN
cuesj-1224	215	5	sakura	sakura	PROPN
cuesj-1224	215	6	,	,	PUNCT
cuesj-1224	215	7	n.	n.	PROPN
cuesj-1224	215	8	hashimoto	hashimoto	NOUN
cuesj-1224	215	9	,	,	PUNCT
cuesj-1224	215	10	k.	k.	PROPN
cuesj-1224	215	11	sasamoto	sasamoto	PROPN
cuesj-1224	215	12	,	,	PUNCT
cuesj-1224	215	13	h.	h.	PROPN
cuesj-1224	215	14	ohashi	ohashi	PROPN
cuesj-1224	215	15	,	,	PUNCT
cuesj-1224	215	16	s.	s.	PROPN
cuesj-1224	215	17	hasumi	hasumi	PROPN
cuesj-1224	215	18	,	,	PUNCT
cuesj-1224	215	19	n.	n.	PROPN
cuesj-1224	215	20	ujihara	ujihara	NOUN
cuesj-1224	215	21	,	,	PUNCT
cuesj-1224	215	22	t.	t.	PROPN
cuesj-1224	215	23	kasahara	kasahara	PROPN
cuesj-1224	215	24	,	,	PUNCT
cuesj-1224	215	25	o.	o.	PROPN
cuesj-1224	215	26	tomonaga	tomonaga	PROPN
cuesj-1224	215	27	,	,	PUNCT
cuesj-1224	215	28	h.	h.	PROPN
cuesj-1224	215	29	nunome	nunome	PROPN
cuesj-1224	215	30	,	,	PUNCT
cuesj-1224	215	31	m.	m.	NOUN
cuesj-1224	215	32	honda	honda	PROPN
cuesj-1224	215	33	and	and	CCONJ
cuesj-1224	215	34	y.	y.	PROPN
cuesj-1224	215	35	iwamoto	iwamoto	PROPN
cuesj-1224	215	36	.	.	PUNCT
cuesj-1224	216	1	effect	effect	NOUN
cuesj-1224	216	2	of	of	ADP
cuesj-1224	216	3	sitagliptin	sitagliptin	NOUN
cuesj-1224	216	4	on	on	ADP
cuesj-1224	216	5	blood	blood	NOUN
cuesj-1224	216	6	glucose	glucose	NOUN
cuesj-1224	216	7	control	control	NOUN
cuesj-1224	216	8	in	in	ADP
cuesj-1224	216	9	patients	patient	NOUN
cuesj-1224	216	10	with	with	ADP
cuesj-1224	216	11	type	type	NOUN
cuesj-1224	216	12	2	2	NUM
cuesj-1224	216	13	diabetes	diabetes	NOUN
cuesj-1224	216	14	mellitus	mellitus	NOUN
cuesj-1224	216	15	who	who	PRON
cuesj-1224	216	16	are	be	AUX
cuesj-1224	216	17	treatment	treatment	NOUN
cuesj-1224	216	18	naive	naive	ADJ
cuesj-1224	216	19	or	or	CCONJ
cuesj-1224	216	20	poorly	poorly	ADV
cuesj-1224	216	21	responsive	responsive	ADJ
cuesj-1224	216	22	to	to	ADP
cuesj-1224	216	23	existing	exist	VERB
cuesj-1224	216	24	antidiabetic	antidiabetic	ADJ
cuesj-1224	216	25	drugs	drug	NOUN
cuesj-1224	216	26	:	:	PUNCT
cuesj-1224	216	27	the	the	DET
cuesj-1224	216	28	jamp	jamp	ADJ
cuesj-1224	216	29	study	study	NOUN
cuesj-1224	216	30	.	.	PUNCT
cuesj-1224	217	1	bmc	bmc	ADJ
cuesj-1224	217	2	endocrine	endocrine	NOUN
cuesj-1224	217	3	disorders	disorder	NOUN
cuesj-1224	217	4	,	,	PUNCT
cuesj-1224	217	5	vol	vol	NOUN
cuesj-1224	217	6	.	.	PROPN
cuesj-1224	217	7	16	16	NUM
cuesj-1224	217	8	,	,	PUNCT
cuesj-1224	217	9	no	no	INTJ
cuesj-1224	217	10	.	.	NOUN
cuesj-1224	217	11	70	70	NUM
cuesj-1224	217	12	,	,	PUNCT
cuesj-1224	217	13	pp	pp	ADJ
cuesj-1224	217	14	.	.	PUNCT
cuesj-1224	218	1	1	1	NUM
cuesj-1224	218	2	-	-	SYM
cuesj-1224	218	3	11	11	NUM
cuesj-1224	218	4	,	,	PUNCT
cuesj-1224	218	5	2016	2016	NUM
cuesj-1224	218	6	.	.	PUNCT
cuesj-1224	219	1	[	[	X
cuesj-1224	219	2	28	28	NUM
cuesj-1224	219	3	]	]	X
cuesj-1224	219	4	y.	y.	PROPN
cuesj-1224	219	5	wamoto	wamoto	PROPN
cuesj-1224	219	6	,	,	PUNCT
cuesj-1224	219	7	n.	n.	PROPN
cuesj-1224	219	8	tajima	tajima	PROPN
cuesj-1224	219	9	and	and	CCONJ
cuesj-1224	219	10	t.	t.	PROPN
cuesj-1224	219	11	kadowaki	kadowaki	PROPN
cuesj-1224	219	12	.	.	PUNCT
cuesj-1224	220	1	efficacy	efficacy	NOUN
cuesj-1224	220	2	and	and	CCONJ
cuesj-1224	220	3	safety	safety	NOUN
cuesj-1224	220	4	of	of	ADP
cuesj-1224	220	5	sitagliptin	sitagliptin	NOUN
cuesj-1224	220	6	monotherapy	monotherapy	NOUN
cuesj-1224	220	7	compared	compare	VERB
cuesj-1224	220	8	with	with	ADP
cuesj-1224	220	9	voglibose	voglibose	NOUN
cuesj-1224	220	10	in	in	ADP
cuesj-1224	220	11	japanese	japanese	ADJ
cuesj-1224	220	12	patients	patient	NOUN
cuesj-1224	220	13	with	with	ADP
cuesj-1224	220	14	type	type	NOUN
cuesj-1224	220	15	2	2	NUM
cuesj-1224	220	16	diabetes	diabetes	NOUN
cuesj-1224	220	17	:	:	PUNCT
cuesj-1224	220	18	a	a	DET
cuesj-1224	220	19	randomized	randomized	ADJ
cuesj-1224	220	20	,	,	PUNCT
cuesj-1224	220	21	double	double	ADJ
cuesj-1224	220	22	-	-	PUNCT
cuesj-1224	220	23	blind	blind	ADJ
cuesj-1224	220	24	trial	trial	NOUN
cuesj-1224	220	25	.	.	PUNCT
cuesj-1224	221	1	diabetes	diabetes	NOUN
cuesj-1224	221	2	,	,	PUNCT
cuesj-1224	221	3	obesity	obesity	NOUN
cuesj-1224	221	4	and	and	CCONJ
cuesj-1224	221	5	metabolism	metabolism	NOUN
cuesj-1224	221	6	,	,	PUNCT
cuesj-1224	221	7	vol	vol	NOUN
cuesj-1224	221	8	.	.	PROPN
cuesj-1224	221	9	12	12	NUM
cuesj-1224	221	10	,	,	PUNCT
cuesj-1224	221	11	pp	pp	ADJ
cuesj-1224	221	12	.	.	PUNCT
cuesj-1224	222	1	613	613	NUM
cuesj-1224	222	2	-	-	SYM
cuesj-1224	222	3	622	622	NUM
cuesj-1224	222	4	,	,	PUNCT
cuesj-1224	222	5	2010	2010	NUM
cuesj-1224	222	6	.	.	PUNCT
cuesj-1224	223	1	[	[	X
cuesj-1224	223	2	29	29	NUM
cuesj-1224	223	3	]	]	PUNCT
cuesj-1224	223	4	a.	a.	NOUN
cuesj-1224	223	5	j.	j.	PROPN
cuesj-1224	223	6	tremblay	tremblay	PROPN
cuesj-1224	223	7	,	,	PUNCT
cuesj-1224	223	8	b.	b.	PROPN
cuesj-1224	223	9	lamarche	lamarche	PROPN
cuesj-1224	223	10	,	,	PUNCT
cuesj-1224	223	11	c.	c.	PROPN
cuesj-1224	223	12	f.	f.	PROPN
cuesj-1224	223	13	deacon	deacon	PROPN
cuesj-1224	223	14	,	,	PUNCT
cuesj-1224	223	15	s.	s.	PROPN
cuesj-1224	223	16	j.	j.	PROPN
cuesj-1224	223	17	weisnagel	weisnagel	PROPN
cuesj-1224	223	18	and	and	CCONJ
cuesj-1224	223	19	p.	p.	NOUN
cuesj-1224	223	20	couture	couture	NOUN
cuesj-1224	223	21	.	.	PUNCT
cuesj-1224	224	1	effect	effect	NOUN
cuesj-1224	224	2	of	of	ADP
cuesj-1224	224	3	sitagliptin	sitagliptin	NOUN
cuesj-1224	224	4	therapy	therapy	NOUN
cuesj-1224	224	5	on	on	ADP
cuesj-1224	224	6	postprandial	postprandial	ADJ
cuesj-1224	224	7	lipoprotein	lipoprotein	ADJ
cuesj-1224	224	8	levels	level	NOUN
cuesj-1224	224	9	in	in	ADP
cuesj-1224	224	10	patients	patient	NOUN
cuesj-1224	224	11	with	with	ADP
cuesj-1224	224	12	type	type	NOUN
cuesj-1224	224	13	2	2	NUM
cuesj-1224	224	14	diabetes	diabetes	NOUN
cuesj-1224	224	15	.	.	PUNCT
cuesj-1224	225	1	diabetes	diabetes	NOUN
cuesj-1224	225	2	,	,	PUNCT
cuesj-1224	225	3	obesity	obesity	NOUN
cuesj-1224	225	4	and	and	CCONJ
cuesj-1224	225	5	metabolism	metabolism	NOUN
cuesj-1224	225	6	,	,	PUNCT
cuesj-1224	225	7	vol	vol	NOUN
cuesj-1224	225	8	.	.	PROPN
cuesj-1224	225	9	13	13	NUM
cuesj-1224	225	10	,	,	PUNCT
cuesj-1224	225	11	no	no	INTJ
cuesj-1224	225	12	.	.	NOUN
cuesj-1224	225	13	4	4	NUM
cuesj-1224	225	14	,	,	PUNCT
cuesj-1224	225	15	pp	pp	ADJ
cuesj-1224	225	16	.	.	PUNCT
cuesj-1224	226	1	366	366	NUM
cuesj-1224	226	2	-	-	SYM
cuesj-1224	226	3	373	373	NUM
cuesj-1224	226	4	,	,	PUNCT
cuesj-1224	226	5	2011	2011	NUM
cuesj-1224	226	6	.	.	PUNCT
cuesj-1224	227	1	[	[	X
cuesj-1224	227	2	30	30	NUM
cuesj-1224	227	3	]	]	X
cuesj-1224	227	4	n.	n.	NOUN
cuesj-1224	227	5	t.	t.	PROPN
cuesj-1224	227	6	y.	y.	PROPN
cuesj-1224	227	7	alibrahim	alibrahim	PROPN
cuesj-1224	227	8	,	,	PUNCT
cuesj-1224	227	9	m.	m.	NOUN
cuesj-1224	227	10	g.	g.	PROPN
cuesj-1224	227	11	chasib	chasib	PROPN
cuesj-1224	227	12	,	,	PUNCT
cuesj-1224	227	13	s.	s.	PROPN
cuesj-1224	227	14	s.	s.	PROPN
cuesj-1224	227	15	h.	h.	PROPN
cuesj-1224	227	16	hamadi	hamadi	PROPN
cuesj-1224	227	17	and	and	CCONJ
cuesj-1224	227	18	a.	a.	NOUN
cuesj-1224	227	19	a.	a.	PROPN
cuesj-1224	227	20	mnsour	mnsour	PROPN
cuesj-1224	227	21	.	.	PUNCT
cuesj-1224	228	1	predictors	predictor	NOUN
cuesj-1224	228	2	of	of	ADP
cuesj-1224	228	3	metformin	metformin	NOUN
cuesj-1224	228	4	side	side	NOUN
cuesj-1224	228	5	effects	effect	NOUN
cuesj-1224	228	6	in	in	ADP
cuesj-1224	228	7	patients	patient	NOUN
cuesj-1224	228	8	with	with	ADP
cuesj-1224	228	9	newly	newly	ADV
cuesj-1224	228	10	diagnosed	diagnose	VERB
cuesj-1224	228	11	type	type	NOUN
cuesj-1224	228	12	2	2	NUM
cuesj-1224	228	13	diabetes	diabetes	NOUN
cuesj-1224	228	14	mellitus	mellitus	NOUN
cuesj-1224	228	15	.	.	PUNCT
cuesj-1224	229	1	ibnosina	ibnosina	PROPN
cuesj-1224	229	2	journal	journal	PROPN
cuesj-1224	229	3	of	of	ADP
cuesj-1224	229	4	medicine	medicine	NOUN
cuesj-1224	229	5	and	and	CCONJ
cuesj-1224	229	6	biomedical	biomedical	ADJ
cuesj-1224	229	7	science	science	NOUN
cuesj-1224	229	8	,	,	PUNCT
cuesj-1224	229	9	vol	vol	NOUN
cuesj-1224	229	10	.	.	PROPN
cuesj-1224	229	11	15	15	NUM
cuesj-1224	229	12	,	,	PUNCT
cuesj-1224	229	13	no	no	INTJ
cuesj-1224	229	14	.	.	NOUN
cuesj-1224	229	15	2	2	NUM
cuesj-1224	229	16	,	,	PUNCT
cuesj-1224	229	17	pp	pp	ADJ
cuesj-1224	229	18	.	.	PUNCT
cuesj-1224	230	1	67	67	NUM
cuesj-1224	230	2	-	-	SYM
cuesj-1224	230	3	73	73	NUM
cuesj-1224	230	4	,	,	PUNCT
cuesj-1224	230	5	2023	2023	NUM
cuesj-1224	230	6	.	.	PUNCT
cuesj-1224	231	1	[	[	X
cuesj-1224	231	2	31	31	NUM
cuesj-1224	231	3	]	]	PUNCT
cuesj-1224	231	4	m.	m.	NOUN
cuesj-1224	231	5	siavash	siavash	PROPN
cuesj-1224	231	6	,	,	PUNCT
cuesj-1224	231	7	m.	m.	NOUN
cuesj-1224	231	8	tabbakhian	tabbakhian	PROPN
cuesj-1224	231	9	,	,	PUNCT
cuesj-1224	231	10	a.	a.	PROPN
cuesj-1224	231	11	m.	m.	PROPN
cuesj-1224	231	12	sabzghabaee	sabzghabaee	PROPN
cuesj-1224	231	13	and	and	CCONJ
cuesj-1224	231	14	n.	n.	PROPN
cuesj-1224	231	15	razavi	razavi	PROPN
cuesj-1224	231	16	.	.	PUNCT
cuesj-1224	232	1	severity	severity	NOUN
cuesj-1224	232	2	of	of	ADP
cuesj-1224	232	3	gastrointestinal	gastrointestinal	ADJ
cuesj-1224	232	4	side	side	NOUN
cuesj-1224	232	5	effects	effect	NOUN
cuesj-1224	232	6	of	of	ADP
cuesj-1224	232	7	metformin	metformin	NOUN
cuesj-1224	232	8	tablet	tablet	NOUN
cuesj-1224	232	9	compared	compare	VERB
cuesj-1224	232	10	to	to	ADP
cuesj-1224	232	11	metformin	metformin	NOUN
cuesj-1224	232	12	capsule	capsule	NOUN
cuesj-1224	232	13	in	in	ADP
cuesj-1224	232	14	type	type	NOUN
cuesj-1224	232	15	2	2	NUM
cuesj-1224	232	16	diabetes	diabetes	NOUN
cuesj-1224	232	17	mellitus	mellitus	NOUN
cuesj-1224	232	18	patients	patient	NOUN
cuesj-1224	232	19	.	.	PUNCT
cuesj-1224	233	1	journal	journal	PROPN
cuesj-1224	233	2	of	of	ADP
cuesj-1224	233	3	research	research	NOUN
cuesj-1224	233	4	in	in	ADP
cuesj-1224	233	5	pharmacy	pharmacy	NOUN
cuesj-1224	233	6	practice	practice	NOUN
cuesj-1224	233	7	,	,	PUNCT
cuesj-1224	233	8	vol	vol	NOUN
cuesj-1224	233	9	.	.	PROPN
cuesj-1224	233	10	6	6	NUM
cuesj-1224	233	11	,	,	PUNCT
cuesj-1224	233	12	no	no	INTJ
cuesj-1224	233	13	.	.	NOUN
cuesj-1224	233	14	2	2	NUM
cuesj-1224	233	15	,	,	PUNCT
cuesj-1224	233	16	pp	pp	ADJ
cuesj-1224	233	17	.	.	PUNCT
cuesj-1224	234	1	73	73	NUM
cuesj-1224	234	2	-	-	SYM
cuesj-1224	234	3	76	76	NUM
cuesj-1224	234	4	,	,	PUNCT
cuesj-1224	234	5	2017	2017	NUM
cuesj-1224	234	6	.	.	PUNCT
cuesj-1224	235	1	[	[	X
cuesj-1224	235	2	32	32	NUM
cuesj-1224	235	3	]	]	PUNCT
cuesj-1224	235	4	l.	l.	PROPN
cuesj-1224	235	5	j.	j.	PROPN
cuesj-1224	235	6	mccreight	mccreight	PROPN
cuesj-1224	235	7	,	,	PUNCT
cuesj-1224	235	8	c.	c.	PROPN
cuesj-1224	235	9	j.	j.	PROPN
cuesj-1224	235	10	bailey	bailey	PROPN
cuesj-1224	235	11	and	and	CCONJ
cuesj-1224	235	12	e.	e.	PROPN
cuesj-1224	235	13	r.	r.	PROPN
cuesj-1224	235	14	pearson	pearson	PROPN
cuesj-1224	235	15	.	.	PUNCT
cuesj-1224	236	1	metformin	metformin	PROPN
cuesj-1224	236	2	and	and	CCONJ
cuesj-1224	236	3	the	the	DET
cuesj-1224	236	4	gastrointestinal	gastrointestinal	ADJ
cuesj-1224	236	5	tract	tract	NOUN
cuesj-1224	236	6	.	.	PUNCT
cuesj-1224	237	1	diabetologia	diabetologia	NOUN
cuesj-1224	237	2	,	,	PUNCT
cuesj-1224	237	3	vol	vol	NOUN
cuesj-1224	237	4	.	.	PROPN
cuesj-1224	237	5	59	59	NUM
cuesj-1224	237	6	,	,	PUNCT
cuesj-1224	237	7	pp	pp	ADJ
cuesj-1224	237	8	.	.	PUNCT
cuesj-1224	237	9	426	426	NUM
cuesj-1224	237	10	-	-	SYM
cuesj-1224	237	11	35	35	NUM
cuesj-1224	237	12	,	,	PUNCT
cuesj-1224	237	13	2016	2016	NUM
cuesj-1224	237	14	.	.	PUNCT
cuesj-1224	238	1	[	[	X
cuesj-1224	238	2	33	33	NUM
cuesj-1224	238	3	]	]	PUNCT
cuesj-1224	238	4	m.	m.	NOUN
cuesj-1224	238	5	rani	rani	PROPN
cuesj-1224	238	6	,	,	PUNCT
cuesj-1224	238	7	s.	s.	PROPN
cuesj-1224	238	8	yadav	yadav	PROPN
cuesj-1224	238	9	,	,	PUNCT
cuesj-1224	238	10	s.	s.	PROPN
cuesj-1224	238	11	choudhary	choudhary	PROPN
cuesj-1224	238	12	,	,	PUNCT
cuesj-1224	238	13	s.	s.	PROPN
cuesj-1224	238	14	sharma	sharma	PROPN
cuesj-1224	238	15	and	and	CCONJ
cuesj-1224	238	16	s.	s.	PROPN
cuesj-1224	238	17	m.	m.	PROPN
cuesj-1224	238	18	pandey	pandey	PROPN
cuesj-1224	238	19	.	.	PUNCT
cuesj-1224	238	20	incidence	incidence	NOUN
cuesj-1224	238	21	of	of	ADP
cuesj-1224	238	22	hypoglycemia	hypoglycemia	NOUN
cuesj-1224	238	23	and	and	CCONJ
cuesj-1224	238	24	other	other	ADJ
cuesj-1224	238	25	side	side	NOUN
cuesj-1224	238	26	effects	effect	NOUN
cuesj-1224	238	27	in	in	ADP
cuesj-1224	238	28	patients	patient	NOUN
cuesj-1224	238	29	of	of	ADP
cuesj-1224	238	30	type	type	NOUN
cuesj-1224	238	31	2	2	NUM
cuesj-1224	238	32	diabetes	diabetes	NOUN
cuesj-1224	238	33	mellitus	mellitus	NOUN
cuesj-1224	238	34	treated	treat	VERB
cuesj-1224	238	35	with	with	ADP
cuesj-1224	238	36	glimepiride	glimepiride	NOUN
cuesj-1224	238	37	versus	versus	ADP
cuesj-1224	238	38	glibenclamide	glibenclamide	NOUN
cuesj-1224	238	39	.	.	PUNCT
cuesj-1224	239	1	international	international	ADJ
cuesj-1224	239	2	journal	journal	PROPN
cuesj-1224	239	3	of	of	ADP
cuesj-1224	239	4	health	health	PROPN
cuesj-1224	239	5	sciences	sciences	PROPN
cuesj-1224	239	6	and	and	CCONJ
cuesj-1224	239	7	research	research	NOUN
cuesj-1224	239	8	,	,	PUNCT
cuesj-1224	239	9	vol	vol	NOUN
cuesj-1224	239	10	.	.	PROPN
cuesj-1224	239	11	4	4	NUM
cuesj-1224	239	12	,	,	PUNCT
cuesj-1224	239	13	no	no	INTJ
cuesj-1224	239	14	.	.	NOUN
cuesj-1224	239	15	2	2	NUM
cuesj-1224	239	16	,	,	PUNCT
cuesj-1224	239	17	pp	pp	ADJ
cuesj-1224	239	18	.	.	PUNCT
cuesj-1224	240	1	68	68	NUM
cuesj-1224	240	2	-	-	SYM
cuesj-1224	240	3	72	72	NUM
cuesj-1224	240	4	,	,	PUNCT
cuesj-1224	240	5	2014	2014	NUM
cuesj-1224	240	6	.	.	PUNCT
cuesj-1224	241	1	[	[	X
cuesj-1224	241	2	34	34	NUM
cuesj-1224	241	3	]	]	PUNCT
cuesj-1224	241	4	k.	k.	PROPN
cuesj-1224	241	5	pranarka	pranarka	PROPN
cuesj-1224	241	6	,	,	PUNCT
cuesj-1224	241	7	a.	a.	NOUN
cuesj-1224	241	8	setiawati	setiawati	PROPN
cuesj-1224	241	9	,	,	PUNCT
cuesj-1224	241	10	s.	s.	PROPN
cuesj-1224	241	11	halim	halim	PROPN
cuesj-1224	241	12	,	,	PUNCT
cuesj-1224	241	13	d.	d.	PROPN
cuesj-1224	241	14	saraswati	saraswati	PROPN
cuesj-1224	241	15	and	and	CCONJ
cuesj-1224	241	16	z.	z.	PROPN
cuesj-1224	241	17	alkaf	alkaf	PROPN
cuesj-1224	241	18	.	.	PUNCT
cuesj-1224	242	1	glimepiride	glimepiride	NOUN
cuesj-1224	242	2	monotherapy	monotherapy	NOUN
cuesj-1224	242	3	in	in	ADP
cuesj-1224	242	4	achieving	achieve	VERB
cuesj-1224	242	5	good	good	ADJ
cuesj-1224	242	6	blood	blood	NOUN
cuesj-1224	242	7	glucose	glucose	NOUN
cuesj-1224	242	8	control	control	NOUN
cuesj-1224	242	9	in	in	ADP
cuesj-1224	242	10	type-2	type-2	NUM
cuesj-1224	242	11	diabetes	diabetes	NOUN
cuesj-1224	242	12	mellitus	mellitus	NOUN
cuesj-1224	242	13	:	:	PUNCT
cuesj-1224	242	14	a	a	DET
cuesj-1224	242	15	prospective	prospective	ADJ
cuesj-1224	242	16	observational	observational	ADJ
cuesj-1224	242	17	study	study	NOUN
cuesj-1224	242	18	.	.	PUNCT
cuesj-1224	243	1	medical	medical	ADJ
cuesj-1224	243	2	journal	journal	PROPN
cuesj-1224	243	3	of	of	ADP
cuesj-1224	243	4	indonesia	indonesia	PROPN
cuesj-1224	243	5	,	,	PUNCT
cuesj-1224	243	6	vol	vol	NOUN
cuesj-1224	243	7	.	.	PROPN
cuesj-1224	243	8	18	18	NUM
cuesj-1224	243	9	,	,	PUNCT
cuesj-1224	243	10	no	no	INTJ
cuesj-1224	243	11	.	.	NOUN
cuesj-1224	243	12	3	3	NUM
cuesj-1224	243	13	,	,	PUNCT
cuesj-1224	243	14	pp	pp	ADJ
cuesj-1224	243	15	.	.	PUNCT
cuesj-1224	244	1	172	172	NUM
cuesj-1224	244	2	-	-	SYM
cuesj-1224	244	3	180	180	NUM
cuesj-1224	244	4	,	,	PUNCT
cuesj-1224	244	5	2009	2009	NUM
cuesj-1224	244	6	.	.	PUNCT
cuesj-1224	245	1	[	[	X
cuesj-1224	245	2	35	35	NUM
cuesj-1224	245	3	]	]	X
cuesj-1224	245	4	r.	r.	PROPN
cuesj-1224	245	5	abdulah	abdulah	PROPN
cuesj-1224	245	6	,	,	PUNCT
cuesj-1224	245	7	t.	t.	PROPN
cuesj-1224	245	8	f.	f.	PROPN
cuesj-1224	245	9	suwandiman	suwandiman	NOUN
cuesj-1224	245	10	and	and	CCONJ
cuesj-1224	245	11	n.	n.	PROPN
cuesj-1224	245	12	handayani	handayani	PROPN
cuesj-1224	245	13	.	.	PUNCT
cuesj-1224	246	1	incidence	incidence	NOUN
cuesj-1224	246	2	,	,	PUNCT
cuesj-1224	246	3	causative	causative	ADJ
cuesj-1224	246	4	drugs	drug	NOUN
cuesj-1224	246	5	,	,	PUNCT
cuesj-1224	246	6	and	and	CCONJ
cuesj-1224	246	7	economic	economic	ADJ
cuesj-1224	246	8	consequences	consequence	NOUN
cuesj-1224	246	9	of	of	ADP
cuesj-1224	246	10	drug	drug	NOUN
cuesj-1224	246	11	-	-	PUNCT
cuesj-1224	246	12	induced	induce	VERB
cuesj-1224	246	13	sjs	sjs	PROPN
cuesj-1224	246	14	,	,	PUNCT
cuesj-1224	246	15	ten	ten	NUM
cuesj-1224	246	16	,	,	PUNCT
cuesj-1224	246	17	and	and	CCONJ
cuesj-1224	246	18	sjs	sjs	PROPN
cuesj-1224	246	19	-	-	PUNCT
cuesj-1224	246	20	ten	ten	NUM
cuesj-1224	246	21	overlap	overlap	NOUN
cuesj-1224	246	22	and	and	CCONJ
cuesj-1224	246	23	potential	potential	ADJ
cuesj-1224	246	24	drug	drug	NOUN
cuesj-1224	246	25	-	-	PUNCT
cuesj-1224	246	26	drug	drug	NOUN
cuesj-1224	246	27	interactions	interaction	NOUN
cuesj-1224	246	28	during	during	ADP
cuesj-1224	246	29	treatment	treatment	NOUN
cuesj-1224	246	30	:	:	PUNCT
cuesj-1224	246	31	a	a	DET
cuesj-1224	246	32	retrospective	retrospective	ADJ
cuesj-1224	246	33	analysis	analysis	NOUN
cuesj-1224	246	34	at	at	ADP
cuesj-1224	246	35	an	an	DET
cuesj-1224	246	36	indonesian	indonesian	ADJ
cuesj-1224	246	37	referral	referral	ADJ
cuesj-1224	246	38	hospital	hospital	NOUN
cuesj-1224	246	39	.	.	PUNCT
cuesj-1224	247	1	therapeutic	therapeutic	ADJ
cuesj-1224	247	2	and	and	CCONJ
cuesj-1224	247	3	clinical	clinical	ADJ
cuesj-1224	247	4	risk	risk	NOUN
cuesj-1224	247	5	management	management	NOUN
cuesj-1224	247	6	,	,	PUNCT
cuesj-1224	247	7	vol	vol	NOUN
cuesj-1224	247	8	.	.	PROPN
cuesj-1224	247	9	13	13	NUM
cuesj-1224	247	10	,	,	PUNCT
cuesj-1224	247	11	pp	pp	ADJ
cuesj-1224	247	12	.	.	PUNCT
cuesj-1224	248	1	919	919	NUM
cuesj-1224	248	2	-	-	SYM
cuesj-1224	248	3	925	925	NUM
cuesj-1224	248	4	,	,	PUNCT
cuesj-1224	248	5	2017	2017	NUM
cuesj-1224	248	6	.	.	PUNCT
cuesj-1224	249	1	[	[	X
cuesj-1224	249	2	36	36	NUM
cuesj-1224	249	3	]	]	PUNCT
cuesj-1224	249	4	the	the	DET
cuesj-1224	249	5	british	british	ADJ
cuesj-1224	249	6	pharmacological	pharmacological	ADJ
cuesj-1224	249	7	society	society	NOUN
cuesj-1224	249	8	.	.	PUNCT
cuesj-1224	250	1	fatal	fatal	ADJ
cuesj-1224	250	2	toxic	toxic	ADJ
cuesj-1224	250	3	epidermal	epidermal	ADJ
cuesj-1224	250	4	necrolysis	necrolysis	NOUN
cuesj-1224	250	5	probably	probably	ADV
cuesj-1224	250	6	related	relate	VERB
cuesj-1224	250	7	to	to	PART
cuesj-1224	250	8	glimepiride	glimepiride	VERB
cuesj-1224	250	9	in	in	ADP
cuesj-1224	250	10	a	a	DET
cuesj-1224	250	11	patient	patient	NOUN
cuesj-1224	250	12	with	with	ADP
cuesj-1224	250	13	a	a	DET
cuesj-1224	250	14	medical	medical	ADJ
cuesj-1224	250	15	history	history	NOUN
cuesj-1224	250	16	of	of	ADP
cuesj-1224	250	17	hypersensitivity	hypersensitivity	NOUN
cuesj-1224	250	18	to	to	ADP
cuesj-1224	250	19	sulfamethoxazole	sulfamethoxazole	NOUN
cuesj-1224	250	20	–	–	PUNCT
cuesj-1224	250	21	trimethoprim	trimethoprim	ADJ
cuesj-1224	250	22	.	.	PUNCT
cuesj-1224	251	1	british	british	ADJ
cuesj-1224	251	2	journal	journal	PROPN
cuesj-1224	251	3	of	of	ADP
cuesj-1224	251	4	clinical	clinical	ADJ
cuesj-1224	251	5	pharmacology	pharmacology	NOUN
cuesj-1224	251	6	,	,	PUNCT
cuesj-1224	251	7	vol	vol	NOUN
cuesj-1224	251	8	.	.	PROPN
cuesj-1224	251	9	87	87	NUM
cuesj-1224	251	10	,	,	PUNCT
cuesj-1224	251	11	pp	pp	ADJ
cuesj-1224	251	12	.	.	PUNCT
cuesj-1224	252	1	1591	1591	NUM
cuesj-1224	252	2	-	-	SYM
cuesj-1224	252	3	1593	1593	NUM
cuesj-1224	252	4	,	,	PUNCT
cuesj-1224	252	5	2021	2021	NUM
cuesj-1224	252	6	.	.	PUNCT
cuesj-1224	253	1	[	[	X
cuesj-1224	253	2	37	37	NUM
cuesj-1224	253	3	]	]	X
cuesj-1224	253	4	g.	g.	PROPN
cuesj-1224	253	5	sargın	sargın	PROPN
cuesj-1224	253	6	,	,	PUNCT
cuesj-1224	253	7	r.	r.	PROPN
cuesj-1224	253	8	köse	köse	PROPN
cuesj-1224	253	9	and	and	CCONJ
cuesj-1224	253	10	t.	t.	PROPN
cuesj-1224	253	11	şentürk	şentürk	PROPN
cuesj-1224	253	12	.	.	PUNCT
cuesj-1224	254	1	sitagliptin	sitagliptin	PROPN
cuesj-1224	254	2	/	/	SYM
cuesj-1224	254	3	metformin	metformin	NOUN
cuesj-1224	254	4	related	relate	VERB
cuesj-1224	254	5	cutaneous	cutaneous	ADJ
cuesj-1224	254	6	leukocyto	leukocyto	NOUN
cuesj-1224	254	7	-	-	PUNCT
cuesj-1224	254	8	clastic	clastic	NOUN
cuesj-1224	254	9	vasculitis	vasculitis	NOUN
cuesj-1224	254	10	in	in	ADP
cuesj-1224	254	11	a	a	DET
cuesj-1224	254	12	patient	patient	NOUN
cuesj-1224	254	13	with	with	ADP
cuesj-1224	254	14	type-2	type-2	NUM
cuesj-1224	254	15	diabetes	diabetes	NOUN
cuesj-1224	254	16	mellitus	mellitus	NOUN
cuesj-1224	254	17	.	.	PUNCT
cuesj-1224	255	1	journal	journal	PROPN
cuesj-1224	255	2	of	of	ADP
cuesj-1224	255	3	academic	academic	ADJ
cuesj-1224	255	4	research	research	NOUN
cuesj-1224	255	5	in	in	ADP
cuesj-1224	255	6	medicine	medicine	NOUN
cuesj-1224	255	7	,	,	PUNCT
cuesj-1224	255	8	vol	vol	NOUN
cuesj-1224	255	9	.	.	PROPN
cuesj-1224	255	10	10	10	NUM
cuesj-1224	255	11	,	,	PUNCT
cuesj-1224	255	12	no	no	INTJ
cuesj-1224	255	13	.	.	NOUN
cuesj-1224	255	14	1	1	NUM
cuesj-1224	255	15	,	,	PUNCT
cuesj-1224	255	16	pp	pp	ADJ
cuesj-1224	255	17	.	.	PUNCT
cuesj-1224	256	1	97	97	NUM
cuesj-1224	256	2	-	-	SYM
cuesj-1224	256	3	99	99	NUM
cuesj-1224	256	4	,	,	PUNCT
cuesj-1224	256	5	2020	2020	NUM
cuesj-1224	256	6	.	.	PUNCT